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ABSTRACT 
Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder, caused 
by a GAA repeat expansion mutation within intron 1 of the FXN gene, resulting in 
reduced level of frataxin protein. Normal individuals have 5 to 40 GAA repeat 
sequences, whereas affected individuals have approximately 70 to more than 1000 GAA 
triplets. Frataxin is a mitochondrial protein involved in iron-sulphur cluster and heme 
biosynthesis. The reduction in frataxin expression leads to oxidative stress, 
mitochondrial iron accumulation and consequential cell death with the primary sites of 
neurons of the dorsal root ganglia and the dentate nucleus of the cerebellum. FRDA, 
which is the most common inherited ataxia, affecting 1:50,000 Caucasians, is 
characterised by neurodegeneration, cardiomyopathy, diabetes mellitus and skeletal 
deformities. 
 
To investigate FRDA molecular disease mechanisms and therapy, several human FXN 
YAC transgenic mouse models have been established: Y47R, containing normal-sized 
(GAA)9 repeats; YG8R and YG22R, which initially contained expanded GAA repeats 
of 90-190 units and 190 units, respectively, but which have subsequently been bred to 
now contain expanded GAA repeats of 120-220 units and 170-260 units, respectively, 
and YG8sR (YG8R with a small GAA band) that was recently generated from YG8R 
breeding. To determine the FXN transgene copy number in the enhanced GAA repeat 
expansion-based FRDA mouse lines, a TaqMan qPCR assay was developed. The results 
demonstrated that the YG22R and Y47R lines had a single copy of the FXN transgene 
while the YG8R line had two copies. The YG8s lines showed less than one copy of the 
target gene, suggesting potential deletion of the FXN gene. Single integration sites of all 
transgenes were confirmed by fluorescence in situ hybridisation (FISH) analysis of 
metaphase and interphase chromosomes. However, in the YG8s line, at least 25% of the 
YG8s cells had no signals, while the remaining cells showed one signal corresponding 
to the transgenic FXN gene. In addition, the analysis of FXN exons in YG8s rescue mice 
by PCR confirmed the presence of all FXN exons in these lines, suggesting the 
incidence of somatic mosaicism in these lines. 
 
Extended functional analysis was carried out on these mice from 4 to 12 months of age. 
Coordination ability of YG8R, YG8sR and YG22R ‘FRDA-like’ mice, together with 
Y47R and C57BL6/J wild-type control mice, was assessed using accelerating rotarod 
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analysis. The results indicated a progressive decrease in the motor coordination of 
YG8R, YG22R and YG8sR mice compared to Y47R or C57BL6/J controls. Locomotor 
activity was also assessed using an open field beam-breaker apparatus followed by four 
additional functional analyses including beam-walk, hang wire, grip strength and foot 
print tests. The results indicated significant functional deficits in the FRDA mouse 
models. Glucose and insulin tolerance tests were also conducted in the FRDA mouse 
models, indicating glucose intolerance and insulin hypersensitivity in the 
aforementioned lines. 
 
To investigate the correlation between the FRDA-like pathological phenotype and 
frataxin deficiency in the FRDA mouse models, frataxin mRNA and protein levels as 
well as somatic GAA repeat instability were examined. The results indicated that 
somatic GAA repeats increased in the cerebellum and brain of YG22R, YG8R and 
YG8sR mice, together with significantly reduced levels of FXN mRNA and protein in 
the liver of YG8R and YG22R compared to Y47R. However, YG8sR lines showed a 
significant decrease in FXN mRNA in all of the examined tissues compared to Y47R 
human FXN and C57BL6/J mouse Fxn mRNA. Protein expression levels were also 
considerably reduced in all the tissues of YG8sR mice compared to Y47R.  
 
Subsequently, the telomere length of human and mouse FRDA and control fibroblasts 
was assessed using qPCR and Q-FISH.  The results indicated that the FRDA cells had 
chromosomes with relatively longer telomeric repeats in comparison to the controls. 
FRDA cells were screened for expression of telomerase activity using the TRAP assay 
and a quantitative assay for hTERT mRNA expression using TaqMan qRT-PCR. The 
results indicated that telomerase activity was not present in the FRDA cells. To 
investigate whether FRDA cells maintained their telomeres by ALT associated PML 
bodies (APBs), co-localisation of PML bodies with telomeres was assessed in these 
cells using combined immunofluorescence to PML and Q-FISH for telomere detection. 
The results demonstrated that the FRDA cells had significantly higher co-localised PML 
foci with telomeric DNA compared to the normal cells. Moreover, telomere sister 
chromatid exchange (T-SCE) frequencies were analysed in the human FRDA cell lines 
using chromosome orientation FISH (CO-FISH). The results indicated a significant 
increase in T-SCE levels of the FRDA cell lines relative to the controls. Furthermore, 
growth curve and population doubling analysis of the human FRDA and control 
fibroblasts was carried out. The results showed that the FRDA fibroblast cell cultures 
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underwent growth arrest with higher cumulative population doubling compared to the 
controls. Though, further analysis of telomere length at different passage numbers 
revealed that the FRDA cells lost telomeres faster than the controls. Finally, the 
telomere dysfunction-induced foci (TIF) assay was performed to detect DNA damage in 
the human FRDA fibroblast cells using an antibody against DNA damage marker γ-
H2AX and a synthetic PNA probe for telomeres. The frequency of γ-H2AX foci was 
significantly higher in the FRDA cells compared to the controls. Similarly, the FRDA 
cells had greater frequencies of TIFs in comparison to the controls, suggesting induced 
telomere dysfunction in the FRDA cells. 
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GENERAL INTRODUCTION 
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1.1 History 
In 1853, Nicholaus Friedreich, a German physician, described a degenerative atrophy of 
the posterior columns of the spinal cord leading to progressive ataxia, sensory loss, 
muscle weakness, often associated with scoliosis, foot deformity and cardiomyopathy. 
His publications in 1866 and 1867 further confirmed his previous work on the discovery 
of a new disease entity while some critics, particularly Charcot, had assumed that 
Friedreich’s patients had tabes, associated with neurosyphilis [1-3]. Friedreich identified 
all the essential clinical and pathological features of the disease except the loss of deep 
tendon reflexes, which was later described by Erb in 1885. Brousse termed the new 
disease Friedreich’s ataxia (currently abbreviated FRDA) in 1882 [2, 3]. In the late 
1970s, Quebec Collaborative Group and Harding established the clinical features of the 
typical FRDA specifically recessive inheritance as an essential feature of FRDA [4, 5]. 
 
1.2 Clinical and Pathological Features 
    1.2.1. Epidemiology 
FRDA is a progressive neurodegenerative disease inherited as an autosomal recessive 
trait with an estimated prevalence of 1 in 50,000 Caucasians [6]. It is the most common 
form of the hereditary ataxias accounted for half of the whole heredodegenerative ataxia 
cases and three-quarters of those with onset before age 25 [7]. The carrier rate has been 
approximated at 1:120-1:60 [6, 8, 9].  
 
    1.2.2. Pathology 
FRDA is a progressive disease that initiates with gait abnormality within patients 
ranging from 2-3 years of age to later than 25 years of age. The essential clinical 
features of FRDA are autosomal recessive inheritance, onset before 25 years of age, 
progressive ataxia of gait and limbs, loss of tendon reflexes in the lower extremities, 
electrophysiologic evidence of axonal sensory neuropathy (within 5 years of onset), 
dysarthria, extensor plantar responses, areflexia at all four limbs, muscle wasting and 
loss of sensation, especially of vibration and joint position sense. Patients lose their 
ability to walk on average 15 years after onset and may be confined to a wheelchair in 
their early teens [3, 10].  
 
There may be other clinical features, as the disease progresses, including nystagmus 
(involuntary rhythmic oscillations of the eyeballs, characterised by a smooth pursuit in 
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one direction and a fast movement in the opposite direction), saccadic-pursuit eye 
movements (rapid correction eye movements to redirect the line of site during smooth 
pursuit of an object), difficulty with swallowing and breathing as well as 
cardiomyopathy, diabetes mellitus and skeletal deformities [1, 3, 11, 12]. Some patients 
can develop optic atrophy (25%) and sensorineural hearing loss (20%) [13]. Slower 
disease progression is often observed in patients with late onset FRDA whereby tendon 
reflexes are often retained [11, 14-16]. Spinal cord atrophy associated with atrophy of 
the brainstem and cerebellum was detected in patients with typical and late onset FRDA 
using magnetic resonance imaging [17-20]. 
 
The neuropathologic discoveries differentiate FRDA from other hereditary ataxias. 
Degeneration of the posterior columns of the spinal cord is considered an early finding 
[13]. The posterior columns consist of the central branches of the axons of large dorsal 
root ganglia (DRG) sensory neurons. These axons extend and form the gracile (Goll) 
and Cuneate (Burdach) tracts which originate at the lumbosacral level and from 
cervicothoracic segments respectively. Demyelination, loss of fibers and fibrillary 
gliosis are more severe in the Goll than in the Burdach tract, indicating that the fibers 
originating from neurons located caudally are more severely affected. Atrophy in the 
spinocerebellar tracts is also observed, resulting in the dorsal being more affected than 
the ventral [6, 13, 20, 21]. Clarke’s column, where the spinocerebellar tracts originate, 
is atrophied; whereas motor neurons in the ventral horns are unaffected. On the other 
hand, the long crossed and uncrossed corticospinal motor tracts are atrophied. In the 
brainstem, where the dorsal column tracts terminate, the gracile and cuneate nuclei, 
indicating transsynaptic degeneration with intense gliosis. The long tracts of fibers, 
particularly the corticospinal fibers, are severely atrophic in distal portions, suggesting a 
dying-back process. The entering roots of cranial sensory nerves are affected while 
cranial nerve nuclei remain normal. Cerebellar atrophy is not a major characteristic of 
FRDA. The cerebellum cortex shows Purkinje cell loss, typically late in the course of 
the disease. Conversely, the dentate nuclei are severely affected. Loss of pyramidal 
(Betz) cells in the primary motor areas of the cerebral cortex is observed provided that 
the pyramidal tract atrophy is advanced. In the peripheral nervous system, sensory 
axonal polyneuropathy is a characteristic of FRDA. The marked loss of large 
myelinated fibers has been observed in the peripheral nerves and also in the DRG cells. 
The features of the changes in the peripheral nerve system are not well understood. 
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Previous studies have indicated that there is a maturational defect in specific neurons 
that remain hypotrophic and subsequently die back gradually [22]. 
 
Enlargement of the heart accompanied by the thickening of the ventricular walls and 
interventricular septum leads to arrhythmias and heart failure, the most common causes 
of death in the majority of FRDA patients. The pathology of the cardiac degeneration 
consists of interstitial fibrosis, hypertrophy and degeneration of cardiac cells, muscle 
necrosis and intracellular accumulation of lipofuscin, iron and calcium deposits. In 
addition, diabetes mellitus associated with a decrease in the number of pancreatic β 
cells, is also observed in 10% of the patients [1, 4, 11, 23-25]. Furthermore, skeletal 
deformities are very common in FRDA patients including pes cavus (hammer toes) and 
kyphoscoliosis (abnormal lateral and posterior curvature of the vertebral column) [4, 
11]. 
 
1.3 Identification of the FRDA Gene 
The primary mapping of the FRDA gene was accomplished in 1988 by Chamberlain et 
al. [26]. The FRDA gene was mapped to chromosome 9 by linkage analysis in 20 
families with at least three affected sibs. The locus was mapped with a closely linked 
marker at 9q13-q21.1, providing a region small enough for identification of candidate 
gene [27, 28]. The FRDA gene, initially referred to as X25, was one of the expressed 
genes in this region, identified by complementary DNA selection and sequence analysis. 
A mutation in X25 was screened in a number of patients which resulted in the 
identification of an expanded trinucleotide repeat (GAA) within the first intron of the 
FRDA gene [6]. This gene encodes the protein called Frataxin which plays a crucial 
role in the development of FRDA. 
 
1.4 Location and Structure of FRDA Gene 
The Frataxin gene is located on the long arm (q) of chromosome 9 between the Giemsa 
bands 13 and 21.1 precisely from base pair 71,650,478 to base pair 71,715,093, Fig. 1.1 
[6, 27, 29]. 
 
The FRDA gene is composed of seven exons, numbered 1 to 5a, 5b and 6, spread over 
95kb of genomic DNA. Transcription goes in the centromere to telomere direction, Fig. 
1.2. The major transcript, exons 1 to 5a, is a 1.3kb mRNA that encodes a 210 amino 
acid protein called frataxin. Exon 5b as a result of alternative splicing can be 
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transcribed, leading to the synthesis of different protein isoforms. Exon 6 is entirely 
noncoding [6, 30]. 
 
The FRDA gene demonstrates tissue-specific levels of expression. Among adult human, 
frataxin mRNA is considerably expressed in heart and central nervous system; 
intermediate levels in liver, skeletal muscle and pancreas; and minimal levels in other 
tissues. In the central nervous system (CNS), expression of frataxin appears to be the 
highest in the spinal cord, with less expression in the cerebellum and very little in the 
cerebral cortex [6, 31]. 
 
 
Fig. 1.1 Schematic representation of human chromosome 9. The blue arrow indicates 
the location of frataxin gene. 
 
Fig. 1.2 Schematic representation of exons and splicing pattern of the FXN gene. The 
gene extends from centromere to telomere of the 9q chromosome. The GAA repeats are 
located in intron1, represented by the red triangle. 
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1.5 Gene Mutations in FRDA 
    1.5.1 Trinucleotide Repeat Expansion 
In 98% of FRDA chromosomes, an abnormal trinucleotide repeat expansion (GAA) 
occurs within the first intron of the frataxin gene [6]. This intron is 12kb in size and the 
triplet repeat is localised within an Alu sequence, 1.4kb after exon 1. Normal 
chromosomes contain between 5 and 40 triplets [32], whereas FRDA chromosomes 
contain 70 to 1700 repeats [11]. The GAA expansion forms a triple helical DNA or R-
loop structures which inhibits transcription of the FRDA gene by inducing 
heterochromatin formation, resulting in reduced frataxin levels [33, 34]. 
 
    1.5.2 Point Mutations 
Point mutations in the frataxin gene are a rare cause of FRDA. In all cases characterised 
so far, only 4% of affected individuals were heterozygous for their point mutation, with 
an expanded GAA repeat on the other homologue of chromosome 9. None of these 
patients harboured point mutations on both alleles [35-37].  
 
The most common point mutations are I154F, M1I and G130V. Patients with the I154F 
mutation have a typical FRDA phenotype, whereas the other cases give rise to atypical 
phenotypes. Therefore, it can be concluded that point mutations associated with loss of 
functional frataxin protein result in a severe phenotype, whereas for other missense 
mutations, the severity of the disease course cannot be predicted [8, 29]. 
 
1.6 Origin of the Expanded GAA Repeat 
Although, the origins of the GAA repeat expansion and its effects on frataxin 
expression are not fully understood, it has been manifested that alleles at the GAA 
repeat site depending on their length can be subdivided into three classes: short normal 
alleles (82%, containing 5-9 triplets), long normal (17%, containing 10-40 triplets) and 
pathological expanded alleles (1%, > 70 triplets). The length polymorphism of normal 
GAA alleles may be generated by small changes most likely due to occasional events of 
polymerase “stuttering” during DNA replication. Such small changes may cause limited 
size heterogeneity within the short normal and the large normal alleles. The jump from 
the short normal to the long normal group can be considered as a singular event with a 
rare recurrence. The linkage disequilibrium studies of the GAA repeat with different 
haplotype markers indicated that pathological expanded and long normal alleles are 
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genetically homogenous and related, whereas short normal alleles appear heterogeneous 
[30, 38, 39]. 
 
1.7 Effect of the GAA Repeat Expansion on Frataxin Gene Expression 
FRDA can be defined as a deficiency of frataxin. The expanded GAA repeat has been 
shown to cause this deficiency by suppressing FRDA gene expression, Fig. 1.3. The 
data obtained from ribonuclease (RNase) protection assays in individuals with FRDA 
revealed a severe reduction in the level of mature frataxin mRNA proportional to the 
size of GAA repeats [30]. Western blot analysis of frataxin in FRDA patients also 
confirmed a severe frataxin deficiency inversely proportional to the expansion sizes, 
providing a biological basis for the correlation between expansion sizes and phenotypic 
features [40, 41]. 
 
1.8 Genotype-Phenotype Correlation 
In the same manner as in the other repeat disorders, the size of the expanded repeat in 
FRDA is inversely related to age of onset and disease severity. However this correlation 
is more complex in FRDA than that in dominant or X-linked triplet-repeat diseases, 
since FRDA patients have two expanded alleles, whereas those suffering from dominant 
diseases only have one expanded allele. The size of the smaller FRDA allele is strongly 
correlated with age at onset and with the rate of disease progression. Montermini et al. 
reported a negative correlation between age at onset and the number of the repeats in 
both small and large alleles. Their results indicated that FRDA patients with larger 
 
Fig. 1.3 Schematic presentation of the frataxin expression. Normal state indicates more 
frataxin protein, whereas affected state (FRDA) shows less frataxin. 
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expansions tended to exhibit earlier onset whereas late-onset FRDA patients exhibited 
smaller alleles [32]. The relatively low correlation coefficients between disease severity 
and the GAA repeat expansion size indicate that other factors including somatic 
mosaicism, genetic and environmental modifiers may influence the phenotypic 
heterogeneity [8, 11, 32]. 
 
1.9 Role of Frataxin in Mitochondria  
The mitochondrion is an essential organelle for cellular biochemistry and ATP 
generation as well as being a well-known location for dynamic electron transport and 
redox chemistry. Heme and iron-sulphur (Fe-S) cluster biosynthesis are the two major 
iron-related metabolic processes in the mitochondrion for the safe delivery, storage and 
usage of iron. Frataxin is a mitochondrial protein that is perceived as an important factor 
in either mitochondrial iron transport or iron-sulphur assembly and transport [42].  
 
Homologous proteins of human frataxin have been identified in mouse and yeast with 
73% and 31% amino acid sequence identity respectively, providing further insight into 
FRDA pathogenesis [43]. YFH1 is a yeast frataxin homologue that encodes a 174 
amino acid protein with homology to frataxin, especially at the C-terminus, localised to 
the mitochondria. Studies of yeast strains deficient in YFH1 demonstrated that the 
frataxin is involved in mitochondria iron homeostasis [44]. In yeast, the AFT1 
transcription factor regulates iron utilisation and homeostasis at the transcriptional level. 
This is mainly attributed to the activation of AFT1 in iron-poor media, resulting in an 
increased cytosolic iron level or inactivation in high cytosolic iron level in iron-rich 
media [45]. In yeast strains deficient cells, AFT1 is activated in both iron-poor and iron-
rich medium, indicating low levels of cytosolic iron in these cells compared to wild-
type cells. Hence, iron passes the plasma membrane into the cytosol through an 
activated high affinity transporter which ultimately leads to the mitochondrial iron 
accumulation. Such mechanism suggests that frataxin may be involved in iron transport 
either by regulating release of mitochondrial iron to the cytoplasm or by inhibiting iron 
transport into the mitochondria [45].  
 
Molecular and biochemical analysis of fibroblasts from FRDA patients manifested 
mitochondrial iron overload in contrast to control cells [46]. Endomyocardial biopsies 
from these patients have shown a generalised deficiency of Fe-S cluster-containing 
proteins (ISPs) (i.e. respiratory chain complexes I, II and III; and mitochondrial and 
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cytosolic aconitase), reduced level of mitochondrial DNA and increased activity of iron 
regulatory protein 1 (IRP1) [47-49, 50, 51]. A similar deficiency in the activity of ISPs 
has been observed in heart muscle of conditional frataxin knockout mice. Since ISPs are 
very sensitive to reactive oxygen species (ROS), deficiency in the activity of ISPs 
suggests oxidative damage in frataxin deficient tissues [42, 52, 53]. Mitochondrial iron 
can react with ROS and generate more toxic ROS such as hydroxyl radical (OH•) via 
the Fenton reaction leading to the oxidation of cellular compounds, Fig. 1.4. Increased 
iron levels in conjunction with defects in respiratory chain complexes result in free-
radical accumulation, ultimately leading to cellular injury and death [47]. According to 
results from mouse models, deficiencies in ISPs occur in the initial phase of the 
pathology, whereas mitochondrial iron accumulation occurs later, indicating that 
mitochondrial iron accumulation cannot be the causative pathological mechanism. 
Moreover, low superoxide dismutase (SOD) induction observed in the diseased mouse 
confirms that either decreased or absent frataxin impairs early antioxidant defences with 
no SOD induction resulting in higher cell lethality in response to oxidative stress [54]. 
 
  
 
 
Fig. 1.4 Schematic representation of the likely pathogenesis of FRDA. A) The normal 
situation in the mitochondrion is shown with iron influx and efflux maintaining low 
mitochondrial iron (Fe) and free radical (OH
·
) levels. Frataxin is likely to be acting 
directly at the level of iron efflux. Yeast data suggest that frataxin may also be indirectly 
limiting the influx of iron into mitochondria by reducing mitochondrial intermediate 
peptidase (MIP) activity. B) In FRDA reduced frataxin results in inhibition of the efflux 
of mitochondrial iron. This leads to reduced cytosolic iron, which results in induction of 
iron uptake systems and this in turn results in further iron uptake into mitochondria. The 
increased iron uptake may be in part the result of over activity of MIP owing to the 
absence of frataxin. The excess mitochondrial iron leads to excess production of toxic 
free radicals by Fenton reaction (Fe
2+ 
+ H2O2→ Fe
3+
+ OH
- 
+ OH
·
) leading to cell damage 
and death [29]. 
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The expression of frataxin is dependent on the type of tissue, indicating tissue-specific 
pathology in FRDA. Tissues such as liver, skeletal muscle and thymus are not affected 
by the disease yet they contain high levels of mitochondria and frataxin is significantly 
expressed in such tissues. While the aforementioned tissues can be replaced due to their 
inherent dividing nature, the affected tissues such as those in the central nervous system, 
heart and pancreas are typically nondividing [29, 42, 43]. Moreover, neurons and 
cardiac myocytes are more susceptible to mitochondrial defects and toxic effects of 
mitochondrial free-radical accumulation due to their high aerobic metabolism 
dependence [55].  
 
1.10 Structure of Human Frataxin 
Human frataxin, a 210 amino acid protein, contains a N-terminal mitochondrial 
targeting sequence that is proteolytically processed after frataxin is imported into the 
matrix. The mitochondrial processing peptidase, MPP-β, is responsible for cleavage of 
the frataxin mitochondrial targeting sequence, generating the human frataxin with 155 
amino acids (residues 56-210) [56-58, 59]. Crystal and solution nuclear magnetic 
resonance (NMR) structures of frataxin show significant sequence similarity between 
the  C-terminal domain of frataxin (residues 90-210) and the CyaY proteins of γ-purple 
bacteria [59-62], providing a common structural features to study possible structure and 
function of frataxin family. Frataxin has a unique fold that combines two terminal 
helices (α1 and α2) which are nearly parallel to each other and to the plane of the large β 
sheet, five antiparallel β-strands that interact with the two helices, and a sixth (and, in 
human frataxin, a seventh) β-strand that intersects the planes to give an overall compact 
 
Fig. 1.5 Structure of frataxin. A) Crystal structure of human frataxin shows the fold of 
human frataxin, a compact αβ sandwich, with α helices and β sheets. Strands β1 – β5 
formed a flat antiparallel construct that interact with the two helices, α1 and α2. B) 
Molecular surface representation of frataxin. Several anionic residues in α1 and β1 are 
shown in red. The anionic surface might be critical for the function of frataxin [60]. 
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Fig. 2 Crystal structure of human frata 
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αβ sandwich structure, Fig. 1.5A [60]. However strand seven is only detected in human 
frataxin with structures extremely similar to those of frataxin orthologs due to high 
degree of amino acid sequence similarity [60]. 
 
A clustering of negatively charged side chains of 12 acidic residues projected from helix 
α1 and strand β1 creates an acidic patch of the surface of the protein, Fig. 1.5B. The 
general structure, including the anionic surface, is conserved in both eukaryotes and 
prokaryotes; however, the architecture of frataxin represents a new protein fold. The 
conserved outer surface of the β sheet might mediate a specific protein-protein 
interaction with partners that may be crucial for its biological functions. Different 
approaches such as NMR experiments and crystallographic experiments were used to 
study the potential binding properties of frataxin to iron, but no chemical changes were 
observed. These results indicate that frataxin does not have any feature resembling 
known iron-binding sites; however, the anionic surface of frataxin is considered to 
contain the putative iron-binding sites based on the resemblance to bacterial ferritin [60, 
61].  
 
Mapping the pathological mutations onto the structure provides an insight into possible 
function of frataxin. However, a small percentage (≈ 2%) of FRDA patients are 
compound heterozygotes, having a combination of increased GAA repeats in one allele 
and a point mutation in the other allele [37, 63-65]. Several mutations are in the protein 
core including L106S, I154F, L156P, W173G, L182H/L182F and H183R leading to 
interruption of the stable and compact structure [55]. Another mutation, D122Y, within 
the anionic patch alters charge within this surface and overall protein polarity. Mutants 
G130V, W155R and R165C are located within the flat, conserved external surface of 
the large β sheet. Therefore, the mutations associated with disease are not only located 
in the compact core structure, but are also located within two conserved surfaces 
including the anionic surface and the conserved outer β sheet surface. Thus, these 
surfaces are critical for frataxin function as the mutations within these surfaces showed 
several effects, including steric strain and electrostatic strain [60]. The mutations in 
FRDA patients have been summarised in Table 1.1 [61]. 
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Table 1.1 Summary of the mutations described in FRDA patients 
Mutation Effect References 
L106S, 
W173G 
Internal cavities with loss of packing energy 
 
64,36 
I154F, L182F 
Steric strain by replacing a buried hydrophobic residue by a 
larger one 
 
6,8 
L156P 
Disruption in the β-sheet hydrogen bonds by introducing a 
proline 
 
36 
L182H 
Electrostatic strain by replacing a buried residue with a 
hydrophilic one 
 
36 
H183R 
Electrostatic stain by replacing a partially uncharged buried 
residue with a bulky charged one 
 
36 
D122Y 
Change of identity of a conserved negatively charged group 
on the surface 
 
36 
G130V 
Steric stain by replacing a glycine which is in a conformation 
that is not allowed for other residues 
 
63 
W155R 
Replacement of a bulky highly conserved aromatic side 
chain with a positively charged residue 
 
66 
R165C 
Replacement of a conserved positively charged group with 
as exposed cysteine that might form intermolecular 
disulphide bound 
 
37 
 
1.11 Molecular Mechanisms of GAA Repeat Expansions 
The exact mechanism through which the GAA repeat mutation inhibits frataxin 
expression is still unknown. However, several combined mechanisms have been 
identified to be involved in the establishment of epigenetic changes in FRDA. GAA 
repeats have been shown to form hairpins; these non-B DNA structures may induce 
DNA methylation. On the other hand, small double-stranded RNA (dsRNA) has also 
been reported to induce transcriptional gene silencing through DNA methylation. 
Therefore, better understanding of the mechanisms involved in GAA-induced inhibition 
of FXN gene transcription associated with FRDA can lead to the development of several 
novel for therapeutic approaches [67]. 
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    1.11.1 Hairpin Formation in FRDA Triplet Repeat Expansion 
Triplet repeat (TR) tracts occur throughout the human genome [68]. Expansions of these 
tracts during their transmission from parent to child are closely associated with more 
than 14 hereditary neuromuscular diseases [69, 70]. TRs associated with FRDA include 
GAA/TTC repeats. The expansions produce an identical sequence to that of the repeat 
tract, varying from a few triplets in a coding region of the gene (type I) to hundreds of 
triplets in a noncoding region of the gene (type II). Repeat instability is dependent on 
the length of the repeat tract and its orientation in the genome. Consequently, long tracts 
of TRs are highly unstable, making them more susceptible to changes in the repeat size 
either through expansion or deletion. These instabilities are presumed to be due to the 
formation of unusual secondary structures such as hairpins, Fig. 1.6. TR expansion is 
predicted to occur as a result of DNA slippage of the Okazaki fragment and TR 
contraction by replication across hairpins formed in the template strand, occurring 
during DNA lagging strand replication of the TR tract [71-73]. The discontinuous 
nature of lagging strand replication, the presence of single-stranded regions (ssDNA) in 
the template and free 5´-ends in the growing strand (Okazaki fragment), presents the 
opportunity for the formation of hairpins [74-76]. 
 
CAG, CTG, GCC and GGC TR tracts synthesised in vitro were shown to form hairpin 
and hairpin-related tetraplex secondary structures through self-annealing [78-81]. 
Lagging strand replication model in bacteria and yeast demonstrated both contractions 
and expansions produced by hairpins during lagging strand replication of TR tracts [72, 
73, 76, 82]. Although the single-stranded expansion products are a great potential target 
for DNA repair, secondary structure formation is believed to protect the expansion from 
 
Fig. 1.6 Schematic representation of hairpin formation in FRDA patient DNA. After 
two rounds of replication, formation of a repetitive hairpin on the nascent strand results 
in repeat expansions (left panel), whereas the presence of the same structure on the 
template strand results in repeat contractions (right panel) [77]. 
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DNA repair activities of the cell, including mismatch repair and flap endonuclease [83-
89]. Synthetic GAA and TTC single-stranded DNAs do not easily self-anneal and 
secondary structures adopted by these oligonucleotides are much less stable than the 
structures formed by single-stranded CAG, CTG, GCC and GGC TRs [78-81, 90-92]. 
The differences in repair presumably are caused by the different abilities of the repeat 
tracts to self-anneal to form hairpins [88]. 
 
Intermediate structures are perceived to be involved in FRDA TR expansions through 
pausing DNA replication and inducing DNA slippage within the repeat tracts. Such 
structures are commonly referred to as sticky DNAs, formed by triplex (purine-purine-
pyrimidine and pyrimidine-purine-pyrimidine) and duplex structures of GAA and TTC 
TR tracts combination [91, 93-96].  
 
    1.11.2 Gene Silencing 
The second characteristic of expanded GAA repeats is heterochromatin formation and 
subsequent gene silencing. Festenstein et al. generated artificial transgenes with a 
heterochromatin-sensitive lymphoid cell-surface marker protein (CD2) in order to 
investigate whether CTG repeats found in myotonic dystrophy or GAA repeats in 
FRDA could silence genes by inducing heterochromatin [97]. This study observed that 
both expanded GAA and CTG repeats could exert position effect variegation (PEV) on 
the CD2 reporter gene expression. PEV occurs when a gene is located within or near 
regions of heterochromatin and results in silencing of the affected gene in a subset of 
cells. Heterochromatin is controlled by the presence of particular types of histone 
modifications (for example, H3K9 methylation), the absence of acetylated histones, and 
the presence of HDACs, DNA methyltransferases, chromodomain proteins (such as 
members of the HP-1 family of repressors) and polycomb group proteins. It has been 
suggested that molecules that reverse FXN gene silencing could relieve the deficiency in 
FXN mRNA and protein in affected individuals [98]. 
 
Production of heterochromatin through triplet repeat expansions can be described by 
different models, Fig. 1.7. Triplet repeats form non-B DNA structures and sticky DNA 
at the FXN locus that may result in stalling of the RNA polymerase (RNAPol). In this 
case cellular checkpoint mechanisms could trigger heterochromatin formation, leading 
to inactivation of the locus. In addition to triplexes, there is also evidence to suggest that 
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R-loop (RNA•DNA hybrid) formation during transcription is intrinsic to long GAA-
TTC repeats [99] in which the nascent transcript forms a duplex with the transcriptional 
template strand. R-loops can result in double-strand breaks (DSBs) and recombination 
via transcription associated recombination. Several factors may contribute to R-loop 
formation, such as defective biogenesis of messenger ribonucleoprotein (mRNP) 
particles, deficiency of proteins responsible for splicing and/or nuclear export of 
transcripts, and sequence composition of the non-template strand [99]. In addition, 
bidirectional transcription has also been shown to contribute to the formation of R-
loops, Fig. 1.7. The newly formed R-loops are presumed to contribute to trinucleotide 
 
Fig. 1.7 Triplet repeat induced heterochromatin formation in FRDA. A) In healthy 
individuals, intron 1 of the frataxin gene contains only a small number of GAA repeats. 
The frataxin gene is transcribed and CTCF binding in exon 1 may be an important 
regulatory element for this locus. In FRDA patient cells, expanded GAA repeats lead to 
formation of a heterochromatic domain, coinciding with loss of CTCF binding and 
silencing of frataxin expression. Interestingly, repression of frataxin correlates with 
upregulation of the FAST-1 antisense transcript, which may originate from the AluSP 
sequence in intron 1. B) Models for initiation of heterochromatin through triplet repeat 
expansions. 1) Triplet repeats form unusual DNA structures that may result in stalling 
of the RNA polymerase (RNAPol). This could trigger a damage signal leading to 
inactivation of the locus. 2) Bidirectional transcription across the frataxin locus may 
produce double stranded RNA, triggering siRNA-mediated heterochromatin formation. 
In addition, R-loops, RNA•DNA hybrids, can arise from bidirectional transcription 
through the trinucleotide repeat. 3) Transcripts containing large GAA triplet repeats 
form hairpin structures that can be cleaved by dicer. It is currently unclear if the 
cleavage products function as siRNAs [100]. 
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repeat instability by aberrant processing via transcription-coupled nucleotide excision 
repair factors [101, 102]. Another model for induction of heterochromatin at 
trinucleotide repeat loci is antisense transcription across the FXN locus which generates 
double stranded RNA, triggering siRNA-mediated heterochromatin formation, Fig. 1.7. 
Thus, production of the FAST-1 transcript could be crucial for the silencing mechanism 
in FRDA. A major regulator for antisense transcript production might be CTCF. In 
FRDA patients, loss of CTCF binding correlates with accumulation of FAST-1 
transcripts, which may originate from the AluSP sequence in intron 1. In a third model, 
transcripts containing expansions of CAG or CUG repeats, as found in fragile X 
syndrome (FXS) and DM1, are capable of forming hairpin structures that can be cleaved 
by dicer, Fig. 1.7. The cleavage products of CNG hairpins, or for FRDA GAA hairpins, 
might resemble siRNAs that potentially trigger heterochromatin formation using a 
similar mechanism [100]. 
 
1.12 Instability of the Expanded GAA Triplet Repeats  
The GAA repeat sequence is unstable when transmitted from parent to child. Instability 
during patent-offspring transmission can also be indirectly demonstrated by the 
detection of two distinct alleles in affected children of consanguineous parents, who are 
expected to be homozygous by descent at the FRDA locus. Both expansions and 
contractions of expanded GAA repeats can be observed in FRDA. Fully expanded 
alleles most often contract during paternal transmission, but further expansion or 
contraction of the pathological GAA repeat can be detected equally during maternal 
transmission. The unstable dynamics of FRDA GAA repeats resembles that of other 
diseases associated with very large expansions in noncoding regions, such as fragile X 
syndrome and myotonic dystrophy, however smaller expansions of CAG repeats in 
coding regions, found in dominant ataxias or Huntington’s disease, show size increases 
during paternal transmission [103]. 
 
In addition to the GAA repeat size, FRDA disease phenotypic variation can also be 
explained by other factors such as somatic mosaicism of the GAA repeat expansion, 
gene modifiers and epigenetic effects. Small-pool PCR analysis of central nervous 
system (CNS) tissues derived from autopsies of patients with FRDA revealed the 
somatic instability of the GAA repeat [38]. Various regions of the CNS demonstrated a 
similar mixture of GAA alleles, with the largest GAA repeats detected in the cerebellar 
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cortex of FRDA patients. However there was no overall relation between GAA repeat 
size and FRDA regions of pathology. In lymphoblastoid cell lines and blood samples 
from FRDA patients, a slight expansion bias and an instability threshold of 44 repeats 
were detected in alleles with <500 triplets and conversely a significant contraction bias 
in alleles with >500 triplets including complete reversion to normal length [104, 105]. 
 
Pook et al. created a transgenic mouse model with a yeast artificial chromosome (YAC) 
carrying the entire human FXN locus containing a 190-GAA repeat in intron 1 to 
investigate the pathogenic GAA repeat associated with FRDA. They generated two 
lines of human FRDA YAC GAA transgenic mice, designated YG8 and YG22, 
containing double motif of 190 and 90 GAA repeats and a single 190-GAA repeat 
sequence respectively. Both lines of transgenic mice exhibited intergenerational and 
somatic GAA repeat instability, with no significant differences in overall instability 
between the two lines, Fig. 1.8 [103]. Miranda et al. created another transgenic knock-in 
mouse model carrying a (GAA)230 insert at the Frda locus which showed neither 
intergenerational nor somatic instability of a 230-GAA repeat sequence [106].  
 
Studies of bacteria, yeast and mammalian cells indicated that both cis and trans-acting 
factors regulate the trinucleotide repeat sequences stability, including the position and 
 
Fig. 1.8 Intergenerational GAA repeat instability in FRDA YAC transgenic mice. A) 
Ethidium bromide-stained agarose gel and B) Southern blot autoradiograph of GAA 
PCR products from representative YG22 and YG8 transgenic mice [103]. 
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orientation of the repeats relative to the replication origins [41, 107, 108]. These studies 
suggested that the presence of replication-associated motifs and chromatin environment 
may be involved in instability mechanisms [109, 110].  
 
To investigate whether somatic instability in FRDA is age dependent, Pook et al. 
compared the levels of somatic instability in tissues derived from young (2 months old; 
2400 individual molecules) and old (12 months old; 2000 individual molecules) YG8 
transgenic mice. The results showed less that 1% of somatic instability in the (GAA)190 
allele through 2 months of age whereas older mice showed a significant increase in 
mutation load due to the accumulation of expansions. The lower level of somatic 
mutations in blood and sperm compared to non-proliferative tissues such as cerebellum 
and DRG implies the role of cell type-specific trans-acting factors that modify specific 
triplet-repeat sequences [103]. 
 
1.13 Experimental Therapeutics for FRDA 
Although there is no effective therapy for FRDA, some experimental therapeutic 
approaches such as antioxidant therapy are currently being exercised in clinical trials to 
increase frataxin expression. Considering the potential for the formation of free radicals 
and oxidative damage when frataxin levels are reduced, antioxidants including 
parabenzoquinones are being investigated as a potential FRDA therapy. Two such 
compounds are coenzyme Q10 (CoQ10) and idebenone, a short-chain parabenzoquinone 
analogue of CoQ10 [111-114].  FRDA patients who were given CoQ10 in addition to 
vitamin E, an antioxidant compound, exhibited significant improvement of ATP 
production in cardiac and skeletal muscle after several months of treatment [115]. In 
addition, idebenone, a potential therapeutic agent to reduce oxidative stress and free 
radicals, has currently finished being tested in two phase III clinical trials in patients 
with FRDA. Rustin et al. reported on the effectiveness of idebenone in reducing 
hypertrophic cardiomyopathy in FRDA [116]. However, none of the pharmacological 
drugs tested had a significant beneficial effect on the neurological symptoms in FRDA 
patients [117]. Nevertheless, several clinical trials are currently being carried out to 
assess the effectiveness of promising antioxidant molecules. EPI-A0001 is a CoQ10 
analogue which has completed phase II clinical trials. The results have shown 
improvements in neurological function in FRDA patients [118]. The EPI-743 (alpha-
tocotrienol quinone) is a new drug based on vitamin E which targets improvement of 
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mitochondrial function and modifies disease progression in patients with inherited 
mitochondrial respiratory chain disorders [119]. This drug is currently being tested on 
FRDA patients in phase II clinical trial. OX1 (indole-3-propionic acid) is a natural 
compound that prevents oxidative stress through a combination of hydroxyl radical 
scavenging activity and metal chelation, currently in preclinical phase for toxicological 
safety. 
 
Other therapeutic trials at the protein level include iron chelators such as 
desferrioxamine [120] and exogenous heme administration [121], which reduce 
intracellular iron. Interestingly, erythropoietin, a known stimulant of heme synthesis, 
can rescue defects in frataxin-deficient cells, but the mechanism(s) by which it increases 
frataxin levels is unknown [122]. Deferiprone, an oral chelating agent, has been 
established to be more effective than desferrioxamine in treating iron overlap in FRDA 
patients. However significant reduction in aconitase activity has been identified as the 
primary side effect of these drugs [123, 124]. Therefore, care should be taken when 
using iron chelators as a therapeutic agent. 
 
Considering that the mutation leaves the coding region intact, gene-based strategies 
designed to increase the frataxin level would be an ideal therapy for FRDA, Fig. 1.9. 
Gene therapy is a viable option for FRDA and other recessive disorders. Recombinant 
adeno-associated viral and lentiviral vectors expressing frataxin cDNA have been 
revealed to partially correct sensitivity to oxidative stress in FRDA primary fibroblasts 
[125]. 
 
Grabczyk and Usdin conducted in vitro studies using T7 RNA polymerase to investigate 
the mechanisms by which expanded GAA repeats reduce FRDA gene transcription 
[126]. Their results provided additional confirmation for a model in which RNA 
polymerase was trapped in an R•R•Y intramolecular triplex. They further demonstrated 
that oligodeoxyribonucleotides specifically designed to block triplex structures were 
capable of increasing transcription through the GAA repeats [127]. This was the first 
proof of concept for the development of therapeutic agents in FRDA that targeted 
triplex formation. Numerous other studies have demonstrated that DNA-binding 
compounds, such as pyrrole-imidazole polyamides or pentamidine, are effective at 
increasing frataxin transcription in primary FRDA lymphocytes [128, 129]. 
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As stated before in section 1.11.2, the second characteristic of expanded GAA repeats 
that results in decreased frataxin is heterochromatin formation, or gene silencing, Fig. 
1.10. A promising therapeutic strategy is to directly target the heterochromatin state of 
the GAA repeat expansion with histone deacetylase inhibitors (HDACi) to restore 
frataxin levels [96]. HDACi prevents the deacetylation of histones and may revert silent 
heterochromatin to an active conformation that is conducive for gene expression [130]. 
 
FRDA cells treated with the highly active HDACi compound 4b [N1-(2-aminophenyl)-
N7- phenylheptanediamide] resulted in a significant increase in frataxin, accompanied 
by increased histone H3 acetylation near the GAA repeat [132]. This result is consistent 
 
Fig. 1.9 Pathological mechanisms involved in FRDA and associated therapeutic 
strategy. FRDA is caused by a GAA expansion mutation within the first intron of 
frataxin gene. The mutation, through either a triplex-helix or a heterochromatin 
formation, impairs transcription and causes a severe decrease of frataxin mRNA 
expression and protein level. Physiological consequences of frataxin deficiency are 
specific ISC enzyme deficits, an intramitochondrial iron accumulation and a higher 
sensitivity to oxidative stress. In the left panel, the different therapeutic strategies 
currently under investigation to counteract defects observed in patients and to develop 
future treatments are presented. rhuEPO, recombinant human erythropoietin; PPAR, 
peroxisome proliferator-activated receptor; HDAC, histone deacetylase; PIH, pyridoxal 
isonicotinoyl hydrazone; DFO, desferrioxamine; VitE, vitamin E; CoQ10, coenzyme Q10 
[95]. 
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with GAA knock-in mice treated with a novel HDACi compound 106 [N1-(2-
aminophenyl)-N7-p-tolylheptanediamide] [52]. Recent  studies  suggested the potential  
therapeutic effects of class III HDACi compounds such as sirtinol, splitomicin and 
nicotinamide (vitamin B3) in the treatment of trinucleotide repeat disorders [133-135]. 
Festenstein et al. have shown that nicotinamide, a class III HDACi, can reverse the 
downregulation of FXN in different FRDA models [135]. In addition to the 
aforementioned molecules which directly target the GAA repeat, a number of other 
molecules have also been reported to increase frataxin mRNA or protein levels whereby 
recombinant human erythropoietin (rhuEPO) has been established to increase frataxin 
protein in lymphocytes from FRDA patients [121].  
 
Since there are many similarities between FRDA and fragile X syndrome (both contain 
non-translated repeats that induce CpG hypermethylation and histone deacetylation), a 
common therapeutic procedure can be designed and implemented for both cases. Fragile 
X lymphoblasts treatment with 5´-azadeoxycytidine, a DNA-demethylating agent, has 
been reported to increase FMR1 message and protein level [136]. Although 5´-
azadeoxycytidine is not clinically suitable due to toxicity effects, it can be used in 
combination with other drugs such as HDAC inhibitors in FRDA treatment [136]. 
 
Fig. 1.10 A model for heterochromatin formation in FRDA. Normal FRDA alleles 
contain open chromatin with acetylated histones (Ac, green). Non B-DNA structures, as 
a consequence of expanded GAA repeats, may induce histone deacetylase (HDAC) 
activity that, along with histone methyltransferases (HMTase), generate methylated 
histones (Me, red). The methylation of lysine 9 on histone H3 is a hallmark of 
heterochromatin and has been found in FRDA patient cells. Further chromatin 
compaction may be aided by the binding of HP1 and increased DNA methylation. 
Agents designed to increase histone acetyltransferase (HAT) activity or inhibit HDAC 
activity would be expected to increase frataxin levels. Indeed, some HDAC inhibitors 
have been found to increase frataxin expression [131]. 
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Furthermore, HDAC inhibitors have been shown to marginally increase message levels 
in fragile X lymphoblasts [136]. Herman et al. tested several different classes of HDAC 
inhibitors on an FRDA lymphoblastoid cell line to examine the effect of such inhibitors 
on the level of frataxin in FRDA. However, BML-210 was reported as the only inhibitor 
which resulted in a significant increase in frataxin message levels, Fig. 1.11 [132].  
 
1.14 Mouse Models for FRDA 
To further investigate the FRDA mechanism and to validate the potential FRDA 
therapeutics procedures, several mouse models have been generated [31, 106].  
 
    1.14.1 Knock-out Models 
Cossee et al. generated Frda knockout mice by targeting exon 4 of Fxn that appeared 
normal as heterozygotes, but homozygous deletion of Fxn caused embryonic lethality a 
few days after implantation, demonstrating a crucial role for frataxin during early 
 
Fig. 1.11 Gene-based strategy to obtain FRDA therapeutics. In FRDA, non B-form 
DNA structures and heterochromatin both contribute to reduce FRDA transcription and 
result in pathogenically low levels of frataxin. The mechanism by which this takes place 
is unknown (??). An ideal gene-based treatment would overcome both obstacles (non B-
form DNA and heterochromatin) to increase frataxin production. Such a therapy might 
include specific DNA-binding compounds that stabilise B form DNA and HDAC 
inhibitors that facilitate chromatin decondensation [137]. 
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embryonic development. This result suggested that the milder phenotype in human is 
due to residual frataxin expression associated with the expansion mutations [138]. 
 
Puccio et al. generated two different conditional knockout models in which Fxn was 
deleted, specifically in skeletal and cardiac muscle. Both models were viable and 
reproduced some morphological and biochemical features of FRDA, providing an 
important resource for pathophysiological studies and testing of new treatments [139]. 
 
    1.14.2 Knock-in Model  
To develop systems for studying both germ-line and somatic repeat instability in 
trinucleotide- repeat disorders, a GAA-repeat-based mouse model of FRDA would be of 
great value [140-146]. However, instability is only apparent when the repeat sequence is 
introduced within the appropriate genomic context, such as a large human genomic 
transgene or knock-in at the endogenous mouse locus [109, 141-143, 147, 148]. Since 
FRDA is caused by an unstable GAA repeat sequence and the Fxn intron 1 region of the 
mouse does not normally contain a GAA repeat sequence, insertion of GAA repeats into 
the Fxn intron 1 region of mice would be an effective way to study the dynamics of 
trinucleotide repeats and their relation to the disease.  Miranda et al. inserted a (GAA)230 
repeat into the appropriate site of Fxn intron 1, the results showed decreased frataxin 
production. However no motor coordination abnormality, iron metabolism, response to 
iron binding, or death due to frataxin reduction was observed [106]. 
 
    1.14.3 FXN YAC Transgenic Mouse Models 
The mouse model developed by Pook et al. provided an essential resource to assess 
potential FRDA therapies that target the mutated, GAA expanded, FXN gene [149]. In 
an initial effort to assess whether human frataxin could function in a mouse background 
and substitute for loss of endogenous murine frataxin, they generated a human wild-type 
FRDA yeast artificial chromosome (YAC) transgenic mouse line, Fig. 1.12, and 
crossbred this with heterozygous Fxn exon 4 deletion knockout mice [149]. They 
obtained phenotypically normal homozygous Fxn knockout offspring that expressed 
only human frataxin in the appropriate tissue and corrected mitochondrial subcellular 
localisation. This result confirmed that 370-kb FXN YAC transgenic construct, 37FA12, 
was functional and could express frataxin during development [149]. Additionally, the 
generation of rescued mice through re-introduction of human frataxin into a mouse null 
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background would be an effective method for future gene therapy studies to correct the 
defect in FRDA patients [138, 149]. 
 
They finally proceeded to generate two lines of human FRDA YAC transgenic mice, 
 
Fig. 1.12 Characterisation of YAC 37FA12 and the Y47 transgenic line. The position of 
YAC 37FA12 with respect to the FRDA locus at 9q13. Genes are represented as solid 
arrows, which indicate the direction of transcription; and the broken lines represent 
incomplete gene sequence. Individual exons are numbered and are shown below the 
relevant gene. STS markers used in the analysis are shown as downward pointing 
arrows [149].  
 
Fig. 1.13 GAA repeat modification of YAC 37FA12. The position and orientation of 
the normal FRDA gene (9 GAA repeats) within the human YAC clone 37FA12 are 
indicated by the arrow. L and R indicate left and right arms of the YAC. A 700-GAA 
PCR product was amplified from FRDA patient DNA using primers S2F and S3R. The 
PCR product was first cloned into pCR2.1 (not shown) and then into YEp24, which 
contains a selectable URA3 gene, with resultant contraction to 230 GAA repeats. Pop-
in/pop-out homologous recombination between Yep24 and YAC 37FA12 FRDA 
sequences produced the 190-GAArepeat YAC clone 1(38), which was subsequently 
used to generate transgenic mice [103].  
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designated as YG8 and YG22 by using a yeast pop-in/pop-out homologous 
recombination strategy, Fig. 1.13 [103, 150].  
 
Both lines of transgenic YAC mice contained transgene sequences spanning the whole 
370-kb human YAC clone, including the left and right arms of the YAC and the entire 
FRDA gene together with GAA repeat expansions. YG8 contained two GAA sequences 
of 90 and 190 repeats, while YG22 contained a single 190 GAA repeat sequence [103]. 
FRDA transgenic mice showed age-related somatic instability in the GAA repeat 
sequence, particularly in the cerebellum, in a manner resembling the human FRDA 
condition [103]. Therefore, these mice will be useful for further detailed studies of 
FRDA GAA-repeat mechanisms. 
 
1.15 Decreased Frataxin mRNA and Protein Expression in FXN YAC Mouse 
Models 
Pook et al. investigated the viability of each GAA FXN transgene by crossbreeding both 
 
Fig. 1.14 mRNA expression analysis. A) A representative RT-PCR image showing 
restriction-digested human frataxin products (112 and 29 bp) and mouse frataxin 
products (75 and 64 bp), together with mouse Hprt controls. mRNA samples were 
isolated from tissues of wild-type, YG22 rescue, YG8 rescue, YG22 transgenic, and 
YG8 transgenic mice (lanes 1, cerebrum; 2, brain stem; 3, cerebellum; 4, heart; 5, 
skeletal muscle). B) Levels of frataxin mRNA expression as a percentage value of wild-
type mouse expression. Values were generated by determining the means of six 
different RT-PCR experiments, each normalized to Hprt. Error bars indicate SEM. 
*
p<0.05, 
**
p<0.01 [31]. 
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the YG22 or YG8 mice (FXN+, Fxn+/+) with heterozygous Fxn knockout mice 
(Fxn+/−) and further breeding the FXN+, Fxn+/− offspring from these crosses with 
Fxn+/−. The resultant rescue mice from both lines showed a normal life span up to at 
least 2 years of age, indicating functional frataxin derived from both GAA repeat-
containing transgenes. To determine the levels of frataxin mRNA expression in YG22 
and YG8 rescue and transgenic mice, semiquantitative RT-PCR was performed using 
primers that were capable of recognising both human and mouse frataxin cDNA. The 
results confirmed the presence of human-only frataxin mRNA transcripts in both YG22 
and YG8 rescue mice, Fig. 1.14A. In addition, both YG8 and YG22 rescue mice 
exhibited comparatively decreased levels of human frataxin mRNA in all tissues (most 
in the cerebellum of both YG22 (62%) and YG8 (57%), together with the skeletal 
muscle of YG8 rescues (57%)) in comparison to endogenous mouse levels, Fig. 1.14B 
[31]. 
 
1.16 Histopathology 
The differentially reduced levels of frataxin in the FXN YAC GAA mouse models are 
sufficient to cause a FRDA-like pathological phenotype. To detect possible neuronal 
abnormalities in these mouse models, neuronal histopathology studies were performed 
by hematoxylin-and-eosin staining and anti-calbindin immunohistology in brain, spinal 
cord and DRG of YG8 and YG22 mouse models. The results revealed prominent giant 
vacuoles in the large sensory neuronal cell bodies of the DRG in both YG8 and YG22 
A B 
 
Fig. 1.15 Neuronal and cardiac histopathology. A) H&E-stained section of lumbar DRG 
from a representative YG22 rescue mouse over 1 year of age, showing two neurons 
containing large vacuoles. Original magnification 400×. B) Perl’s staining of a heart 
section from a representative YG22 rescue mouse over 1 year of age, showing 
characteristic blue staining indicating iron deposition. Original magnification 600× [31]. 
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rescue mice while such a pathological change was not observed in wild type controls, 
Fig. 1.15A. The occurrence of DRG vacuoles showed a progressive position dependent 
profile from affected distal lumbar regions at only 6 months of age to more proximal 
cervical regions at 13-15 months. This profile resembles the distal-to-proximal “dying-
back” phenomenon of neurodegeneration that is observed in FRDA patients [31].  
 
To determine potential hypertrophic cardiomyopathy, histopathology analysis of heart 
was performed by H&E, trichrome Masson and Perl’s staining in YG8 and YG22 
rescue mice. The results showed iron deposition in cardiomyocytes after 1 year of age, 
Fig. 1.15B. These were the first GAA repeat expansion-based FRDA mouse models that 
exhibited progressive FRDA-like pathology [31]. 
 
1.17 GAA Repeat Expansion Induces Epigenetic Changes in FRDA 
Previous studies have implicated that the mutation may induce epigenetic changes and 
heterochromatin formation, thereby hampering gene transcription. In support of this 
hypothesis, studies using FRDA patient blood and lymphoblastoid cell lines have shown 
 
Fig. 1.16 Analysis of histone modifications in human brain tissue. ChIP quantitative 
PCR results for the FXN promoter/exon1 (Pro), upstream GAA (Up) and downstream 
GAA (Down) amplified regions are represented as the relative amount of 
immunoprecipitated DNA compared with input DNA, having taken negligible 2Ab 
control values into account. FXN values were normalized with human GAPDH and all 
values have been adjusted so that all of the Upstream GAA mean values from the 
unaffected individuals are 100%. In each case two individual ChIP samples from two 
FRDA patients and two unaffected controls were analysed in triplicate. The means and 
SEMs of these values are shown [67]. 
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increased DNA methylation of specific CpG sites upstream of the expanded GAA 
repeat sequence and histone modifications in regions flanking the GAA repeat that are 
both consistent with transcription inhibition, Fig. 1.16.  
 
These changes include deacetylation of histone H3 and H4 lysine residues and increased 
dimethylation and trimethylation of H3K9. Bisulfite sequencing and chromatin 
immunoprecipitation (ChIP) analysis of the FXN flanking GAA regions have confirmed 
the DNA methylation changes with hypermethylation in the upstream GAA region and 
hypomethylation in the downstream GAA region [67]. 
 
In order to determine whether such epigenetic changes are actually present in the most 
clinically relevant FRDA tissues, chromatin immunoprecipitation analysis indicated an 
overall decreased histone H3K9 acetylation together with increased H3K9 methylation 
of FRDA brain tissue. Further studies of brain, cerebellum and heart tissues from GAA 
repeat expansion-containing FRDA YAC transgenic mice (YG8, Y47 and YG22) 
exhibited comparable epigenetic changes to those detected in FRDA patient tissue. 
Therefore, these are excellent FRDA mouse models for the investigation of the 
therapeutic studies targeting epigenetic modifications of the FXN gene to increase 
frataxin expression [67]. 
 
1.18 Overview of Telomeres 
The genome is susceptible to double-strand breaks (DSBs) through exposure to several 
factors including reactive oxygen species (ROS) and ionizing radiation (IR). However, 
DSBs can also be artificially created during antibody production and meiosis. It is 
important to note that unrepaired DSBs are highly detrimental to cell function [151]. 
 
Natural chromosomes contain telomeres at their physical ends which resemble DSBs, 
yet telomeres are immune from inappropriate engagement into repair reactions, Fig. 
1.17 [151]. This is mainly attributed to the formation of a higher order structure which 
circumvents DNA damage surveillance mechanisms. However, telomeres are 
established as one of the major sites affected through the process of DNA damage 
provided that their respective higher order structure is altered [152]. Consequently, 
dysfunctional telomeres are incorporated into end-to-end chromosome fusions resulting 
in genome instability. Several telomere binding and DNA damage proteins are involved 
in the protective structure and maintenance of telomeres, however, the function of these 
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proteins is yet to be fully established. Consequently, investigation of the dynamic 
interaction between telomeres, telomere binding proteins and proteins of the DNA 
damage response (DDR) is a major focus of the telomere field and cancer research 
[151].  
 
1.19 The End Replication Problem 
Telomeres form a protective nucleoprotein cap at the end of the chromosome to protect 
the chromosome terminus from numerous deleterious activities such as degradation by 
nucleases, recognition as a DNA break by DNA damage repair machinery, and 
inappropriate recombination. While the new DNA is synthesised in the 5´ to 3´ 
direction, the 3´ to 5´ leading strand is copied to completion in the forward direction, 
Fig. 1.18A. However, the 5´ to 3´ lagging strand is synthesised in fragments utilising an 
RNA primer at the 3´ end of the lagging strand to assist DNA synthesis in fragments in 
the 5´ to 3´ direction, Fig. 1.18B.  Once the DNA fragments of the lagging strand are 
synthesised, they are joined by DNA polymerase I and ligase to construct single 
continuous strand of DNA, Fig. 1.18C. The final segment of 5´ to 3´ DNA (where the 
RNA primer was bound) is not completely replicated and a 3´ single strand overhang is 
formed, Fig. 1.18D. The process of terminal chromosomal lost in DNA replication is 
termed “the end-replication problem” [153, 154]. 
 
1.20 Telomere Structure and Function 
To prevent DNA sequences from continual erosion at their physical ends due to end-
replication problem, chromosomes are capped by telomeres which consist of hexameric 
sequences of repeated nucleotides [155]. Telomeres can be defined as discrete, tandem 
 
Fig. 1.17 DNA repair model. A double-strand break (denoted by radiating lines) is 
recruited into an end-joining reaction whereas a telomere (blue wavy lines) is stable and 
refractory to be detected as DNA damage. Black lines designate non-telomeric sequence 
[151]. 
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arrays of simple DNA repeats that contain the ends of linear chromosomes, capable of 
providing chromosome end protection through circumventing the end-replication 
problem. Telomere erosion occurs during each round of DNA replication due to the end 
replication problem; however it can also be accelerated by exposure to oxidative stress 
[156]. Telomeres initiate replicative senescence once they reach a critical length due to 
shortening. 
 
    1.20.1 Structure of Telomeres 
Both the sequence and length of telomeres vary between species. Telomeric DNA is 
composed of tandem arrays of short, G-rich repeats. In humans, the repeat is TTAGGG 
and in most plants is TTTAGGGG [157].  Although the number of telomere repeats is 
variable, a telomere requires a certain minimum number of repeats to be functional.  
Human telomeres range from 10 to 15kb whereas the telomeres of the mouse, Mus 
musculus, are typically longer than 25kb [158, 159]. 
 
 
Fig. 1.18 The end replication problem. A) New DNA is synthesised in the 5´ to 3´ 
direction, the 3´ to 5´ leading strand is copied to completion during the replication. B) 
The 5´ to 3´ lagging strand is synthesised in segments in the 5´ to 3´ direction utilising 
an RNA primer. C) The fragments are then joined by DNA polymerase I and DNA 
ligase to form a constant strand of DNA. D) The ending portion of the lagging strand, 
where the RNA primer binds, remains unreplicated, and a 3´ single strand overhang is 
formed [154]. 
31 
 
    1.20.2 G-overhangs 
The common and essential feature of all telomeres is the existence of a G-rich strand 
running in the 5´ to 3´ direction relative to the terminus in a short single-stranded (ss) 3´ 
overhang. This guanine-rich strand is longer than the complementary c-rich strand, 
forming a 3´ single strand protrusion known as the G-overhang. The first evidence for 
the presence of G-overhangs originated from the ciliates Oxytricha nova and Euplotes 
crassus in which the overhang was only 14 nucleotide (nt) long [160]. Subsequently, ss 
TG1-3 tails were found in Saccharomyces cerevisiae by non-denaturing Southern 
blotting [161]. In plants, at least half of the telomeric ends possess the overhang, 
approximately 20-30 nt long [162]. G-overhangs have also been detected in humans, 
approximately 150 nt long [163]. 
 
The length of G-overhang varies among different species; however it is proportional to 
the length of bulk telomere tracts. Longer G-overhangs are detected in organisms 
sheltering longer telomere tracts. For instance, in vertebrates the G-overhang is 
approximately 250 nt long [163], while in Tetrahymena G-overhangs are only14-21 nt 
long [162]. 
 
The exact mechanism of G-overhang generation is yet to be discovered.  G-overhangs 
are naturally produced during the lagging strand synthesis, when the most 3´ RNA 
primer is removed as depicted in Fig. 1.19. Although, the G-overhang provides a 
substrate for telomerase elongation and the leading strand replication mechanism 
produces a blunt end DNA product, Fig. 1.19, G-overhangs are present on both 
chromosome ends due to the replication of either the leading or lagging strand 
mechanisms. Therefore, an alternative mechanism for G-overhang generation must be 
present to construct a symmetrical terminus [163, 164]. The presence of asymmetric G-
overhangs in mammalian cells indicates that G-overhangs on the leading and lagging 
strands are generated by different mechanisms. It is presumed that G-overhangs are 
formed through a combination of telomerase action and nucleolytic resection of the C-
strand, Fig. 1.19 [165]. Moreover, it has been reported that the absence of Mre11, a 
nuclease involved in telomere length maintenance and DNA double-strand break repair, 
results in G-overhang signal reduction [165] and telomere dysfunction due to improper 
telomere function. The G-overhang is an essential structural and functional feature of 
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the chromosome which protects telomeres from end-to-end chromosome fusions during 
telomere replication in vivo [165]. 
 
    1.20.3 T-loop 
Jack Griffith detected lariat-like molecules in enriched telomeric restriction fragments in 
vitro by electron microscopy of Psoralen/UV cross-linked DNA [167]. G-overhangs are 
involved in the formation of the protective structure known as the t-loop, in which they 
fold back and invade the duplex telomeric repeats, creating a displacement loop (D-
 
Fig. 1.19 Telomere replication. The G-rich and C-rich strands are produced by the 
leading and lagging strand synthesis respectively. The newly replicated strands are 
represented in black while the last RNA primer is illustrated in purple. Removal of the 
last RNA primer leads to the generation of G-overhang on the 3´ end of the lagging 
strand. Nuclease digestion of the 5´ to 3´ C-strand is presumed to occur on telomeres 
replicated by the leading strand synthesis to create a G-overhang. Telomerase extends 
the 3´ overhang through reverse transcription. The RNA subunit binds the 3´ overhang. 
Telomerase is represented by the pink oval. Newly added telomere repeats are shown in 
red [166]. 
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loop) consisting of ss G-rich repeats. T-loop was found in vitro in many evolutionary 
distant species, including plants and animals [167-169]. However, t-loops have not been 
found in budding yeast even though their telomere repeats are highly irregular. This 
may be due to the limited base-pairing between the G-overhang and a C-rich strand of 
duplex DNA, preventing t-loop formation in S. cerevisiae [170]. Although the exact 
function of the t-loop in vivo is not known, it is presumed to be involved in chromosome 
end protection via sequestering the G-overhang and the telomeres from deleterious 
manners [171]. The t-loop is thought to unfold during the S-phase to make telomeres 
accessible for telomere repeat addition via telomerase as shown in Fig. 1.20.  
 
    1.20.4 Telomere Function 
As previously stated, the higher order structure of telomeres allows them to act as a 
protective measure at chromosome ends. Telomeres circumvent end-to-end 
chromosome fusions, preventing the formation of dicentric chromosomes. Additionally, 
the protective structure of telomeres prevents the loss of genetic information from sub-
telomeric regions which may occur via stochastic processes. Furthermore, telomeres 
have an important role in distinguishing chromosome ends from DNA DSBs and 
preventing DNA damage signalling [172]. 
 
 
Fig. 1.20 Proposed structure for telomeres. The 3´ G-rich telomere overhang invades 
and displaces duplex telomeric DNA, forming a t-loop. During DNA replication and 
telomerase action, the t-loop unfolds during the S phase. 
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Chromosome instability due to end-to-end fusion takes place when telomeres reach a 
critical length and cells bypass replicative apoptosis [173]. The function of enzyme 
telomerase is to add repetitive telomere sequence to chromosome ends in order to 
maintain or elongate the telomeres. Telomere erosion in cells with mutation within 
shelterin protein is abnormally rapid due to unprotected telomeres recruiting DNA 
damage response factors, resulting in either apoptosis or senescence [173]. 
 
1.21 Hayflick’s Limit and Telomere Length 
Hayflick’s limit, discovered by Leonard Hayflick in 1961, is referred to as a clock or 
timing mechanism, representing the replicative limit of normal cells undergoing a 
specific number of population doublings (PD). This is presumably due to the telomeres 
reaching a critical length. This phenomenon can cause cell senescence due to cell 
division blockage when the Hayflick’s limit is reached in telomeres of human cells.  
This mechanism appears to be directly related to ageing, genomic stability and the 
development of cancer [174, 175]. 
 
1.22 Telomere Length Dynamics 
Several studies have reported that telomere length varies in human tissues and between 
individuals. Mean telomere length was found to be similar between different tissues of a 
single foetus, although it significantly varied between individuals [176]. Particularly, 
the telomere length of haematopoietic stem cells (HSC) usually varies between 8.5kb 
and 13kb at birth [177]. The factors that determine the telomere length variations at 
birth are not fully understood, yet it is thought to be genetically determined. For 
instance, the telomere length variability of peripheral blood lymphocytes (PBL) is less 
in monozygotic twins than in dizygotic twins [178, 179]. Consequently, variations in the 
proliferative potential of HSCs of different individuals could be justified by substantial 
variations in the mean telomere length between individuals. 
  
Telomeres are dynamic structures that can shorten or lengthen. A balance between 
telomere shortening and lengthening activities in each cell leads to the formation of 
species-specific length of the telomere tract [180]. Moreover, the rate of telomere loss 
differs among different cell types. For example, the rate of telomere loss in vitro 
cultured endothelial cells is approximately 190bp/PD while it is approximately 50bp/PD 
in fibroblasts [181].  
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Telomere shortening is primarily due to incomplete replication of the DNA ends which 
is attributed to the semiconservative nature of the DNA replication process. The 
shortening process involves the removal of the last RNA primer from the extreme 5´ 
terminus of the daughter strand during the lagging strand synthesis where this single-
stranded region cannot be filled in by the DNA replication mechanism. This DNA 
amplification failure is referred to as the end replication problem [154, 182]. However, 
the shortening process could occur through other active mechanisms including telomere 
rapid deletion (TRD) of exceptionally long telomeres and telomere attrition caused by 
deficiency in key regulators of telomere length [182]. 
 
1.23 Telomere Length Maintenance Mechanisms 
Telomere maintenance mechanism is crucial for immortalisation. However, the majority 
of normal human somatic cells do not employ such a mechanism, with the exception of 
HSCs, Endothelial Progenitor Cells (EPCs) and germ cells [183, 184]. Telomere 
maintenance in human cells may be due to the enzyme telomerase or an alternative 
lengthening of telomeres (ALT) mechanism. In the absence of enzyme telomerase or 
ALT mechanism, telomeres become critically short and may result in DNA degradation, 
telomere fusions, activation of DNA damage pathways and ultimately senescence or cell 
death [184]. 
 
    1.23.1 Telomerase 
As previously stated, telomeres shorten with each cell division due to the end- 
replication problem. Consequently, once telomeres reach a critical length, after a finite 
number of cell division, the protective cap can no longer be produced and chromosome 
ends are recognised as a DSB [152]. Telomere loss can be counteracted by the action of 
a specialised enzyme called telomerase. Telomerase is a ribonucleoprotein reverse 
transcriptase, capable of telomere elongation using the G-overhang as a substrate. The 
human telomerase enzyme consists of three components: the reverse transcriptase 
catalytic unit hTERT, the RNA template hTR or hTERC and the nucleolar 
phosphoprotein dyskerin [185, 186]. 
 
Extension of G-rich telomeric DNA by telomerase involves several steps including 
alignment, nucleotide addition and translocation, Fig. 1.21. The RNA subunit of 
telomerase contains a sequence complementary to the G-rich telomeric repeat. In 
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humans, this sequence is 5´ CUAACCCUAAC 3´, which is employed as a template for 
extending the 3´ G-overhang of the telomere through reverse transcriptase subunit 
(hTERT), Fig. 1.21. Subsequently, endogenous DNA polymerases extend the 5´ lagging 
strand. The human telomerase RNA component (hTR) is constitutively expressed in 
human cells. TERC characteristics at the nucleotide level differ amongst various tissues 
except the template region. Nevertheless, TERCs share a common highly conserved 
secondary structure that comprises of a pseudoknot, template, template boundary 
regions and an H/ACA domain, which is important for pre ribonucleo proteins (RNP) 
formation and nucleolar localisation of the telomerase RNP itself. Dyskerin is necessary 
for the stability of hTR and the entire telomerase complex. Dyskeratosis congenita, a 
pathology which results in bone marrow failure due to progressive telomere shortening, 
occurs as a result of mutation in Dyskerin [187, 188]. 
 
hTERT is the limiting component of telomerase activity, since telomerase activity is 
reconstituted through ectopic expression of hTERT. The TERT subunit of telomerase is 
a reverse transcriptase (RT) that varies in size, ranging from 148 nt in ciliates to 400-
600 nt in vertebrates and to approximately 1300 nt in yeast [189]. The TERT contains 
all seven canonical RT motifs (1, 2, A, B, C, D, E) which are conserved in other RTs. In 
 
Fig. 1.21 The mechanism of telomere extension by human telomerase. A) Alignment. 
Telomerase is orient by Watson-Crick base pairing between the RNA template and the 
3´ terminus of the G-overhang. B) Extension of the G-overhang. Six nucleotides are 
added (shown in red). C) Translocation of telomerase. Once the 5´ boundary in the 
RNA is reached, telomerase translocates so that the RNA template is repositioned for 
the next round of synthesis. Pink oval and curved black lines represent TERT and 
TERC respectively. 
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addition, TERT consists of a large N-terminal extension and a small C-terminal 
extension, both of which are required for telomerase activity. TERT is a unique RT as it 
stably associates with the intrinsic TERC component. Another feature that distinguishes 
TERT from other RTs is the capability to processively add short repeats. There are 
various mechanisms regulating TERT expression and telomerase activity. hTERT is 
presumed to be positively and negatively regulated by phosphorylation and 
ubiquitination respectively. Telomerase expression is repressed by several genes 
implicated in tumorigenesis, including the Menin, Mad/Myc pathway and TGFβ target 
Sip1 [190]. 
 
The telomerase activity in vivo has been extensively investigated using knockout mice 
that did not express either RNA template (mTR or mTERC) or catalytic reverse 
transcriptase subunit (mTERT) [191, 192]. These investigations revealed that mTR and 
mTERT were not essential for survival since the knockout mice were fertile and viable 
for at least four generations. However, these knockout mice showed greater rate of 
telomere shortening with no detectable telomerase activity. Despite the absence of 
telomerase activity, HSCs isolated from the mTR or mTERT knockout mice 
successfully engrafted lethally irradiated mice [193]. Nevertheless, the number of times 
the HSCs derived from the control mice could be serially transplanted was twice that of 
the knockout mice. These findings indicated that telomerase may contribute in limiting 
the telomere shortening during serial transplantation, thus extending the lifespan of 
HSCs.  
 
In humans, telomerase is expressed in actively dividing tissues such as germline and 
cancer cells but not in most somatic cells. Telomerase activity can be accessed in vitro 
using a single-stranded telomeric DNA primer, radio labelled nucleotides and the 
telomere repeat amplification protocol (TRAP) assay. However, the TRAP assay is 
more accurate since it utilises PCR for telomerase detection [194]. Telomerase has a 
general affinity for G-rich oligonucleotide sequences where it preferentially binds to 
telomeric sequence primers over non-telomeric sequences. Nevertheless, many 
telomeric-like sequences can be extended through the enzyme [195].  
 
    1.23.2 ALT Mechanism 
Recent developments in telomerase detection techniques demonstrated that around 10% 
of human tumours and 25% of tumour cell lines did not express telomerase activity 
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[196]. The results indicated that the cells lacking telomerase activity appeared to have 
long, heterogeneous telomeres, ranging in length from 10 to 50kb. Further analysis 
indicated that the telomeres in such cells were maintained through an alternative 
lengthening of telomeres (ALT) mechanism which involves recombination of telomeric 
ends, Fig. 1.22 [196]. However, the exact mechanism involved in such a process is yet 
to be determined. Although the ALT mechanism is commonly associated with tumour 
cells, it may maintain telomeres in normal murine tissues [197]. 
 
There are several unique features that characterise ALT cell lines, including 
heterogeneous telomere length, presence of extra-chromosomal linear and circular 
telomeric DNA (ECTR), high frequency of telomere-sister chromatid exchanges (T-
SCE) and ALT associated promyelocytic leukemia bodies (APBs) [155, 198]. 
 
Telomere length in ALT cells is highly variable. Analysis of ALT cells using terminal 
restriction fragment (TRF), Q-FISH and single telomere length analysis revealed that 
these cells included long and heterogeneous telomeres ranging from 2 to greater than 20 
kb within an individual cell [199-201]. This heterogeneity is generated by a 
combination of gradual telomere attrition and rapid lengthening or shortening events. 
 
Fig. 1.22 ALT mechanism. In the absence of telomerase, telomere elongates via rolling 
circle amplification. 
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The former is due to the shortening of telomeres at a rate similar to that reported for 
telomeres of somatic cells without telomerase, mainly due to incomplete replication, 
while the later can be explained by homologous recombination (HR) with unequal T-
SCE.  
 
ECTR DNA molecules are also present in ALT cells which take many forms including 
predominantly double-stranded telomeric circles (t-circles), partially single-stranded 
circles and linear double-stranded DNA [202]. However, very limited information is 
available regarding the ECTR molecules other than that they are commonly, but not 
exclusively, associated with the ALT-associated promyelocytic leukemia bodies (APBs) 
[203].  
 
ALT cells also contain unique large specialised ALT-associated promyelocytic 
leukemia (PML) nuclear bodies (APBs) ranging in size from 0.1 to 1μm. PML nuclear 
bodies are nuclear matrix-associated structures of unknown function that contain PML 
protein and have been implicated in a wide variety of cellular processes including 
oncogenesis, apoptosis and DNA damage responses. PML in APBs is also accompanied 
by SP100 protein. In addition, PML protein co-localises with telomeric DNA, telomere 
binding proteins and several proteins involved in DNA replication, recombination and 
repair [204, 205]. Although, the exact role of APBs in the ALT mechanism is still 
unknown, there is a clear association between the presence of APBs and the utilisation 
of ALT in telomere maintenance [198]. 
 
Another characteristic of ALT cells is the occurrence of T-SCEs with higher frequency 
than telomerase-positive cells or normal cells. The molecular explanation of T-SCEs is 
yet to be fully established; nevertheless, several studies have shown that the activation 
of ALT results in the recruitment of proteins required for SCE at telomeres. In addition, 
it has been previously reported that telomeric DNA in ALT cells contains nicks and 
gaps which may lead to structural impediment to DNA replication and therefore result 
in T-SCEs. Moreover, SCEs may also originate from the DNA damage since telomeres 
are vulnerable to breakage and SCEs are involved in the repair of double-strand breaks 
[206, 207]. The previous findings [208, 209] has led to the hypothesis that unequal T-
SCEs in ALT cells can result in one daughter cell with an elongated telomere 
(prolonged proliferative capacity) and another daughter cell with a shortened telomere 
(decreased proliferative capacity). Therefore, this could lead to unlimited proliferation 
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of the cell population, provided there exists a mechanism with which elongated 
telomeres can be segregated into one daughter and shortened telomeres into the other 
[202, 208].  
 
1.24 Telomeres and Ageing 
Telomeres shorten stochastically and also during each cell division. Progressive 
telomere loss, due to cell division, is an important timing mechanism linked to 
replicative senescence, which is characteristic of “ageing” both in cell culture and in 
vivo [210].
 
The hypothesis of ageing in telomeres is based on the detection of shorter 
telomeres in somatic tissues of older individuals compared to the younger ones. This 
trend holds true when comparing somatic and germline cells whereby telomeres in the 
former cells are shorter.
 
Telomeres of cells obtained from young individuals 
progressively shortened when grown in cell culture. In contrast, elongating telomeres in 
vitro by telomerase expression extended the proliferative capacity of the cultured human 
cells [210].
 
Furthermore, examination of children diagnosed with progeria revealed the 
existence of shorter telomeres in some somatic tissues than the age-matched controls 
[211].
 
Although further investigation is necessary to determine the impact of cellular 
senescence due to telomere loss on biological ageing, recent findings indicate the 
contribution of impaired telomere maintenance to both accelerated and normal ageing 
[212]. 
 
1.25 Telomere Length and FRDA 
Telomeres at the ends of chromosomes become shorter as cells divide in the process of 
ageing. Telomere length has been considered as a biological marker of age. In humans, 
telomere length shortening is associated with pathogenesis of diseases, including 
cancers, dementia, hypertension, diabetes mellitus, cardiovascular diseases, dyskeratosis 
congenita, ulcerative colitis, atherosclerosis and metabolic syndrome. Telomere 
shortening has also been found in age-related neurodegenerative diseases such as 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease [213]. 
FRDA is a neurodegenerative disorder caused by a reduction in frataxin expression, 
resulting in mitochondrial dysfunction and oxidative damage. Oxidative-induced 
telomere DNA damage is an important determinant of telomere shortening since it 
accelerates the rate of telomere attrition and chromosomal instability [156]. Although 
recent research demonstrated a significant telomere shortening in human FRDA 
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peripheral blood leukocytes [214], there is very limited information available regarding 
the status of telomere length in FRDA cells. Therefore, the hypothesis has been made 
that oxidative-mediated telomere shortening may contribute to FRDA pathogenesis. 
 
1.26 Aims of the Project 
FRDA is a progressive neurodegenerative disorder with no effective therapy. The 
Ataxia Research Group at Brunel University established a GAA repeat expansion-based 
FXN yeast artificial chromosome (YAC) transgenic mouse model in a Fxn-null 
background. Copy number variation (CNV) frequency difference between the cases and 
control subjects at specific loci is necessary to determine whether a given CNV plays a 
role in the progression of a disease or impacts the expression of a clinical trait. 
Therefore, the first aim of this research project was to investigate the copy number and 
integration sites of the FXN gene in different mouse models and to determine the 
distribution of the FXN transgenes among the mouse chromosome, chapter II. 
 
On the other hand, FRDA mouse models are likely to have impaired function of the 
human transgene-derived frataxin with potential functional deficiencies in motor 
coordination ability and changes in physical status that are consistent with the FRDA 
disease [31]. In addition, 10-30% of the FRDA patients develop overt diabetes and 30% 
have impaired glucose tolerance [215]. Therefore, the effects of FXN deficiencies on 
function of FRDA mouse models were investigated using different tests of motor 
coordination, balance and strength. Subsequently, glucose and insulin tolerance tests 
were carried out to investigate the possibility of diabetes in the FRDA mouse models, 
chapter III. 
 
Furthermore, the frataxin mRNA and protein levels as well as the somatic GAA repeat 
instability were examined in the FRDA mouse models to identify their correlation with 
FRDA-like pathological phenotype, chapter IV. 
 
Moreover, it has been demonstrated that the FRDA cells are more sensitive to ionising 
radiation than the control cells, suggesting that FRDA is a DNA repair-deficient 
disorder [216]. In addition, oxidative stress has been reported to accelerate the rate of 
telomere attrition and chromosomal instability [156]. Therefore, it was hypothesised 
that telomere length may be shortened due to oxidative damage in the FRDA patients. 
Consequently, the telomere length and rate of telomere shortening in the FRDA cells 
were measured, chapter V. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II  
 
DETERMINATION OF AMPLIFICATION OF 
THE FXN GENE USING TAQMAN COPY 
NUMBER AND FLUORESCENCE IN SITU 
HYBRIDISATION ASSAYS 
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2.1 Introduction 
Copy number variation (CNV) is an important polymorphism associated with genetic 
diseases such as cancer, immune diseases and neurological disorders. It can influence 
the expression of genes within and/or close to the rearranged region(s). CNV can be 
caused by genomic rearrangements such as deletion, duplication, inversions and 
translocations, allowing transcription levels to be higher or lower than those that can be 
achieved by controlling the transcription of a single copy. They form at a faster rate in 
comparison to other types of mutation and can arise both meiotically and somatically 
[217-219]. Therefore, copy number variation frequency difference between cases and 
control subjects at specific loci is necessary to determine whether a given CNV plays a 
role in disease or impacts the expression of a clinical trait. 
 
Copy number variations in the genome can be detected using different techniques such 
as array comparative genomic hybridisation (aCGH), SNP arrays from GWAS (Genome 
Wide Association Studies) [220], CNV-seq [221], TaqMan copy number and 
fluorescence in situ hybridisation (FISH) assays. In this chapter two different 
techniques, TaqMan copy number and FISH assays, were performed to investigate the 
copy number and integration site of the FXN transgene. The former is one of the most 
sophisticated techniques designed for the detection and measurement of CNV in the 
human genome. This technique is quantitative and robust with high reproducibility, 
accuracy, specificity and sample throughput. The latter is widely used for the analysis of 
genes and chromosomes.  
 
2.2 Hypothesis and Research Objectives 
    2.2.1 Hypothesis 
As previously described in section 1.14 (chapter I), the Ataxia Research Group at 
Brunel University established GAA repeat expansion-based FXN YAC transgenic 
mouse models in a null background, YG8R and YG22R, containing 190+90 and 190 
GAA repeat sequence respectively. This was achieved by crossbreeding human 
genomic YAC transgenic mice that contained the entire FXN gene and expanded GAA 
repeats with heterozygous Fxn knockout mice. A new YG8sR (YG8R with a small 
GAA band) line was recently generated by crossbreeding YG8R with Y47R (control 
transgenic mice contained the same human FXN YAC transgene but with normal-sized 
GAA repeats) containing a contraction of GAA repeat sequence to a single band with 
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120 GAA repeat units. It was hypothesised that the number of integral copies of the 
FXN gene can vary between different lines due to duplication, either within intron 1 or 
other segments, or deletion of the FXN gene, originating from unequal crossing-over 
between homologous chromosomes, Fig. 2.1. 
 
    2.2.2 Research Objectives 
- To investigate the copy number variation of the FXN gene in YG8, YG22, 
YG8s and Y47 Lines using TaqMan copy number assay 
- Investigation of homozygous and hemizygous YG8 copy number using 
TaqMan copy number assay 
- Comparison of the FXN gene copy number of YG8, YG22, YG8s and Y47 
lines within different generations using TaqMan copy number assay 
- To verify the results obtained from copy number assay and to determine the 
integration site of the FXN transgene using fluorescence in situ hybridisation 
assay 
 
2.3 Materials and Methods 
    2.3.1 TaqMan
®
 Copy Number Assay 
        2.3.1.1 Genomic DNA Extraction 
Genomic DNA (gDNA) was isolated from mouse-tails using phenol/chloroform 
method. Tails, 5mm in length, were collected in 1.5ml tubes (Eppendorf) and digested 
 
Fig. 2.1 Copy number variation by homologous recombination. The duplication of the 
FXN gene containing GAA repeats may undergo two paths, within intron1 (left) or 
within other segments (right). The same mechanism can result in deletion. 
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by adding 400µl of digestion buffer (100mM Tris-HCl pH 8.0 (hydroxymethyl 
aminomethane-HCl), 5mM EDTA, 200mM NaCl, and 0.2% SDS and 10µl of 50mg/ml 
proteinase K (BDH). The samples were subsequently mixed and incubated in a 55˚C 
waterbath overnight. The next day, the incubated samples were vortexed and 400µl of 
phenol, equilibrated with Tris-HCl pH 8.0, was added. Samples were vortexed 
(Whirlimixer) for 15 seconds and centrifuged (Eppendorf Micro Centrifuge Model 5415 
R) at 16100 rcf for 5 minutes. The  supernatant  containing  the DNA was  removed and  
 
Table 2.1 Sample reading from DNA extraction 
Sample name A260/280nm ratio A260/230nm ratio DNA concentration (ng/µl) 
WT(8J.38) 1.92 2.83 172.4 
YG8(8.2286) 1.67 2.27 112.9 
YG8(8.196) 1.94 2.30 533.7 
YG8(8.230) 1.89 2.30 550.6 
YG8(8.1973) 1.84 1.50 37.9 
YG8(8.1070) 1.91 1.25 49.9 
YG22(1450) 1.93 2.98 139.9 
YG22(PMS2.602) 1.93 2.22 454.1 
YG22(PMS2.608) 1.92 2.19 450.0 
YG22(PMS2.609) 1.92 2.34 289.7 
YG8s(8.2329) 1.92 2.12 247.5 
YG8s(8.2330) 1.89 2.17 283.9 
Y47(Y.30) 1.87 2.76 144.6 
Y47(Y.1) 1.86 2.21 194.3 
Y47(Y.2) 1.87 1.94 145.2 
Y47(Y47.15) 1.85 1.56 58.9 
Y47/43 1.89 2.29 568.0 
Y47/15/6/3 2.01 1.45 289.1 
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transferred to a clean 1.5ml microcentrifuge tube containing 500µl of chloroform/ 
isoamyl alcohol (24:1, v/v) and gently mixed by inverting tubes and centrifuged again at 
16100 rcf for 5 minutes. Next, 350µl of the resulting supernatant was removed to a fresh 
microcentrifuge tube containing 800µl of absolute ethanol and 30µl of 3M Na-acetate 
(pH 5.2). Samples were mixed well by inverting tubes several times and subsequently 
placed at -80˚C for 10-15 minutes. Genomic DNA was precipitated following this step 
and formed a visible mass. The DNA was pelleted by centrifugation at 16100 rcf for 30 
minutes at 4˚C. After removing the supernatant; the DNA was washed with 1ml of 70% 
ethanol and centrifuged at 16100 rcf for 20 minutes at 4˚C. The ethanol was discarded 
and the DNA pellets were air-dried for 10-15 minutes at RT. The dried pellets were 
resuspended in 50µl T.E. (10mM Tris, 1mM EDTA, pH 8.0) buffer and stored at 4˚C. 
The concentration of DNA was read on the ND1000 spectrophotometer at 260 and 
280nm wavelengths using 1µl of DNA. Table 2.1 illustrates the DNA readings extracted 
from the mouse-tails utilised in this experiment. 
 
        2.3.1.2 GAA PCR 
A GAA polymerase chain reaction (PCR) was performed on mouse genomic DNA 
samples to detect the genotype. The primers listed in Table 2.2 were utilised.  
 
Table 2.2 Primer Sequences for GAA PCR 
Primer Sequence (5´3´) Product size (bp) 
GAA Forward GGGATTGGTTGCCAGTGCTTAAAAGTTAG 
421 
GAA Reverse GATCTAAGGACCATCATGGCCACACTTGCC 
    
1µl of DNA was used for amplification in PCR. The following reagents were added to 
the DNA in a 0.2ml tube: 
 
- 12.5µl of 2× Qiagen Master Mix (Qiagen) containing MgCl2, Taq DNA 
polymerase and dNTPs) 
- 5µl of Q buffer  
- 1µl of 50µM GAA reverse primer  
- 1µl of 50µM GAA forward primer  
- Nuclease free water to 25µl    
 
47 
 
The samples were mixed and the reactions were carried out in a PTC-225 Pelter 
Thermal Cycler (MJ Research) using the following program, Table 2.3. 
 
Table 2.3 GAA PCR program 
Steps Temperature Duration Cycles 
Denaturation 94˚C 2 mins 1 
Denaturation 94˚C 10 sec  
Annealing 60˚C 30 sec 10 
Elongation 68˚C 45 sec  
Denaturation 94˚C 10 sec  
Annealing 60˚C 30 sec 20 
Elongation 68˚C 1 min, with 20 sec increments  
Extension 68˚C 10 mins 1 
 
To visualise the amplicons, a 1% agarose gel made with 100ml 1× TBE (89mM Tris-
borate, 2mM EDTA, pH 8.3) buffer was prepared. 1μl of 10mg/ml of ethidium bromide 
(EtBr) was added per 100ml of agarose gel before pouring the gel into a Flowgen 
agarose gel electrophoresis tank. Once the agarose gel was set, 300ml of 1× TBE buffer 
was added and each PCR sample was loaded into appropriate wells in the gel. 5µl of 
1kb plus DNA ladder (Invitrogen, UK) was used to accurately size the PCR product. 
The gel was run at 70V for 30-60 minutes until the PCR products were run three 
quarters of the way into the gel. The PCR products were then visualised using a UVP 
GDAS (Gel Documentation Analysis System) 1200 under the ultraviolet light. Three 
 
Fig. 2.2 Agarose gel electrophoresis of GAA PCR reaction products from FRDA 
transgenic mouse tissues. Lanes 1 to 9 are templates. Lane 10, 11 and 13 are positive, 
negative and dH2O negative controls respectively. A 1kb
+ 
DNA Ladder was used for 
size evaluation. 
 1        2       3       4       5        6       7        8        9      10     11      12      13   
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controls (positive, negative and blank (water) controls) were used. A single band should 
be seen in a positive lane, and no band should be seen in a negative control lane. The 
size of the PCR products must match the expected product size, Fig. 2.2. 
 
        2.3.1.3 Fxn KO PCR 
This PCR was performed to identify the wild type or knockout Fxn alleles. The primers 
listed in Table 2.4 were used. 
 
Table 2.4 Primer Sequences for KO PCR 
Primer Sequence (5´3´) Product size (bp) 
WJ5 CTGTTTACCATGGCTGAGATCTC Wild-type allele 
(WJ5-WN39)=520 
WN39 CCAAGGATATAACAGACACCATT 
Mutant allele        
(WJ5-WC76)=245 WC76 CGCCTCCCCTACCCGGTAGAATTC 
 
1µl of DNA was used for amplification in PCR. The following reagents were added to 
the DNA in a 0.2ml tube: 
 
- 12.5µl of 2× Kapa Master Mix (Kapa Biosystem, UK) containing MgCl2, Taq 
DNA polymerase and dNTPs) 
- 0.5µl of 50µM WJ5 primer  
- 0.5µl of 50µM WN39 primer 
- 0.1µl of 50µM WC76 primer 
- Nuclease free water to 25µl    
 
The samples were mixed and the reactions were carried out in a PTC-225 Pelter 
Thermal Cycler (MJ Research) using the following program, Table 2.5. 
 
Table 2.5 KO PCR program 
Steps Temperature Duration Cycles 
Denaturation 94ºC 1 min 1 
Denaturation 94 ºC 20 sec  
Annealing 54 ºC 20 sec 30 
Elongation 72 ºC 20 sec  
Extension 72ºC 10 mins 1 
 
The amplicons were analysed by agarose gel electrophoresis in 1× TBE buffer as 
previously described in Section 2.3.1.2. The PCR products were then visualised using a 
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UVP GDAS 1200 under the ultraviolet light. Four controls (wild-type, heterozygous, 
rescue and blank (negative) controls) were used. The size of the PCR products must 
match the expected product size, Fig. 2.3. 
        2.3.1.4 Preparation of Genomic DNA Samples 
Genomic DNA (gDNA) was quantified using the UV absorbance (A260/A280) 
measurement, ensuring A260/A280 ratio greater than 1.7, and diluted to 5ng/µl using 1× 
TE (Tris-EDTA) buffer (pH 8.0) to make a 5× stock solution. 
 
        2.3.1.5 TaqMan
® 
Copy Number Assays 
TaqMan
®
 copy number assays are run simultaneously with a TaqMan
®
 copy number 
reference assay in a duplex real-time polymerase chain reaction (PCR). The copy 
number assay amplifies the target gene or genomic sequence of interest and the 
reference assay amplifies a sequence that is known to exist in two copies in a diploid 
genome. A TaqMan
®
 copy number reference assay (Applied Biosystems), containing 
mouse-specific Tert (Telomerase Reverse Transcriptase) forward and reverse primers 
and a TaqMan TAMRA
™
 probe, and two predesigned TaqMan
® 
copy number assays 
(Applied Biosystems), containing human-specific FXN forward and reverse primers  
and a TaqMan MGB probe, were used in this experiment, Table 2.6. The location of the 
TaqMan
®
 copy number assays is shown in Fig. 2.4. The TaqMan MGB probe includes a 
FAM™ reporter dye attached to the 5´ end, a nonfluorescent quencher (NFQ) and a 
minor groove binder (MGB) attached to the 3´ end (MGBs increase the melting 
temperature (Tm) without increasing the probe length, allowing the design of shorter 
 
 
Fig. 2.3 Agarose gel electrophoresis of KO PCR reaction products from FRDA 
transgenic mouse tissues. Lanes 1 to 8 are templates. Lanes 9, 10 and 11 are wild-type, 
heterozygous, rescue positive controls respectively. Lanes 12 and 13 are 1kb
+ 
DNA and 
negative control (dH2O) respectively.  
1     2    3   4    5     6    7    8    9   10  11  12  13 
-520bp  
-245bp 
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probes). The TaqMan TAMRA
™
 probe includes  VIC
®
 reporter dye attached to the 5´ 
end and TAMRA
™
 quencher attached to the 3´ end. 
 
Table 2.6 TaqMan
® 
Copy Number Human-specific FXN Assays 
Assays Chr 
Reporter 
Dye 
Context Sequence (5´3´) 
Location on 
Transcript or 
Gene 
Product 
size (bp) 
Hs05092416-cn 9 FAM CTCCAGCAGAGCTAAGCATCAAGTA Within Intron3 106 
Hs02407730-cn 9 FAM TTCGAACCAACGTGGCCTCAACCAG Intron1- Exon2 
2 
     80 
 
 
 
 
 
 
 
 
 
Fig. 2.4 Schematic representation of the TaqMan
®
copy number assays located on the 
FXN gene, cytoband 9q21.11c, the blue and green squares indicate the location of the 
Hs05092416-cn and Hs02407730-cn assays respectively. 
 
        2.3.1.6 Preparation of the Reactions 
The master mixes listed in Table 2.7 were prepared for an extra 2 reactions in 1.5ml  
 
Table 2.7 Reaction mixture component and volumes 
Reaction mixture component 
Volume per well (µl) 
96-well plate 
2× TaqMan® Universal Master Mix (Applied Biosystems) 
containing AmpliTaq
®
GoldDNA polymerase, ultra-pure and 
dNTPs 
10.0 
TaqMan® Copy Number Assay, 20× working stock 1.0 
TaqMan® Copy Number Reference Assay, 20× 1.0 
Nuclease-free water 4.0 
Total Volume 16.0 
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centrifuge tube based on the reaction volume and the number of reactions (using four 
replicates of each sample). 
The following samples were run on each plate using four replicates for each gDNA 
sample: 
 
- Samples or Unknowns: gDNA samples in which the copy number of the target 
is unknown. 
 
- No Template Controls (NTC): A sample that does not contain a DNA 
template, used for the detection of contamination and background fluorescence. 
 
- Calibrator sample: A DNA sample with a known copy number for the target of 
interest. 
     
16µl of the reaction mixture  was added into each well of a MicroAmp
® 
Fast Optical 
96-well Reaction Plate (Applied Biosystems) using a p20 pipette (Gilson). The diluted 
gDNA samples were mixed and spun (Microcentrifuge 5415 C, Eppendorf) briefly 
before pipetting to the plate. 4µl of gDNA (5ng/µl) was added to the wells containing 
the reaction mixture. The reaction plate was sealed with MicroAmp
®
 Optical Adhesive 
Film (Applied Biosystems) and centrifuged for 10 seconds at 101 rcf. The reaction plate 
was loaded into a ABI Prism
®
 7900 HT real-time PCR instrument (Applied Biosystems) 
using the following program: 
During PCR, the gDNA template is denatured and each set of assay primers anneals to 
its specific target sequences. Each TaqMan probe anneals specifically to its 
 
Fig. 2.5 Schematic diagram of qPCR program 
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complementary sequence between forward and reverse primer binding sites. When each 
oligonucleotide probe is intact, the proximity of the quencher dye to the reporter dye 
causes the reporter dye signal to be quenched. During each round of PCR, the target and 
reference sequences are simultaneously amplified by AmpliTaq
®
Gold DNA 
polymerase. This enzyme has a 5´ nuclease activity that cleaves probes that are 
hybridized to each amplicon sequence. When an oligonucleotide probe is cleaved by the 
AmpliTaq
®
Gold DNA polymerase 5´ nuclease activity, the quencher is separated from 
the reporter dye increasing the fluorescence of the reporter. Accumulation of PCR 
products can be detected in real time by monitoring the increase in fluorescence of each 
reporter dye at each PCR cycle, Fig. 2.6. 
 
The number of copies of the target sequence in each genomic DNA sample was 
determined by relative quantitation (RQ) normalized to the known copy number of the 
reference sequence using the comparative Ct (∆∆Ct) method and the Ct data were 
subsequently compared to a calibrator sample known to have two copies of the target 
sequence, analysed by Applied Biosystems CopyCaller™ Software v.2.0. The predicted 
 
Fig. 2.6 PCR and detection of target and reference gDNA sequences in a duplex 
reaction [222] 
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copy number values were calculated by rounding up the actual copy number values (for 
example, calculated values of 0.4 and 0.5 corresponded to predicted values of 0 and 1 
respectively). 
 
        2.3.1.7 Statistical Analysis 
All statistical analysis (standard deviation) was performed using CopyCaller® Software 
v.2.0 (Applied Biosystems).  
 
    2.3.2 Fluorescence in situ Hybridisation Assay 
        2.3.2.1 Cell Culture 
Fibroblast cell lines were studied for the detection of human FXN gene by fluorescence 
in situ hybridisation. The cell cultures consisted of four mouse fibroblastic cell lines 
developed from four different FRDA transgenic mice (YG8R, YG22R, YG8sR and 
Y47R). Mouse fibroblasts were established from kidney of FRDA transgenic mice 
using the method described by Gomes-Pereira and Monckton [223]. The mouse was 
dissected on a clean bench and the kidney was collected aseptically in 50ml 1× sterile 
ice-cold PBS. The kidney was transferred to a laminar-flow hood to avoid 
contamination and placed on a 10cm tissue culture dish with 10ml of ice-cold sterile 
PBS and washed briefly to remove blood cells and fat tissues. The tissue was minced 
into approximately 1mm
3
 cubes and transferred into a sterile 15ml conical tube 
containing 10ml sterile ice-cold PBS. These tissue pieces were allowed to settle down 
over a period of 2 minutes after which the PBS was aspirated. Subsequently, they were 
washed twice with 10ml sterile PBS. Then 5ml of prewarmed 0.25% trypsin/EDTA 
solution was added and the culture dish was incubated in a humidified 5% CO2 
incubator at 37˚C for 30 minutes by gently inverting the tube after every 5 minutes. The 
plunger was removed from a 5ml syringe and the pieces of tissue and enzymatic 
solution were transferred into the syringe. The plunger was placed back in syringe and 
the contents of the syringe were squirted into a 25cm
2
 tissue culture flask, through a 
sterile 18-gauge needle. The tissue culture flask was placed in the incubator for an 
additional 15 minutes. The contents of the flask were transferred into a 15ml conical 
tube, the pieces of cellular debris were allowed to settle down over a period of 2 
minutes and then the supernatant was transferred into a fresh 15ml conical tube for 
centrifugation at 389 rcf for 5 minutes. The supernatant was removed and the cell pellet 
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was cultivated in a 25cm
2
 tissue culture flask containing 5ml of DMEM culture medium 
(Gibco) supplemented with 10% fetal bovine serum (Gibco) and 2% Pen-Strep (Gibco). 
The primary cultures were incubated at 37˚C in a 5% CO2 humidified incubator. The 
primary fibroblasts were ready in 5-7 days in culture. 
 
          2.3.2.1.1 Mycoplasma PCR Testing 
Mycoplasma PCR was carried out using Mycosensor™ PCR Assay Kit (Stratagene). 
Briefly, 100μl of supernatant was taken carefully from a culture flask into a sterile 
1.5ml Eppendorf tube and incubated for 5 minutes at 95˚C in a water bath. 10μl of 
strataClean was added to the tube and mixed well by flicking the tube followed by the 
centrifugation at 15700 rcf for 1 minute. 20μl of supernatant was transferred to a fresh 
0.5ml PCR tube and placed on ice until required to use. 5μl of supernatant was used for 
amplification in PCR. The following reagents were added to the samples in a 0.25ml 
tube: 
 
- 5μl 10× PCR buffer (Qiagen) 
- 2.5μl Q buffer (Qiagen) 
- 1μl 25mM MgCl2 
- 1μl 10mM dNTP mix 
- 2μl primer mix 
- 0.5μl TaqDNA polymerase (5U/μl) 
- 4μl internal control template 
- 29μl dH2O 
 
The samples were mixed and the reactions were carried out in a PTC-225 Pelter 
Thermal Cycler (MJ Research) using the following program, Table 2.8.  
 
Table 2.8 Mycoplasma PCR program 
Steps Temperature Duration Cycles 
Denaturation 94ºC 30 sec 1 
Denaturation 94ºC 30 sec  
Annealing 55ºC 1 min 35 
Elongation 72ºC 1 min  
Extension 72ºC 10 mins 1 
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To visualise the results, 10-15μl of PCR products were separated in 2% agarose TBE 
mini-gels along with a 1kb
+
 DNA ladder (Invitrogen) at 75V for ~30 minutes, Fig. 2.7. 
 
          2.3.2.1.2 Harvesting of Cultures and Preparation of Slides 
Culture medium, PBS and Trypsin/EDTA solutions were prewarmed to 37˚C in a water 
bath. Before harvesting, cells were treated with 0.1µg/ml colcemid (Sigma) for 1 hour. 
The medium was removed by vacuum suction and cells were washed gently with sterile 
PBS. Adherent fibroblasts were digested with trypsin/EDTA for 5 minutes at 37˚C in 
the CO2 incubator to bring them into suspension. The trypsin/EDTA solution was 
neutralized by adding 10ml of DMEM culture medium. Cells were collected by 
centrifugation at 389 rcf for 5 minutes and treated with 10ml of hypotonic solution 
(0.075M KCl) for 15 minutes at 37˚C and fixed with methanol:acetic acid (3:1). The 
process of fixation was repeated two more times for 10 and 30 minutes at RT 
respectively and each time 1ml of fresh fixative was added drop wise, followed by the 
addition of 2ml of extra fixative solution. Subsequently, the cell pellets were 
resuspended in fresh fixative solution and 15µl of cell suspension was spread on a wet 
slide which was then air-dried.  
 
 
 
 
Fig. 2.7 Agarose gel electrophoresis of mycoplasma PCR reaction products from 
FRDA transgenic mouse fibroblast cell lines. Lanes 1 to 4 are templates. Lane 5 and 6 
are positive and negative controls respectively. A 1kb
+ 
DNA Ladder was used for size 
evaluation. 
Samples 
Positive 
Control 
Negative 
Control 
- 500bp  
- 315bp 
  1kb+ 
Ladder 
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        2.3.2.2 Preparation of DNA Probes 
          2.3.2.2.1 Bacterial Artificial Chromosomes (BACs) 
The BACs, 265B8 and 876N18, used in this study were a kind gift from Dr. Joseph 
Sarsero (Murdoch Children's Research Institute, Melbourne, Australia) [224]. Bacterial 
cells containing the probe were first grown as streaks on an agar plate containing luria 
Bertani LB medium (1% (w/v) NaCl, 1% (w/v) Bactotryptone, 0.5% (w/v) yeast extract, 
1.5% (w/v) Agar and 12.5µg/ml chloramphenicol. Plates were incubated overnight at 
37˚C and the positive colonies were then taken from the culture and cultivated again in 
10ml of fluid LB-broth culture medium supplemented with 12.5µg/ml chloramphenicol 
overnight with vigorous shaking at 37˚C. 500µl of an overnight bacterial culture was 
mixed with 500µl of glycerol (80% in LB medium) and stored at -20˚C or at -80˚C for 
long term storage. 4ml of the overnight culture was centrifuged for 10 minutes at 800 
rcf and the supernatant was discarded. The pellet was resuspended in 300μl of P1 buffer 
containing 15mM Tris-HCl (pH 8.0), 10mM EDTA and 100µg/ml RNase A (sigma-
Aldrich) and the cells were lysed by adding 300μl of P2 lysis buffer containing 0.2M 
NaOH and 1% SDS followed by gentle mixing and 5 minutes incubation at RT. The 
lysate was then neutralised by adding 300μl of buffer P3 containing 3M Potassium 
Acetate, gently mixed and incubated on ice for 10 minutes. The reaction was 
centrifuged at 9300 rcf for 10 minutes at 4˚C and the supernatant containing the DNA 
was transferred to a fresh 2ml tube. The DNA was precipitated by adding 800μl of ice-
cold isopropanol, mixing and incubating overnight at -20˚C. After overnight incubation 
the tubes were centrifuged at 9300 rcf for 15 minutes at 4˚C. The DNA pellet was 
washed with 500µl of ice-cold 70% ethanol, centrifuged at 9300 rcf for 10 minutes at 
4˚C, air-dried and dissolved in 40μl of ddH2O. The DNA was stored at -20˚C. 
 
          2.3.2.2.2 Confirmation of Probe Amplification Region Using PCR 
 
In order to verify the inserts and amplification regions, the probe DNAs were subjected 
to PCR amplification with primers for FRDA exon 1-5b, STM7 exon 14 and FR6 [225], 
Table 2.9. As represented in Fig. 2.8, a 188kb BAC clone 265B8 contained exon 1 to 5b 
of the human FXN locus and PIP5K1B (STM7) gene upstream of the FRDA locus, 
whereas 876N18 clone contained the entire human FXN locus following FR6 gene 
downstream of exon 5. 
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Table 2.9 PCR Primers for Amplification of FXN (X25) Exons 
Exon Forward Primer (5´3´) Reverse Primer (5´3´) 
Size 
(bp) 
Annealing 
Temp. 
PIP5K14 TAAAGCTGCATTTATTCTTGAG CTGATGTTGATGTGGTAACAG 254 50 
FXN1 AGTAGCCGGCCTCCTGG GTGGGGCCAACTCTGCC 83 60 
FXN2 AGTAACGTACTTCTTAACTTTGGC AGAGGAAGATACCTATCACGTG 166 50 
FXN3 AAAATGGAAGCATTTGGTAATCA AGTGAACTAAAATTCTTAGAGGG 227 55 
FXN4 AAGCAATGATGACAAAGTGCTAA TGGTCCACAATGTCACATTTCGG 241 55 
FXN5a CTGAAGGGCTGTGCTGTGGA TGTCCTTAAAACGGGGCT 222 55 
FXN5b CCCATGCTCAAGACATACTCC ACAGTAAGGAAAAAACAAACAGCC 224 55 
FR6 CCTTTCCTGGATGCATTGTGT TCATGAGGGTGGGACTCTCA 157 58 
 
          2.3.2.2.3 Measurement of DNA Concentration 
DNA concentration was measured with a Nanodrop spectrophotometer (Nanodrop 
2000C, Thermo Scientific, UK) using 1μl of the DNA sample, Table 2.10. The purity of 
the sample was determined by the OD260/OD280 ratio. For pure DNA sample this ratio 
should be between 1.7 and 2.0.  
 
            Table 2.10 Quality Check of the DNA Probes 
BACs DNA Concentration ng/µl Ratio 260/280 
RP11-265B8 693.2 1.84 
RP11-876N18 486.2 1.79 
 
Fig. 2.8 PCR screen for amplification regions of 265B8 and 876N18 clones using 1% 
agarose gel. 265B8 contained exon 1 to 5b of the human FXN locus and PIP5K14 
(STM7-exon 14) gene upstream of the FRDA locus, whereas 876N18 clone contained 
the entire human FXN locus following FR6 gene downstream of exon 5. −, negative 
control (dH2O); +, positive controls (Mp.42 and 62341B) were used as controls. A 1kb
+ 
DNA Ladder (Invitrogen) was used for size evaluation. 
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          2.3.2.2.4 Labelling of DNA Probes 
In order to detect human FXN sequences on FRDA transgenic mouse chromosomes, the 
corresponding 265B8 and 876N18 probes were labelled with biotin and digoxigenin 
respectively and detected immunologically with the antibodies coupled to fluorescent 
fluorochromes. The nick translation method is based on the ability of the DNase I to 
introduce randomly distributed breaks of a single strand, or nicks, into DNA. The nicks 
are then filled by DNA-polymerase I, which replaces the removed nucleotides with 
digoxigenin- or biotin-labelled ones.  Labelling by nick translation was performed with 
DIG-Nick Translation (Roche) and Biotin-Nick Translation kits (Roche) as follows:  
 
- 5μl dNTP Mix (minus dTTP)  
- 1μl dUTP conjugated with biotin or digoxigenin 
- 1μg of probe DNA 
- ddH2O up to a volume of 45μl 
 
5μl of PolI/DNaseI mix was added to the reaction and mixed gently followed by 
incubation for 2 hours at 16˚C. 
 
          2.3.2.2.5 Gel Electrophoresis 
Because the actual size of the probe after labelling reaction plays an important role in 
maximising specific hybridisation and decreasing background, the fragments of the 
probe broken by nick translation should be between 200 to 500bp in length. In order to 
check that the probe DNA has reached a suitable size, 5µl of the labelled probes were 
loaded onto a 2% agarose gel and proceeded with electrophoresis. A XIII DNA size 
Ladder (Peq GOLD) was used for size evaluation. 
 
          2.3.2.2.6 Purification of Labelled Probes 
In order to remove un-incorporated labelled nucleotides, the FISH probes were run 
through illustra Microspin G50 columns (GE Healthcare, UK). After purification, 5µl of 
salmon sperm DNA (11.0mg/ml, Invitrogen), 10µl 3M NaAC and 2.25V of ice-cold 
100% ethanol were added to the DNA suspension. The DNA was then precipitated 
overnight at -20˚C and centrifuged at 15700 rcf for 30 minutes at 4˚C. The pellet was 
washed with 200µl of ice-cold 70% ethanol and centrifuged at 15700 rcf for 15 minutes 
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at 4˚C. After air drying, the DNA pellet was resuspended in 20μl ddH2O and stored at -
20˚C until use.  
 
        2.3.2.3 Dual Colour Fluorescence in situ Hybridisation Assay 
          2.3.2.3.1 Slide Denaturation 
Slides were washed three times for 5 minutes with 2× SSC in a Coplin jar on a shaking 
platform followed by dehydration in 70%, 90% and 100% ethanol for 3 minutes and air-
drying. The chromosomal DNA on the glass slides were then denatured in 70% 
formamide in 2× SSC under the fume hood at 70˚C for 5 minutes. The slides were 
moved quickly to a coplin jar containing ice-cold 2× SSC for 5 minutes on a shaking 
platform to stop the denaturing of the DNA and wash the non specific binding. 
Subsequently, the slides were dehydrated in 70%, 90% and 100% ethanol for 3 minutes 
and air-dried. 
 
          2.3.2.3.2 Probe Denaturation 
Before hybridisation, dual colour FISH probes were prepared. 5µl of Cot-1 human DNA 
(Roche) was added to 5µl of competitor DNAs (Biotin-labelled and digoxigenin-
labelled probes) to reduce non-specific background hybridisation signals. The pellets 
were dried in a vacuum desiccator for 15 minutes and resuspended in 10µl of 
hybridisation buffer (Sigma). The probe mix was denatured by incubating at 65˚C for 
10 minutes, followed by preannealing at 37˚C for 10 minutes. 
 
          2.3.2.3.3 Hybridisation 
10μl of the probe mix was applied for each slide, covered with a 22×22mm2 coverslip 
and sealed with bicycle glue. The slides were subjected to hybridisation at 37˚C 
overnight using a humid-chamber in a water bath. 
 
          2.3.2.3.4 Post-Hybridisation Washes and Detection of Labelled Probes 
After hybridisation, the slides were washed in 2× SSC for 5 minutes on a shaking 
platform to remove the coverslips. Subsequently, slides were placed in a prewarmed 
coplin jar containing 0.4× SSC for 5 minutes at 70˚C followed by washing in 2× SSC 
for 5 minutes at RT. The slides were then incubated in freshly prepared blocking 
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solution (1.8g (3% w/v) of bovine serum albumin (BSA) (Acrose Organic) in 60ml of 
4× SSC/Tween
®
20) for 1 hour at 37˚C to stop non-specific bindings. 
 
Biotin-labelled and digoxygenin- labelled probes were detected with Cy3-conjugated 
streptavidin and fluorescein isothiocyanate (FITC)-conjugated anti-digoxigenin 
antibody respectively as follows: 
 
- 1.5μl of Avidin D-Texas Red (final concentration of 2μg/ml) (Vector 
Laboratories) and 1.5μl of mouse anti- digoxigenin (final dilution of 1:666) 
(Sigma-Aldrich) were diluted in 1ml of blocking solution. 75μl of this solution 
was added onto each slide, covered with parafilm and incubated in humid 
chamber at 37˚C for 20 minutes. Slides were washed three times in 4× 
SSC/Tween
®
20 for 5 minutes on a shaking platform in the dark. 
- 10μl of biotinylated anti-Avidin D (final concentration of 5μg/ml) (Vector 
Laboratories) and 1μl of rabbit anti- mouse-FITC (final dilution of 1:1000) 
(Sigma-Aldrich) were diluted in 1ml of blocking solution. 75μl of this solution 
was added onto each slide, covered with parafilm and incubated in humid 
chamber at 37˚C for 20 minutes. Slides were washed three times in 4× 
SSC/Tween
®
20 for 5 minutes on a shaking platform in the dark. 
- 1.5μl of Avidin D-Texas Red (final concentration of 2μg/ml) and 10μl of 
monoclonal anti- rabbit-FITC (final dilution of 1:100) (Sigma-Aldrich) were 
diluted in 1ml of blocking solution. 75μl of this solution was added onto each 
slide, covered with parafilm and incubated in humid chamber at 37˚C for 20 
minutes. Slides were washed three times in 4× SSC/Tween
®
20 for 5 minutes on 
a shaking platform in the dark followed by an additional wash in 1× phosphate 
buffered saline (PBS) (Sigma-Aldrich) for 5 minutes on a shaking platform at 
RT.  
- The slides were mounted with DAPI counterstain (4´,6-diamidino-2-
phenylindole dihydrochloride)/Antifade (0.1μg/ml, MP Biochemicals), covered 
with a 22×40mm
2
 coverslip and sealed with bicycle glue. 
 
          2.3.2.3.5 Microscope Analysis and Imaging 
The slides were visualised through an Olympus BX41 Fluorescence microscope (Zeiss) 
equipped with a Sensys cooled CCD camera under 100× immersion oil objective. 
61 
 
SmartCapture3 sofware (Digital Scientific) was used for acquisition and storage of 
FISH analysis. 50 cells were quantified for each sample. 
 
    2.3.3 Confirmation of The Presence of FXN Exons in YG8s Lines Using PCR 
In order to verify the presence of FXN exons in YG8s rescue mice, two different YG8s 
lines (8.2330 and 8.2329) were screened for deletion mutations using PCR. The same 
primers as those previously described in Table 2.9, Section 2.3.2.2.2 were utilised for 
FRDA exons 1-5b. The PCR reaction was performed in a total volume of 25μl using 
200ng/μl of genomic DNA, 50μM of each primers and 12.5µl of 2× Kapa Master Mix 
(for exon 1 PCR 12.5µl of 2× Qiagen Multiplex PCR Master Mix and 5µl of Q buffer 
were used). PCR amplification was performed on a MJ Research PTC-225 thermal 
cycler using the following parameters: initial denaturation 94˚C, 1 minute, 35 cycles of 
denaturation 94˚C, 20 seconds, annealing (˚C represented in Table 2.9) 20 seconds, and 
extension 72˚C, 20 seconds, followed by a final extension of 10 minutes, 72˚C.  
 
        2.3.3.1 Optimisation of FXN Exon 1 Annealing Temperature Using Gradient 
PCR 
 
In order to determine the optimal annealing temperature for exon 1 primers, gradient 
PCR was performed using the gradient function of the universal block set from a 
gradient of 53˚C to 59.7˚C. The PCR reaction was performed in a total volume of 25μl 
 
Fig. 2.9 Determination of optimal annealing temperature for FXN exon 1 Primers using 
gradient PCR. The calculated primer annealing temperature was 53˚C; the actual 
annealing temperature was 59.7˚C. 
53˚C 53.9˚C 54.8˚C 56˚C 57.7˚C 59.7˚C Negative 
Control 
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using 200ng/μl of genomic DNA, 50μM of each forward and reverse FXN exon 1 
primers, 12.5µl of 2× Qiagen Multiplex PCR Master Mix and 5µl of Q buffer. PCR 
amplification was performed on a MJ Research PTC-225 thermal cycler using the 
following test parameters: initial denaturation 94˚C, 2 minutes, 30 cycles of 
denaturation 94˚C, 30 seconds, annealing 53˚C to 59.7˚C, 30 seconds and elongation 
72˚C, 1 minute followed by a final extension of 5 minutes, 72˚C. As shown in Fig. 2.9, 
best conditions were found in well 10 and 11 of the cycler where the temperature was 
59.7˚C. 
2.4 Results 
    2.4.1 Investigation of CNV in FRDA Mouse Models Using TaqMan
®
 Copy 
Number Assay 
 
        2.4.1.1 Detection of CNV of the FXN Gene in YG8, YG22, YG8s and Y47 
Lines 
 
To detect and measure CNV in the human genome, YG8, YG22, YG8s, Y47 and WT 
lines were investigated using real-time PCR and unquenching of fluorescent probes for 
the target sequence. As previously described in Section 2.3.1.5, two sets of TaqMan
®
 
copy number assays were applied in this experiment. Hs05092416-cn assay, represented 
in blue, was designed to amplify a 106bp fragment of FXN within intron 3 while 
Hs02407730-cn assay, represented in red, was designed to amplify an 80bp fragment of 
FXN within intron 1 and exon 2. A TaqMan
®
 copy number reference assay containing 
mouse-specific Tert was used as the reference which was known to have two copies in a 
diploid genome. Wild type (WT) line served as a negative control with no copy number 
to verify the specificity of the primers. The preliminary results indicated that YG22 and 
Y47 lines had a single copy of the FXN gene whereas the YG8 line showed two copies 
of the target gene, further confirming the duplication hypothesis, Fig. 2.10. YG8s line 
showed less than one copy of the target gene (CN=0.33) presumed to indicate the 
deletion of the FXN gene, Fig. 2.10. The YG8 (8.2286) line was used as a calibrator. 
The copy number of the calibrator was assessed using a sample (Y47.15) with two copy 
number which was previously calculated by competitive copy number PCR analysis 
[149]. 
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        2.4.1.2 Investigation of Homozygous YG8 Copy Number 
As part of this investigation the copy number of homozygous YG8 lines was also 
measured. Based on the hemizygous results, Fig. 2.10, homozygous YG8 lines were 
expected to have 4 copies which were confirmed with the TaqMan copy number assay 
within intron 1 and exon 2, Fig. 2.11. However, the results with the TaqMan copy 
number assay within intron 3 showed up to 6 copies, confirming the presence of 
duplication, Fig. 2.11.  
 
        2.4.1.3 CNV within Different Generations in Y47, YG8 and YG22 Lines 
The relative copy number of YG22 and Y47 lines was studied within different 
generations. The results indicated an increase in copy number of different YG22 lines 
which further confirmed the variation in FXN copy number within different generations 
of this line. The increased FXN copy number in YG22 (PMS2-/-.602, PMS2+/-.608 and 
PMS2
-/-
.609) confirmed the  presence of duplication, Fig. 2.12. Although, previously  
 
 
Fig. 2.10 Copy number variation in YG8, YG22, YG8s and Y47 lines. Two TaqMan 
copy number assays were applied; Hs05092416-cn assay, represented in blue, was 
designed to amplify a 106bp fragment of FXN within intron 3 and Hs02407730-cn 
assay, represented in red, was designed to amplify an 80bp fragment of FXN within 
intron 1 and exon 2. Wild type (WT) served as a negative control with no copy number 
while YG8 (8.2286) line was used as a calibrator. Error bars indicate standard deviation. 
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generated Y47 lines, Y47/43, a sibling of first generation (Y47.15); and Y47/15/6/3, 
third generation, had two copies of the FXN gene [149], no difference was detected in 
the copy number of recently generated Y47 lines (Y.1, Y.2 and Y.30), Fig. 2.13. The 
apparent discrepancy can be explained by the difference between the C57BL6/J 
background of the former and the later lines. No difference was identified in FXN copy 
number of all studied hemizygous YG8 lines (data not shown). 
 
    2.4.2 Investigation of CNV in FRDA Mouse Models Using Fluorescence in situ 
Hybridisation Assay 
 
Fluorescence in situ hybridisation (FISH) using dual colour probes containing the entire 
RP11-265B8 and RP11-876N18 sequences was performed on both metaphase and 
interphase spreads of YG8, YG22, YG8s and Y47 cell lines. RP11-265B8 and RP11-
876N18 probes were detected with Cy3-conjugated streptoavidin and fluorescein 
isothiocyanate (FITC)-conjugated  anti-digoxigenin antibody  respectively to determine  
 
Fig. 2.11 Copy number variation in homozygous YG8 lines. Two TaqMan copy number 
assays were applied; Hs05092416-cn assay, represented in blue, was designed to 
amplify a 106bp fragment of FXN within intron 3 and Hs02407730-cn assay, 
represented in red, was designed to amplify an 80bp fragment of FXN within intron 1 
and exon 2. Wild type (WT) served as a negative control with no copy number, YG8 
(8.2286) line used as a calibrator. Error bars indicate standard deviation. 
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Fig. 2.12 Copy number variation in YG22 lines within different generations. Two 
TaqMan copy number assays were applied; Hs05092416-cn assay, represented in blue, 
was designed to amplify a 106bp fragment of FXN within intron 3 and Hs02407730-cn 
assay, represented in red, was designed to amplify an 80bp fragment of FXN within 
intron 1 and exon 2. YG8 (8.196) line with copy numbers of two used as a calibrator. 
 
 
 
Fig. 2.13 Copy number variation in Y47 lines within different generations. Two 
TaqMan copy number assays were applied; Hs05092416-cn assay, represented in blue, 
was designed to amplify a 106bp fragment of FXN within intron 3 and Hs02407730-cn 
assay, represented in red, was designed to amplify an 80bp fragment of FXN within 
intron 1 and exon2. Y47 (Y47.15) line with copy numbers of two used as a calibrator. 
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the integration site of the transgenic FXN gene in YG8 (8.234), YG22 (1107), YG8s 
(MEF-M3) and Y47 (478.18) cell lines. All four cell lines were found to have a single 
integration site by analysis of metaphase chromosomes (Fig. 2.14; Metaphase). YG8 
showed three hybridisation signals indicating the presence of a single integration site 
containing multiple copies of the transgenic FXN gene (Fig. 2.14; YG8 Interphase), 
whereas YG22 and Y47 showed one signal indicating one copy of the FXN transgene 
(Fig. 2.14; YG22 and Y47 Interphase). At least 25% of the YG8s cells had no signals 
(Fig. 2.15), while 75% of those showed one signal corresponded to the transgenic FXN 
gene (Fig. 2.14; YG8s Interphase). This discrepancy can be explained by somatic 
mosaicism of the YG8s in which one copy of the transgene is indeed present, but in 
only 75% of the total number of cells. It is important to note that only 5% of the control 
cells had no signals. 
 
 FITC Cy3 Merged 
Y
G
8
s 
   
 
Fig. 2.15 Detection of mosaicism in YG8s transgenic mice. At least 25% of the YG8s 
cells had no signal, indicating mosaicism in YG8s lines.  
 
 
    2.4.3 Detection of FXN Exons in YG8s Rescue Mice 
As previously discussed in sections 2.4.1.1 and 2.4.2, the identities of the cloned FXN 
fragment in YG8s lines were investigated by FISH and copy number assays. The copy 
number results showed less than one copy of the FXN gene (CN=0.33) in YG8s lines 
presumed to indicate the deletion of the FXN gene. In contrast the results from the FISH 
assay indicated the authenticity of the cloned fragment. In order to further examine the 
presence of FXN exons in YG8s rescue mice, two different YG8s lines (8.2330 and 
8.2329) were screened for deletion mutations by PCR which allowed for a relatively 
rapid analysis of the exon sequences. The presence of all FXN exons was confirmed 
using human FXN-exon specific primers, Fig. 2.16.  
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Fig. 2.14 Determination of the integration site of the transgenic FXN gene by FISH. Biotin-labelled RP11-265B8 and digoxigenin- labelled RP11-876N18 
probes were hybridised onto interphase and metaphase chromosomes (DAPI stained) of YG8 (8.234), YG22 (1107), YG8s (MEF-M3) and Y47 (478.18) cells. 
YG8, Y47, YG22 and YG8s Metaphase: all four cell lines showed a single integration site of the FXN transgene by metaphase analysis. YG8 Interphase: 
YG8 showed three hybridisation signals corresponded to the transgenic FXN, Y47 and YG22 Interphase: whereas YG22 and Y47 showed one signal 
indicating one copy of the FXN transgene. YG8s Interphase: 75% of the YG8s cells showed one signal indicating one copy of the target gene. 
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2.4 Discussion 
In order to investigate the difference in the FXN gene copy number in different samples, 
two assays corresponding to the gene of interest and the reference gene were adopted to 
simultaneously quantitate both genes in the same DNA samples using real-time PCR. A 
single copy gene should have a relative copy number of 1, therefore, a relative copy 
number greater than 1 indicates the presence of duplication of the target gene while a 
number smaller than 1 implies deletion of such gene. When duplication occurs, multiple 
copies of a gene may be closely linked on the same chromosome or may be separated 
from each other by a large genomic distance. In order to identify the copy number of the 
FXN gene, three different experiments were performed. Firstly, the copy numbers of 
YG8, YG22, YG8s and Y47 lines were measured. The results indicated that the YG22 
and Y47 lines had a single copy of the FRDA gene while the YG8 line was shown to have 
two copies of the FRDA gene. These results were in good agreement with those 
previously reported [103, 149]. The YG8s lines showed less than one copy of the target 
gene (CN=0.33) presumed to indicate the deletion of the FXN gene. Secondly, the copy 
number of homozygous YG8 lines was measured using the TaqMan copy number assay. 
The results showed that the YG8 lines had relative copy number of four within intron 1 
 
Fig. 2.16 Validation of the presence of FXN exons in YG8s rescue mice by PCR. Agarose 
gel is showing PCR products of A) exon 1, B) exon 2, C) exon 3, D) exon 4, E) exon 5a 
and F) exon 5b. Lane 1 and 2 are 8.2329 (YG8s) and 8.2330 (YG8s) respectively. Lane 3 
to 9 are 8E47.1 (Y47R), 8E47.2 (YG8ER), 8E47.6 (YG8ER), D.147 (YG8ER) and 
8J47.144 (Y47R) used as positive controls respectively. Lane 10 and 11 are 1kb
+
 DNA 
ladder and negative control respectively.  
A 
1   2  3  4   5   6   7  8   9 10 11 1   2  3  4   5   6   7  8   9 10 11 
B 
D 
F 
C 
E 
-83bp  
 
-227bp  
 
-222bp  
 
-166bp 
-241bp  
 
-224bp  
 
69 
 
and exon 2 and up to 6 copies within intron 3. The former was in good agreement with the 
theoretical expectations based on the hemizygous results while the later confirmed the 
duplication hypothesis. Finally, the copy number of hemizygous YG22, YG8 and Y47 
lines was investigated within different generations. The results indicated an increase in 
copy number of YG22 lines from 1 to 2, confirming the variation in FXN copy number 
within different generations of this line. However, no difference was detected in the copy 
number of recently generated Y47 lines even though the previously generated Y47 lines 
were shown to have two copies of the FRDA gene. These findings were in good 
agreement with those previously reported [149]. Such discrepancy can be associated with 
the differences in the C57BL6/J background of the former and the later lines. No 
difference was detected in FXN copy number of all the studied hemizygous YG8 lines. 
 
To further investigate the copy number and integration site of the FXN gene, FISH assay 
was performed on both metaphase and interphase spreads of YG8, YG22, YG8s and Y47 
cell lines. Metaphase analysis of YG8, YG22, YG8s and Y47 chromosomes by dual 
colour FISH indicated a single integration site of the transgenic FXN gene in all cell lines. 
YG8 showed three hybridisation signals indicating the presence of a single integration 
site containing multiple copies of the transgenic FXN gene, whereas YG22 and Y47 
showed one signal indicating one copy of the FXN transgene. In YG8s lines, at least 25% 
of the YG8s cells had no signals, while the remaining cells showed one signal 
corresponding to the transgenic FXN gene.  
 
In addition, the analysis of FXN exons in YG8s rescue mice by PCR confirmed the 
presence of all FXN exons in these lines. These results suggested the incidence of somatic 
mosaicism in YG8sR cells indicating that the FXN gene is missing in some cells but not 
in all of YG8sR cells. However, according to the copy number results, the copy number 
of FRDA gene in YG8sR mice was not exactly 0 when compared with WT negative line. 
These results suggested the presence of the FXN gene in this line since the complete 
deletion of the FRDA gene would lead to embryonic lethality.  Furthermore, the observed 
copy number in YG8sR line is unlikely to be due to the contamination in the samples 
since two different samples were used and PCR analysis of all exons were positive for 
these lines. Consequently, the somatic chromosomal mosaicism observed in YG8sR 
mouse jeopardised the accuracy of the FXN copy number measurement using the TaqMan 
copy number assay. In contrast, fluorescence in situ hybridisation technique is the most 
effective method for the detection of somatic mosaicism since a large number of cells can 
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be individually examined for the presence or absence of a specific deletion [226]. Further 
investigation of the somatic mosaicism in YG8sR mice could be carried out in the future 
studies using the BAC probes together with mouse centromere- and/or telomeres specific 
probe [227, 228] to confirm the incidence of mosaicism in this line. 
 
As previously discussed, the FISH and copy number results indicated that YG8R lines 
have multiple, rather than single, copies of the FXN transgene integrated into a single 
chromosomal site. In addition, results from the Jackson Laboratory using single 
nucleotide polymorphism (SNP) assay showed that the transgenes are localised on Chr 16 
of the YG8R mouse chromosomes. Accordingly, it was of particular interest to determine 
how the FXN transgenes in the YG8R line have become distributed among the mouse 
chromosome. However, both TaqMan copy number and FISH assays were not capable of 
providing such information, therefore other techniques such as Fibre FISH should be 
utilised in future investigations in order to characterise the FRDA transgenes in different 
mouse models. 
 
In conclusion, TaqMan copy number assay allowed for the detection of the copy number 
variations of the FXN gene between different lines and generations in both hemizygous 
and homozygous transgenes. FISH assay further confirmed the FXN copy number 
variation and also detected the somatic chromosome mosaicism in YG8sR line which 
could not be identified with TaqMan copy number assay. Due to the limitation of TaqMan 
copy number assay in identifying mosaicism, the combination of FISH and TaqMan copy 
number assay could provide the most accurate results for chromosomal investigations 
with the additional benefit of retaining information at the single-cell level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER III  
 
FUNCTIONAL STUDIES OF FRDA MOUSE 
MODELS 
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3.1 Introduction 
As previously discussed in section 1.14 (chapter I), the Ataxia Research Group at Brunel 
University established GAA repeat expansion mutation-based mouse models of FRDA, 
YG8R and YG22R, containing 190+90 and 190 GAA repeat sequences respectively. 
However, a new YG8sR (YG8R with a small GAA band) line, containing a contraction of 
GAA repeat sequence to a single band with 120 GAA repeat units, was recently generated 
from YG8R breeding. YG8R, YG8sR and YG22R mice are likely to have impaired 
function of the human transgene-derived frataxin with potential functional deficiencies in 
motor coordination ability and changes in physical status that are consistent with FRDA 
disease.  In addition, 10-30% of FRDA patients develop overt diabetes and 30% have 
impaired glucose tolerance which can result from lack of insulin secretion by the insulin-
producing ß cells in the pancreas, insulin resistance in muscle, liver and fat, or from a 
combination of both [215]. Frataxin is involved in iron metabolism, thus, depletion of 
frataxin leads to increased levels of ROS within pancreatic islets. This could potentially 
lead to both hyperglycemia and impaired insulin secretion [229]. Recent studies have 
revealed that FRDA patients exhibit some degree of insulin resistance, suggesting the 
possibility of an additional role for frataxin in mediating insulin signalling and insulin 
secretion [215]. Therefore, it is of great importance to further investigate the insulin and 
glucose tolerance responses in the FRDA mouse models. The aim of this chapter was to 
characterise the effects of FXN deficiencies on function of FRDA mouse models using 
different tests of motor coordination, balance and strength. In addition, glucose and 
insulin tolerance tests were carried out to investigate the possibility of diabetes in FRDA 
mouse models. 
 
3.2 Materials and Methods 
To assess the functional outcome of FRDA mice and the effects of mutant FXN gene on 
their functional capacity, the accelerating rotarod analysis together with locomotor 
activity test, body weight measurement, beam-walk, hang wire, grip strength and foot 
print tests were conducted. Furthermore, the effect of deficient frataxin on glucose and 
insulin tolerance was assessed. Detailed explanation of the experimental procedures is 
outlined below. 
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    3.2.1 Body Weight Analysis 
Mouse body weights were recorded once a month from 4-12 months of age using a Mettler 
Toledo balance (Mettler Toledo PB1501, UK), Fig. 3.1. 10 mice including 5 males and 5 
females from each group (C57BL/6J (B6), Y47R, YG22R, YG8R and YG8sR) were 
assessed.  
 
    3.2.2 Rotarod Test 
The motor deficits associated with FRDA were assessed using a Ugo-Basille 7650 
accelerating rotarod treadmill apparatus, designated for testing the balance and 
coordination aspects of general motor function, Fig. 3.2. The rotarod device consisted of a 
rotating rod, driven by an electric motor, upon which the animals were placed. Mutant 
and control littermate mice (n=10 including 5 males and 5 females used for each group) 
were placed on the rods and four trials were performed with the speed of the rotation 
gradually increasing from 4 to 40 rpm. Each trial lasted approximately 3 to 5 minutes, 
separated by a rest period of 200 seconds between each trial. The time score where the 
mouse completes the task (by staying on the rotarod for 400s) or falls from the apparatus 
was recorded. Mice were assessed monthly for an 8 month period from 4-12 months of age 
(i.e. 9 time points). 
 
 
 
 
 
 
 
Fig. 3.1 Body weight analysis of the mice 
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    3.2.3 Beam-breaker Test 
Average velocity, ambulatory distance, vertical and jump count and time were measured 
over a 2 minute period and repeated four times for each mouse using a beam-breaker 
activity monitor (MED-OFA-510 activity chamber, Med Associates), Fig.3.3. The system 
consisted of 2 subject containment environment (chamber) and infrared (I/R) transmitters 
connected to the computer with data acquisition/analysis software (SOF-811), Fig.3.4.  
Locomotor activity of the mice (n=10 including 5 males and 5 females used for each 
group) was assessed monthly over an 8 month period from 4-12 months of age. Data 
analysis and manipulation was performed using Microsoft Excel.  
 
 
Fig. 3.3 Beam-breaker activity monitor chambers 
 
 
 
 
Fig. 3.2 Rotarod apparatus 
75 
 
    3.2.4 Beam-walk Test 
Beam-walk test was performed to compare the motor coordination and balance 
capabilities of FRDA transgenic and control mice. The test was carried out with two 
wooden beams of 90cm long, one with an external diameter of 12mm and the other 
22mm. The beams were placed horizontally 50cm above the bench surface with one end 
mounted on a narrow support with a 60W lamp while a darkend escape box was located 
at the other end of the beam as illustrated in Fig. 3.5.  Motor function was assessed by 
measuring the time taken for the mouse to cross the beam and enter the escape box. 
Mutant and control littermate mice listed in Table 3.1 received two trainings and were 
assessed four times on the wider and narrower beams respectively with a rest period of 5 
minutes between each trial.  
 
  
Fig. 3.5 Beam-walk device. Motor function of the mice was measured using 
22×900mm (left) and 12×900mm (right) beams. 
 
 
 
 
 
Fig. 3.4 Beam-breaker activity monitor software 
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Table 3.1 The details of FRDA/control mice used for functional studies 
 
Mouse 
 
Genotype Gender 
Total 
Number  
Number of 
Male & 
Female 
Average 
Weight 
(g) 
Weight 
(g) 
Average 
Age 
(month) 
 
B6 
C57BL6/J 
Control 
Male 
10 
5 
32.5 
34.8 14.8 
Female 5 30.2 13.6 
 
Y47R 
Transgenic 
Control 
Male 
10 
5 
43.1 
52.7 16.2 
Female 5 34.4 15.6 
 
YG22R 
FRDA 
YG22 
Rescue 
Male 
10 
5 
38.2 
41.1 14.0 
Female 5 35.2 16.0 
 
YG8R 
FRDA 
YG8 Rescue 
Male 
10 
5 
36.0 
40.7 13.9 
Female 5 31.3 15.8 
 
YG8s R 
 
FRDA 
YG8 Small 
Rescue 
Male 
10 
5 
38.1 
44.4 13.0 
Female 5 31.8 12.0 
 
    3.2.5 Hang Wire Test 
The hang wire test was performed to assess the grip strength of the mouse models. The 
mutant and control littermate mice used in this study are listed in Table 3.1. The mice 
were hung from a horizontally positioned wire (2mm in diameter and 30cm long) with 
each end affixed to a vertical stand, Fig. 3.6. Bedding material was placed underneath the 
wire to break the fall. The test commenced shortly after the mouse held onto the wire and 
the length of time before the fall was recorded. Four trials were performed with a rest 
period of 5 minutes between each trial. 
 
 
 
Fig. 3.6 Hang wire test 
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    3.2.6 Grip Strength Test 
The grip strength meter (Salter Brecknell Model 12 Spring Balance) was used to assess 
the forelimb grip strength, Fig. 3.7. The mice were held by the scruff of the neck with one 
hand and the base of the tail with the other hand. They were then free to grasp a metal 
grid attached to a meter as they were moved along the axis of the grid. The peak force 
with which mice pulled the grid was measured in four trials with a rest period of 5 
minutes between each trial. The mutant and control littermate mice used in this study are 
listed in Table 3.1. 
 
    3.2.7 Foot Print Test 
To obtain the footprints, mouse paws were dipped in nontoxic water-based food dye 
(forepaws in black and hindpaws in blue colour). The mice were allowed to walk along a 
 
 
Fig. 3.7 Grip strength test 
 
 
Fig. 3.8 Footprint analysis. Footprint patterns were quantitatively assessed for six 
parameters including left hind and front stride length, right hind and front stride length, 
fore base width and hind base width as shown on footprint patterns of a control (top 
panel) and FRDA mouse (bottom panel).  
Control 
FRDA 
Left front stride 
Right front stride 
Left hind stride 
Right hind stride 
Hind base Fore base 
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38.5cm long, 9.5cm wide gangway (with 7cm high side walls) with white paper lining the 
floor. All mice had one training run and were then given three trials. Three steps from the 
middle portion of each run with a total number of nine steps for each mouse were 
measured for left hind and front stride length, right hind and front stride length, fore base 
width (the width between the right and left forelimbs) and hind base width (the width 
between the right and left hindlimbs), Fig. 3.8. The mutant and control littermate mice 
used in this study are listed in Table 3.1. 
 
    3.2.8 Glucose Tolerance Test 
In order to determine the blood glucose readings, 1mg/g glucose solution (D-Glucose, 
Sigma Aldrich) was injected intraperitoneally into the mice after a 16 hour fasting period. 
Blood glucose was measured from the tail vein immediately prior to glucose 
administration and after 20, 40 and 60 minutes with a glucometer (ACCU-CHEK
® 
Aviva 
blood glucose meter, Roche). The mutant and control littermate mice used in this study 
are listed in Table 3.1. 
 
    3.2.9 Insulin Tolerance Test 
For intraperitoneal insulin-tolerance test, the mice listed in Table 3.2 were fasted for 16 
hours. Blood glucose was measured from the tail vein and the mice received an 
intraperitoneal injection of insulin (0.75U/kg, Sigma Aldrich) and blood glucose was 
measured again at time points of 20, 50 and 80 minutes after injection. 
 
Table 3.2 The details of the mice used for insulin tolerance test  
 
Mouse 
 
Genotype Gender 
Total 
Number  
Number 
of Male 
& 
Female 
Average 
Weight 
(g) 
Weight 
(g) 
Average 
Age 
(month) 
 
B6 
C57BL6/J 
Control 
Male 
8 
2 
29.6 
37.5 3.8 
Female 6 26.9 3.7 
 
Y47R 
Transgenic 
Control 
Male 
10 
5 
22.6 
22.4 4.5 
Female 5 22.7 4.5 
 
YG22R 
FRDA 
YG22 
Rescue 
Male 
9 
5 
44.3 
49.4 11.2 
Female 4 38.1 13.1 
 
YG8JR 
FRDA 
YG8 Rescue 
Male 
10 
5 
20.5 
22.1 1.4 
Female 5 18.9 1.5 
 
YG8s R 
 
FRDA 
YG8 Small 
Rescue 
Male 
9 
4 
35.3 
41.2 13.5 
Female 5 30.5 12.6 
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    3.2.10 Statistical Analysis 
Functional measurements were statistically analysed by two way analysis of variance 
(ANOVA) and/or Student’s t test. The level of significance used throughout was P≤0.05. 
 
3.3 Results 
    3.3.1 Investigation of Motor Deficits in FRDA Mice Using Rotarod Test 
Motor coordination was assessed on a rotarod treadmill at monthly time points from 4-12 
months of age in YG8R and YG22R and YG8sR FRDA mice. C57BL/6J (B6) and Y47R 
(containing the human FXN YAC transgene with normal-sized GAA repeats) mice were 
used as the controls. 10 mice were assessed for each group, 5 males and 5 females. As 
evident in Fig. 3.9, the coordination ability of the YG22R, YG8R and YG8sR mice was 
significantly reduced when compared to B6 and Y47R controls, Table 3.3. This trend held 
true when both male and female values were taken together, Fig. 3.9A, or when male and 
female values were considered alone, Fig. 3.9B and Fig. 3.9C. However, the results from 
Student’s t test at 12 months indicated a considerable decrease in rotarod performance of 
all FRDA mice in comparison to B6 when males and females were taken together or 
when males were considered alone, Table 3.4. In contrast, detailed analysis of the female-
only values showed no statistically significant difference at 12 months, although a 
declining trend in rotarod performance was observed, Table 3.4. A possible explanation 
for such a trend may be due to the differences in body weight of males and females.  
 
Table 3.3 Two-way ANOVA analysis of rotarod performance in FRDA mice  
 
Mouse 
 
Genotype Gender Versus B6  
Versus B6 
(Male & 
Female) 
Versus 
Y47R 
Versus Y47R 
(Male & 
Female) 
 
YG22R 
FRDA 
YG22 
Rescue 
Male P=2.03E-29 
 
 
P=8.89E-10 
 
 
P=4.84E-09 
 
 
P=0.03 
 
Female P=0.001 
 
P=0.01 
  
YG8R 
FRDA 
YG8 
Rescue 
Male P=9.48E-36 
 
 
 
P=3.25E-34 
 
 
P=7.09E-13 
 
 
 
P=3.77E-16 
 
 
Female P=9.88E-06 
 
P=1.51E-06 
 
 
 
YG8s R 
 
FRDA 
YG8 Small 
Rescue 
Male P=1.27E-11 
 
 
 
 
P=2.32E-12 
 
P=0.76 
 
 
P=5.59E-06 
 
Female P=1.26E-14 
 
 
P=4.01E-12 
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The body weight from selected littermates was also recorded monthly from 4-12 months 
of age. YG22R, YG8R and YG8sR mice demonstrated a significant increase in weight 
compared to B6 control when both male and female values were taken together, Fig. 
3.10A. A similar trend was also observed when male and female values were considered 
alone, Fig. 3.10B and Fig. 3.10C. The statistical significance of the differences was 
evaluated by two-way ANOVA, Table 3.5. The increase in weight may be attributed to 
the observed decreased locomotor activity of the mice. However, unlike B6, Y47R 
showed a considerable increase in weight in comparison to all the tested mice. This in 
turn may have affected their rotarod performance as evident in Fig. 3.9 and Fig. 3.10. In 
addition, the greater rotarod performance of the females in comparison to the males may 
be due to their lower body weight. Since body weight influences the rotarod performance, 
the rotarod values were corrected for body weight. As represented in Fig. S.1, the 
difference in the rotarod performance of B6 and Y47R controls was small in magnitude 
when normalised by the weight factor. Although the decline in the rotarod performance of 
Y47R was attributed to the increase in the body weight, other genetic factors may play a 
part in the observed trend since Y47R mice are transgenic. The statistical significance of 
 
 
Fig. 3.9 Rotarod analysis of YG22, YG8 and YG8s rescue mice. Rotarod analysis of 
YG22R, YG8R and YG8sR compared to B6 and Y47R controls shows a coordination 
deficit in all three rescue mice when A) both male and female values were taken together 
(n=10 mice per genotype) or B) male alone (n=5 mice per genotype) or C) female alone 
(n=5 mice per genotype). Error bars indicate SEM and values represent mean ± SEM.  
C 
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the differences was evaluated by two-way ANOVA and Student’s t test as depicted in 
Table S.1 and Table S.2 respectively. 
 
Table 3.4 Student’s t test analysis of rotarod performance in FRDA mice from 4 to 12 months 
 
Mouse 
Male 
and 
Female 
4m 5m 6m 7m 8m 9m 10m 11m 12m 
 
YG22R 
Vs B6 
 
0.28 
 
0.37 
 
0.34 
 
0.73 
 
0.03 
 
0.004 
 
2.95E-05 
 
0.0003 
 
0.0008 
 
Vs Y47R 
 
0.31 
 
0.56 
 
0.66 
 
0.17 
 
0.17 
 
0.04 0.2 
 
0.79 
 
0.16 
 
 
YG8R 
Vs B6 
 
4.35E-05 
 
0.49 
 
0.0002 
 
0.0002 
 
7.39E-09 
 
4.44E-06 
 
1.7E-06 
 
7.92E-08 
 
0.0001 
 
Vs Y47R 
 
2.83E-05 
 
0.03 
 
0.001 
 
9.31E-06 
 
0.01 
 
6.74E-05 
 
0.15 
 
0.55 
 
0.08 
 
 
YG8sR 
 
Vs B6 
 
0.92 0.08 0.92 
 
0.79 
 
0.09 
 
0.001 
 
3.07E-05 
 
3.58E-08 
 
8.95E-05 
 
Vs Y47R 
 
0.99 
 
0.48 
 
0.64 
 
0.19 
 
0.02 
 
0.01 
 
0.40 
 
0.39 
 
0.06 
 
 
Mouse 
 
Male 4m 5m 6m 7m 8m 9m 10m 11m 12m 
 
YG22R 
Vs B6 
 
0.04 
 
0.01 
 
0.01 
 
0.007 
 
0.001 
 
1.1E-06 
 
1.23E-07 
 
8.49E-06 
 
5.67E-07 
 
Vs Y47R 
 
0.07 
 
0.002 
 
0.02 
 
0.007 
 
0.72 
 
0.0001 
 
0.08 
 
0.55 
 
0.09 
 
 
YG8R 
Vs B6 
 
0.001 
 
0.009 
 
0.0001 
 
2.47E-05 
 
5.24E-06 
 
1.11E-05 
 
3.47E-07 
 
8.89E-05 
 
5.91E-06 
 
Vs Y47R 
 
0.001 
 
0.001 
 
0.0003 
 
2.2E-05 
 
0.02 
 
0.002 
 
0.22 
 
0.74 
 
0.48 
 
 
YG8sR 
 
Vs B6 
 
0.03 
 
0.50 
 
0.01 
 
0.007 
 
0.003 
 
8.87E-07 
 
5.64E-06 
 
5.69E-05 
 
4.35E-06 
 
Vs Y47R 
 
0.05 
 
0.23 
 
0.03 
 
0.006 
 
0.66 
 
3E-05 
 
0.87 
 
0.90 
 
0.59 
 
 
Mouse 
 
Female 4m 5m 6m 7m 8m 9m 10m 11m 12m 
 
YG22R 
Vs B6 
 
0.51 
 
0.0006 
 
0.18 
 
0.01 
 
0.70 
 
0.21 
 
0.99 
 
0.46 
 
0.50 
 
Vs Y47R 
 
0.63 
 
0.02 
 
0.11 
 
0.50 
 
0.02 
 
0.92 
 
0.64 
 
0.32 
 
0.61 
 
 
YG8R 
Vs B6 
 
0.01 
 
0.09 
 
0.19 
 
0.53 
 
0.0002 
 
0.05 
 
0.32 
 
0.0003 
 
0.62 
 
Vs Y47R 
 
0.005 
 
0.67 
 
0.38 
 
0.03 
 
0.31 
 
0.005 
 
0.21 
 
0.13 
 
0.04 
 
 
YG8sR 
 
Vs B6 
 
0.02 
 
0.0002 
 
0.10 
 
0.0001 
 
0.07 
 
0.57 
 
0.40 
 
0.0002 
 
0.50 
 
Vs Y47R 
 
0.03 
 
0.004 
 
0.06 
 
0.15 
 
0.0002 
 
0.57 
 
0.26 
 
0.09 
 
0.02 
 
 
Table 3.5 Two-way ANOVA analysis of body weight in FRDA mice 
 
Mouse 
 
Genotype Gender Versus B6  
Versus B6 
(Male & 
Female) 
Versus 
Y47R 
Versus Y47R 
(Male & 
Female) 
 
YG22R 
FRDA 
YG22 
Rescue 
Male P=1.26E-05 
 
 
 
P=2.34E-05 
 
 
 
P=6.43E-10 
 
 
 
P=0.0006 
 
Female P=0.01 
 
P=0.54 
  
YG8R 
FRDA 
YG8 
Rescue 
Male P=9.04E-06 
 
 
 
 
P=0.009 
 
 
P=1.83E-07 
 
 
 
 
P=0.0001 
 
 
Female P=0.93 
 
P=0.05 
 
 
 
YG8s R 
 
FRDA 
YG8 Small 
Rescue 
Male P=1.06E-07 
 
 
 
 
 
P=6.31E-05 
 
 
P=0.001 
 
 
P=0.01 
 
Female P=0.51 
 
 
P=0.006 
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    3.3.2 Investigation of Motor Deficits in FRDA Mice Using Beam-breaker Test 
Locomotor activity of the mice, including average velocity, ambulatory distance, vertical 
count and time, jump count and time were measured over a 2 minute period and repeated 
four times for each mouse using a beam-breaker activity. 10 mice including 5 males and 5 
females were assessed monthly for each group over an 8 month period from 4-12 months 
of age. Statistical analysis was performed by two-way ANOVA method for all the 
experimental results, Table 3.6.  As shown in Fig. 3.11, YG8R, YG22R and YG8sR mice 
exhibited significantly lower average velocity (total distance covered divided by the total 
time elapsed) compared to B6 and Y47R controls. A similar trend was observed when 
male and female were taken together, Fig. 3.11A, or analysed separately, Fig. 3.11B and 
Fig. 3.11C respectively. 
 
 
 
 
Fig. 3.10 Body weight analysis of mice. A) Weight analysis of YG22R, YG8R and 
YG8sR compared to B6 and Y47R controls when both male and female values were 
taken together (n=10 mice per genotype).  The results indicated a significant increase in 
weight of all FRDA mice in comparison to B6 control. A similar tendency was seen when 
B) male and C) female values were analysed separately (n=5 mice per genotype). Error 
bars indicate SEM and values represent mean ± SEM. 
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Ambulatory distance (total distance covered by the mice within a specific time) traveled 
by FRDA mice were significantly less than the controls when male and female were taken 
together, Fig. 3.12A. The same trend held true when males, Fig. 3.12B, and females, Fig. 
3.12C, were analysed separately except in the case of YG8sR female where higher 
ambulatory values were observed; possibly due to their lower body weight. 
  
 
Fig. 3.11 Average velocity of mice. A) YG8R, YG22R and YG8sR displayed 
significantly decreased average velocity compared to B6 and Y47R controls when both 
male and female values were taken together (n=10 mice per genotype). Analysis of A) 
males and B) females separately (n=5 mice per genotype) revealed that all three deficient 
genotypes had decreased average velocity compared to the controls. Error bars indicate 
SEM and values represent mean ± SEM. 
C 
87 
 
 
 
 
 
A 
B 
88 
 
The vertical count and time (total number and time when the mouse stands with the hind 
legs) were also measured. As evident in Fig. 3.13, a significant decrease in the vertical 
count and time was detected in the FRDA mice compared to the controls when analysing 
males and females together and separately. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.12 Ambulatory distance of mice. A) YG8R, YG22R and YG8sR displayed 
significantly decreased ambulatory distance compared to B6 and Y47R controls when 
both male and female values were taken together (n=10 mice per genotype). Analysis of 
B) males and C) females separately (n=5 mice per genotype) revealed the same pattern, 
except YG8sR female which had greater ambulatory distance. Error bars indicate SEM 
and values represent mean ± SEM.  
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Fig. 3.13 Vertical time and count of mice. A) Vertical time and D) count were 
significantly decreased in YG8R, YG22R and YG8sR compared to B6 and Y47R controls 
when both male and female values were analysed together (n=10 mice per genotype). 
Analysis of B, E) males and C, F) females separately (n=5 mice per genotype) revealed 
the same pattern. Error bars indicate SEM and values represent mean ± SEM.  
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Subsequently, the Jump count and time (total number and time that the mouse jumps) 
were recorded. As evident in Fig. 3.14, a significant decrease in jump count and time was 
detected in the FRDA mice compared to the controls when analysing males and females 
together and separately. 
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Fig. 3.14 Jump time and count of mice. A) Jump time and D) count were significantly 
decreased in YG8R, YG22R and YG8sR compared to B6 and Y47R controls when both 
male and female values were taken together (n=10 mice per genotype). Analysis of B, E) 
males and C, F) females separately (n=5 mice per genotype) revealed the same pattern. 
Error bars indicate SEM and values represent mean ± SEM.  
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Table 3.6 Two-way ANOVA analysis of locomotor activity in FRDA mice  
Locomotor 
Activity 
Mouse Gender Versus B6 
Versus B6 
(Male & 
Female) 
Versus 
Y47R 
Versus Y47R 
(Male & 
Female) 
 
 
 
Average 
Velocity 
 
 
 
 
YG22R 
Male P=0.007 
 
 
P=0.002 
 
P=0.008 
 
 
P=0.4 
 
Female P=0.08 
 
P=0.1 
  
YG8R 
Male P=1.91E-05 
 
 
P=7.26E-12 
 
 
P=0.2 
 
 
P=0.004 
 
Female P=9.79E-08 
 
P=2.95E-08 
  
YG8s R 
 
Male P=7.87E-12 
 
 
P=1.74E-12 
 
P=0.1 
 
 
P=0.001 
 
Female P=0.001 
 
P=0.002 
 
Ambulatory 
distance 
 
YG22R 
Male P=0.007 
 
 
P=0.0001 
 
 
P=0.3 
 
 
P=0.01 
 
 
Female P=0.006 
 
P=0.01 
 
YG8R 
Male P=5.01E-08 
 
 
P=1.22E-12 
 
 
 
P=0.0001 
 
 
P=1.04E-08 
 
 
Female P=3.18E-06 
 
P=1.61E-05 
  
YG8s R 
 
Male P=1.28E-14 
 
 
P=0.004 
 
 
P=2.39E-09 
 
 
P=0.1 
 
 
Female P=0.004 
 
P=0.004 
 
 
Vertical 
Time 
 
YG22R 
Male P=0.6 
 
 
P=0.0006 
 
 
 
P=0.1 
 
 
P=0.5 
 
 
Female P=1.95E-06 
 
P=0.002 
  
YG8R 
Male P=0.008 
 
 
P=1.87E-07 
 
 
 
 
P=0.8 
 
 
P=0.03 
 
 
 
Female P=1.47E-06 
 
P=0.001 
  
YG8s R 
 
Male P=4.42E-07 
 
 
P=1.88E-12 
 
 
 
P=0.01 
 
 
P=5.62E-05 
 
 
 
Female P=1.07E-06 
 
P=0.001 
 
Vertical 
Count 
 
YG22R 
Male P=0.02 
 P=2.71E-06 
 
 
 
 
P=0.07 
 
 
P=0.8 
 
 
Female P=1.89E-06 
 
P=0.06 
  
YG8R 
Male P=0.0007 
 
 
P=1.48E-09 
 
 
 
 
 
P=0.5 
 
 
P=0.2 
 
 
 
Female P=4.86E-08 
 
P=0.01 
  
YG8s R 
 
Male P=2.26E-12 
 P=1.05E-16 
 
 
 
 
P=0.001 
 
 
 
 
 
P=0.0004 
 
 
 
 
Female P=7.08E-06 
 
P=0.09 
 
Jump Time 
 
YG22R 
Male P=0.6 
 P=0.5 
 
 
 
 
P=0.4 
 
 
P=0.7 
 
 
Female P=0.5 
 
P=0.1 
  
YG8R 
Male P=0.0001 
 
 
P=0.01 
 
 
 
 
 
P=0.04 
 
 
P=0.06 
 
 
 
Female P=0.9 
 
P=0.4 
  
YG8s R 
 
Male P=7.84E-10 
 P=4.67E-05 
 
 
 
 
 
P=5.17E-05 
 
 
P=0.0008 
 
 
 
 
 
Female P=0.9 
 
P=0.3 
 
Jump Count 
 
YG22R 
Male P=0.1 
 P=0.05 
 
 
 
 
P=0.8 
 
 
P=0.2 
 
 
Female P=0.1 
 
P=0.03 
  
YG8R 
Male P=1.3E-09 
 P=6.42E-07 
 
 
 
 
 
 
P=0.0002 
 P=0.0001 
 
 
 
 
Female P=0.3 
 
P=0.09 
  
YG8s R 
 
Male P=8.34E-14 
 P=2.37E-09 
 
 
 
 
 
 
P=5.05E-07 
 
 
P=2.41E-06 
 
 
 
 
 
 
Female P=0.4 
 
P=0.1 
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    3.3.3 Investigation of Motor Deficits in FRDA Mice Using Beam-walk Test 
Beam-walk performance was assessed for the investigation of motor deficiencies in 
YG8R and YG22R and YG8sR FRDA mice while B6 and Y47R were used as the 
controls. 10 mice, 5 males and 5 females, were assessed for each group and the average 
latency of 4 trials on 22×900mm and 12×900mm beams was recorded. As evident in Fig. 
3.15A, the FRDA mice took significantly longer to cross both 22mm and 12mm beams 
compared to the controls when analysing males and females together. However, no 
significant difference was detected in the beam-walk performance of YG22R on the 
12mm beam compared to Y47R control. This may be due to the higher body weight of 
YG22R mice, affecting their balance and performance on the narrower beam. The same 
trend was observed when female values were considered alone, Fig. 3.15C. All three 
female deficient genotypes took significantly longer than B6 and Y47R to cross the 
22mm and 12mm beams except YG22R on the latter beam. The significance of these 
observations was confirmed by Student’s t test which indicated a significant effect of 
genotype on the latency between mutant and control mice when traversing both beams. 
The analysis of YG8R, YG22R, and YG8sR males also showed a coordination deficit on 
both 22mm and 12mm beams when compared to B6 controls, Fig. 3.15B. However, 
detailed analysis of the male values on the 12mm beam indicated no significant difference 
in comparison to Y47R due to their higher weight. These results suggest that although the 
beam-walk is an effective model to assess severity of the FRDA disease, other factors 
such as body weight and age might have an impact on the experimental results. 
 
In order to assess the effect of body weight on animals’ performance, the beam-walk 
values were normalised by the body weight. As shown in Fig. S.2, body weight did not 
change the pattern of significance when both males and females were considered together 
or females alone. However, the difference between the FRDA and Y47R male mice was 
significant when the values were normalised. 
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    3.3.4 Investigation of Motor Deficits in FRDA Mice Using Hang Wire Test 
To further assess the neurological consequences of frataxin depletion, mutant mice were 
analysed by hang wire test. The mice were hung from a horizontally positioned wire with 
each end affixed to a vertical stand and the length of time the mouse held onto the wire 
was recorded. 10 mice were assessed for each group including 5 males and 5 females. 
As represented in Fig. 3.16, the YG8R, YG22R and YG8sR mice fell off the hang wire  
 
 
Fig. 3.15 Beam-walk analysis of mice. A) Analysis of YG8R, YG22R and YG8sR 
compared to B6 and Y47R controls showed a coordination deficit on both 22mm and 
12mm beams in all rescue mice (n=10 mice per genotype) when both male and female 
values were taken together. However, no significant difference in beam-walk of YG22R 
on the 12mm beam was observed in comparison to Y47R control. B) Beam-walk analysis 
of YG8R, YG22R, and YG8sR male mice compared to B6 control (n=5 mice per 
genotype) revealed that all three deficient genotypes required significantly more time to 
cross the 22mm and 12mm beams, however there was no significant difference between 
these mice and Y47R control. C) Analysis of female littermates of both YG8R and 
YG8sR (n=5 mice per genotype) showed that these mice took significantly longer than B6 
and Y47R to cross both 22mm and 12mm beams. Although YG22R followed a similar 
performance trend as that of YG8R and YG8sR on the 22mm and 12mm beams compared 
to B6 and Y47R controls, the difference in beam-walk on 12mm beam was not 
significant. Error bars indicate SEM and values represent mean ± SEM. Asterisks indicate 
significant differences between mutant and control mice (
*
P<0.05, 
**
P<0.01 and 
***
P<0.001). Statistical differences between mutant and B6 control mice are indicated by 
the top line drawn over the bars while the bottom line indicates the differences between 
mutant and Y47R control mice. 
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quicker when compared to Y47R and B6 controls, suggesting a reduced strength. This 
trend held true when male and female values were taken together, Fig. 3.16A, or when 
male and female values were considered separately (for comparison with B6), Fig. 3.16B 
and Fig. 3.16C respectively. Significant differences between the performances of mutant 
and control mice were confirmed by the Student’s t test. A significant difference was also 
seen between female mutant and Y47R control mice, Fig. 3.16B. However, no significant 
difference was observed between male mutant and Y47R control mice, Fig. 3.16C. This 
may be attributed to the heavier weight of Y47R male mice, preventing them from 
clinging to the wire for any extended period of time. 
 
 
 
 
 
Fig. 3.16 Hang wire analysis of mice. A) Analysis of YG8R, YG22R and YG8sR 
revealed impaired neuromuscular strength and lack of coordinated motor control 
compared to B6 and Y47R controls when both male and female values were taken 
together (n=10 mice per genotype). Analysis of YG8R, YG22R and YG8sR B) males and 
C) females separately (n=5 mice per genotype) revealed the same pattern compared to B6 
and Y47R controls. However, there was no significant different between all male mutant 
and Y47R control mice. Error bars indicate SEM and values represent mean ± SEM. 
Asterisks indicate significant differences between mutant and control mice (
*
P<0.05, 
**
P<0.01 and 
***
P<0.001). Statistical differences between mutant and B6 control mice are 
indicated by the top line drawn over the bars while the bottom line indicates the 
differences between mutant and Y47R control mice. 
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    3.3.5 Investigation of Motor Deficits in FRDA Mice Using Grip Strength Test 
To further assess forelimb grip strength, a grip strength meter was used to measure the 
peak force with which mice pulled a wire. 10 mice were assessed for each group, 5 males 
and 5 females, to identify the correlation between the hang wire and grip strength 
performance of the FRDA mice. The results showed a significant decrease in grip 
strength of all YG8R, YG22R and YG8sR mice compared to Y47R and B6 controls. This 
trend held true when both male and female values were taken together, Fig. 3.17A, or 
when male and female values were considered alone, Fig. 3.17B and Fig. 3.17C 
respectively. The significance of the difference between the groups was confirmed by 
Student’s t test, indicating the significance of the difference between the performance of 
mutant and control mice. 
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Fig. 3.17 Grip strength analysis of mice. A) Analysis of YG8R, YG22R and YG8sR 
revealed significantly reduced grip strength compared to B6 and Y47R controls when 
both males and females were analysed together (n=10 mice per genotype). Analysis of B) 
males and C) females separately (n=5 mice per genotype) revealed a significant decrease 
in grip strength of all mutant mice compared to the controls. Error bars indicate SEM and 
values represent mean ± SEM. Asterisks indicate significant differences between mutant 
and control mice (
*
P<0.05, 
**
P<0.01 and 
***
P<0.001). Statistical differences between 
mutant and B6 control mice are indicated by the top line drawn over the bars while the 
bottom line indicates the differences between mutant and Y47R control mice. 
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    3.3.6 Investigation of Gait Deficits in FRDA Mice Using a Foot Print Test 
To characterise the motor behavioural phenotype of FRDA mice, gait abnormalities were 
assessed by analysing the footprint pattern of mutant and control mice while they walked 
along a narrow gangway. As evident in Fig. 3.8, the control mice walked in a straight line 
with a regular and even alternating stride, whereas YG8R, YG22R and YG8sR mice 
progressively moved from side to side while walking along the gangway, demonstrating 
an overall loss of control of fine movement. Moreover, further analysis of the footprints 
indicated that both hind and front stride length decreased in YG8R, YG22R and YG8sR 
FRDA mice compared to Y47R and B6 controls, Fig. 3.18. This trend held true when 
both male and female values were taken together (n=10 mice per genotype), Fig. 3.18A, 
or when female values were considered alone (n=5 mice per genotype), Fig. 3.18B. 
Although, FRDA male mice exhibited the same pattern in stride length in comparison to 
the controls (n=5 mice per genotype), Fig. 3.18C, only stride length in left hindlimb and 
right forelimb of YG8sR, and left forelimb and right forelimb of YG22R were 
significantly different compared to those of the controls. There was also a significant 
decrease in right hindlimb of YG8sR mice compared to Y47R control.  
 
 
A 
*** *** *** 
*** *** *** 
*** *** *** 
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*** *** *** 
*** *** *** 
*** *** *** 
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Fig. 3.18 Stride length analysis of mice. A) Analysis of YG8R, YG22R and YG8sR 
revealed significantly reduced stride length compared to B6 and Y47R controls when 
both male and female values were taken together (n=10 mice per genotype). Analysis of 
B) males and C) females separately (n=5 mice per genotype). Error bars indicate SEM 
and values represent mean ± SEM. Asterisks indicate significant differences between 
mutant and control mice (
*
P<0.05, 
**
P<0.01 and 
***
P<0.001). Statistical differences 
between mutant and B6 control mice are indicated by the top line drawn over the bars 
while the bottom line indicates the differences between mutant and Y47R control mice. 
B 
P=0.1 
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FRDA mice were also analysed for hind base and fore base width. The results indicated 
significantly shorter base width of both hind and forepaws, Fig. 3.19. This trend held true 
when both male and female values were analysed together (n=10 mice per genotype), Fig. 
3.19A, or when male and female values were considered alone (n=5 mice per genotype), 
Fig. 3.19B and Fig. 3.19C respectively. However, there was no significant difference in 
hind base width of YG8R male mice compared to B6 male control.  
 
 
 
 
A 
*** *** *** 
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*** *** P=0.7 
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In addition, the average stride length (left/right hindlimb and left/right forelimb), Fig. S.3, 
and the average base width (hind and fore base width), Fig. S.4, followed the same pattern 
as those previously observed in Fig. 3.19. The significance of the difference between the 
groups was confirmed by Student’s t test. The results highlighted the non-uniformity in 
step alteration and lack of coordination in FRDA mouse models, also inherent in FRDA 
patients.  
 
    3.3.7 Glucose Tolerance Response in FRDA Mouse Models 
To determine the prevalence of abnormalities in glucose handling in FRDA mice, a 
glucose tolerance test was performed in three FRDA mouse models (YG8R, YG22R and 
YG8sR) and two controls (Y47R and B6) after a 16h fasting period. 1mg/g glucose was 
administered intraperitoneally and blood glucose concentration was measured prior to 
 
 
Fig. 3.19 Base width analysis of mice. A) Analysis of YG8R, YG22R and YG8sR 
revealed significantly shorter base width of both fore and hindpaws compared to B6 and 
Y47R controls when both male and female values were taken together (n=10 mice per 
genotype). Analysis of B) males and C) females separately (n=5 mice per genotype) 
showed a significant decrease in both fore and hind base width in all mutant mice 
compared to the controls. Error bars indicate SEM and values represent mean ± SEM. 
Asterisks indicate significant differences between mutant and control mice (
*
P<0.05, 
**
P<0.01 and 
***
P<0.001). Statistical differences between mutant and B6 control mice are 
indicated by the top line drawn over the bars while the bottom line indicates the 
differences between mutant and Y47R control mice. 
*** *** *** 
*** *** *** 
*** *** *** 
*** *** *** 
C 
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glucose administration and after 20, 40 and 60 minutes using a glucometer. 10 mice, 5 
males and 5 females, were assessed for each group. As evident in Fig. 3.20A, blood 
glucose concentration was higher in all three FRDA mouse models compared to Y47R 
and B6 controls when both male and female values were analysed together, suggesting 
glucose intolerance response in these mice. However due to large individual variations, 
the differences did not reach the statistical significance analysed by Student’s t test, 
except YG8sR which had a significant glucose intolerance response at 40 and 60 minute 
time points compared to Y47R and B6 controls respectively (P<0.05), Fig. 3.20A. A 
similar tendency was observed when male values were considered alone. A significant 
difference was identified in YG22R at 40 minute time point and in YG22R and YG8sR 
mice at 60 time point compared to Y47R and B6 controls (P<0.05), Fig. 3.20B. 
Surprisingly, female mice responded differently to the glucose tolerance test. The 
excursions in glucose indicated no difference in female YG22R, YG8sR and control 
mice, except YG8R which had a higher glucose concentration after 40 minutes, Fig. 
3.20C. The basal glucose concentrations of FRDA and control mice were similar, 
however between the genders, female mice displayed a lower basal glucose level than 
their male counterparts. This might be due to the lower body weight of the female mice 
and thus higher insulin sensitivity, Fig. 3.20D. Fold change analysis did not provide 
additional information regarding the glucose tolerance test, Fig. S.5. For all time points, 
statistical analysis using two-way ANOVA was performed for all the groups, Table 3.7. 
 
 
* YG8s v Y47 
A 
 
* YG8s v B6 
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Table 3.7 Two-way ANOVA analysis of glucose tolerance in FRDA mouse models 
 
Mouse 
 
Genotype Gender Versus B6  
Versus B6 
(Male & 
Female) 
Versus 
Y47R 
Versus Y47R 
(Male & 
Female) 
 
YG22R 
FRDA 
YG22 
Rescue 
Male P=0.001  
P=0.8 
 
P=0.0009  
P=0.2 
 
Female P=0.09 
 
P=0.4 
  
YG8R 
FRDA 
YG8 
Rescue 
Male P=0.07 
 
 
P=0.1 
 
P=0.1 
 
 
P=0.02 
 
Female P=0.001 P=0.7 
  
YG8s R 
 
FRDA 
YG8 Small 
Rescue 
Male P=0.003 
 
 
 
P=0.004 
 
P=0.005 
 P=0.0003 
Female P=0.3 
 
P=0.02 
 
 
 
    3.3.8 Insulin Tolerance Response in FRDA Mouse Models 
To determine insulin sensitivity in FRDA mice, an insulin tolerance test was performed in 
three FRDA mouse models (YG8R, YG22R and YG8sR) and two controls (Y47R and 
B6) after a 16h fasting period. 0.75U/kg insulin was administered intraperitoneally and 
 
 
Fig. 3.20 Glucose tolerance test of mice. A) Glucose concentration was higher in YG8R, 
YG22R and YG8sR compared to B6 and Y47R controls when both male and female 
values were taken together (n=10 mice per genotype). B) Similar results were obtained 
when male values were considered alone (n=5 mice per genotype). C)  Analysis of female 
mice showed no difference between the FRDA and control mice (n=5 mice per genotype). 
D) The disparity in body weight of males and females. Error bars indicate SEM and 
values represent mean ± SEM. Asterisks indicate significant differences between mutant 
and control mice (
*
P<0.05, 
**
P<0.01 and 
***
P<0.001), analysed by Student’s t test. 
** 
 
D 
 
** 
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blood glucose concentration was measured prior to insulin administration and after 20, 50 
and 80 minutes using a glucometer. 10 YG8R (5 males and 5 females), 9 YG22R (5 
males and 4 females), 9 YG8sR (4males and 5 females), 8 B6 (2 males and 6 females) 
and 10 Y47R (5 males and 5 females) were assessed. As evident in Fig. 3.21A, control 
mice did not show any apparent lowering of blood glucose. In contrast; FRDA mice, 
except YG8R, showed lower blood glucose levels after 50 minute time point, indicating a 
relative increase in insulin sensitivity with respect to control littermates, Fig. 3.21A. The 
results from the male littermates indicated that although the blood glucose concentration 
was normalised after 50 minutes, FRDA male mice exhibited a more rapid glucose 
lowering after insulin injection, Fig. 3.21B. Female FRDA mice had a greater reduction in 
blood glucose concentration after 50 minutes, suggesting insulin hypersensitivity, Fig. 
3.21C. However, YG8R had smaller changes in blood glucose after insulin injection; this 
may be due to their lower body weight, Fig. 3.21D. Fold change analysis also revealed the 
difference in glucose concentration between the mutant and control mice, Fig. S.6. The 
significance of the difference between the groups was confirmed by Student’s t test. 
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3.5 Discussion 
Previous studies demonstrated that both YG22R and YG8R FRDA mice expressed 
comparatively decreased levels of human frataxin in comparison to the endogenous 
mouse levels [31]. However, the results indicated that YG8R exhibited slightly less 
frataxin expression in comparison to YG22R. Therefore, it was hypothesised that the 190 
and 190 + 90 GAA repeat expansion mutation sizes within YG22 and YG8 may induce 
the FRDA-like pathological phenotype and functional deficits. To determine the effect of 
reduced frataxin level on FRDA-like pathological phenotype and functional deficits, 
coordination ability of YG8R, YG22R and recently generated YG8sR was assessed using 
an accelerating rotarod apparatus over an 8 month period from 4 to 12 months of age. B6 
and Y47R (containing the human FXN YAC transgene with normal-sized GAA repeats) 
were used as the controls. The YG8R, YG22R and YG8sR showed a significant decline 
 
 
Fig. 3.21 Insulin tolerance test of mice. A) YG8R, YG22R and YG8sR showed lower 
blood glucose level after insulin injection compared to B6 and Y47R controls when both 
male and female values were considered. B) Although the blood glucose concentration 
was normalised after 50 minutes, FRDA male mice exhibited a more rapid glucose 
lowering after insulin injection. C)  Female mice showed a greater reduction in blood 
glucose concentration after 50 minutes. D) The disparity in body weight of males and 
females. Error bars indicate SEM and values represent mean ± SEM. Asterisks indicate 
significant differences between mutant and control mice (
*
P<0.05, 
**
P<0.01 and 
***
P<0.001). 
D 
 
** 
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in their motor function compared to B6 and Y47R controls, though, the degree of 
impairment was more significant in YG8R mice. However, Y47R littermate controls 
exhibited significantly reduced rotarod performance after 7 months of age which was not 
expected. A possible explanation for such performance irregularity may be due to the 
higher initial weight of Y47R. On the other hand, analysis of the male and female values 
alone indicated that the former are more affected than the latter. This may be due to 
several factors. Firstly, lower body weight of the females may have contributed to the 
improved function of these mice. Secondly, females may be more capable of adapting to 
the experimental environment and conditions compared to the male mice. Moreover, body 
weight analysis of YG22R, YG8R and YG8sR demonstrated an increase in weight 
compared to B6. The increase in weight may be attributed to the observed decreased 
locomotor activity of the mice. However, unlike B6, Y47R showed a considerable 
increase in weight in comparison to all the tested mice. In order to reduce the effect of 
body weight on rotarod performance, the results were normalised by the body weight 
factor. The normalised results indicated small difference in the rotarod performance of B6 
and Y47R controls. However, the decline in the rotarod performance of Y47R may not 
have been solely due to the body weight since Y47R were transgenic and other genetic 
factors may have contributed. Therefore, it is suggested to use B6 as the control in the 
future studies. The coordination deficiency in YG8R and YG22R was previously assessed 
by rotarod analysis and open field assay using WT control [31]. The results obtained as 
part of this investigation were in good agreement with those previously reported [31], 
further supporting the notion that the additional 90 GAA repeats in the YG8 line may be 
responsible for an even more pronounced functional deficiency.  
 
The locomotor activity analysis using beam-breaker apparatus showed a significant 
decrease in average velocity, ambulatory distance, vertical time and count, jump time and 
count of the mutant mice compared to B6 and Y47R controls which were consistent with 
those previously reported [31]. However, YG8sR females showed greater ambulatory 
distance which was not expected. A possible explanation for such performance 
irregularity may be due to the lower body weight of these mice, suggesting gender 
dependent differences in body weight and functional activity of the FRDA mouse models. 
To further assess the motor behaviour and balance in the FRDA mice, beam-walk test was 
utilised using two different beam sizes, 12mm and 22mm. The results indicated that the 
FRDA mice took significantly longer to cross both beams in comparison to the controls. 
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However the difference was more significant when compared to the B6 control. This may 
be due to the higher body weight of Y47R mice, affecting their balance and performance. 
Muscle strength, assessed by forelimb grip strength and hang wire tests, was significantly 
decreased in all the FRDA mice compared to B6 and Y47R controls. Gait parameters 
(stride length and base width) of the mutant and control mice were also evaluated by 
footprint analysis. The results showed a non-uniform gait pattern with significantly 
decreased stride length and base width in the FRDA mice compared to B6 and Y47R 
controls. These results were in good agreement with those previously reported [230]. The 
identified functional deficits in the FRDA mouse models may be due to the reduced levels 
of frataxin, inducing an FRDA-like phenotype. If so, then these functional tests provide 
an experimental approach capable of detecting the phenotypic consequences of the 
reduced level of frataxin in the FRDA mice, making them amenable to novel therapeutic 
strategies. 
 
Another symptom of FRDA disease is susceptibility to diabetes. FRDA patients are at 
risk of getting increased blood sugar levels or glucose intolerance, with approximately 
20% progressing to overt diabetes as well as neurological problems. Therefore, glucose 
and insulin tolerance tests were performed in the FRDA mouse models to determine the 
prevalence of abnormalities in glucose handling and insulin sensitivity. The glucose 
tolerance results indicated that the FRDA mice were glucose intolerant. However, males 
and females responded differently, the excursions in glucose were similar in the female 
FRDA and the controls. This might be due to the lower body weight of the females, thus 
higher insulin sensitivity. Basal blood glucose level did not change amongst the tested 
mouse models. Taken together, these results indicated that insulin secretion following a 
glucose injection was delayed in the FRDA mice. This delay was more paramount in the 
males, suggesting increased body weight contributed to insulin resistance. Furthermore, 
the glucose-lowering effect of exogenous insulin was enhanced in the FRDA mouse 
models during insulin tolerance test, suggesting insulin hypersensitivity in these lines. 
Insulin hypersensitivity supports the existence of several pathways of insulin signalling, 
promoting glucose uptake and utilisation in peripheral tissues by either insulin-dependent 
or insulin-independent mechanisms. These results were consistent with those previously 
reported [215], suggesting mitochondrial dysfunction due to frataxin deficiency in the 
FRDA mouse models may contribute to pancreatic ß cell dysfunction. On this account, it 
is of interest to assess the relative contribution of insulin resistance and ß cell dysfunction 
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or deficiency in genes of the insulin receptor substrate (IRS) family in the future studies. 
This may provide a novel treatment strategy for the prevention of the disorder envisaged 
in FRDA patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV  
 
GAA REPEAT INSTABILITY AND FXN 
GENE AND PROTEIN EXPRESSION IN 
FRDA MOUSE MODELS 
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4.1 Introduction 
As previously stated in section 1.14 (chapter I), two lines of human FXN YAC transgenic 
mice which contained GAA repeat expansions of 190 repeats and 190+90 repeats, 
designated YG22R and YG8R respectively, were generated by the Ataxia Research 
Group, Brunel University. A new YG8sR (YG8R with a small GAA band) line was 
recently generated from YG8R breeding. Previous studies demonstrated that both YG8R 
and YG22R FRDA mice expressed comparatively decreased levels of human frataxin 
mRNA and protein in comparison to the endogenous mouse levels [31]. Other studies 
also revealed YG8 and YG22 to have decreased mRNA levels in brain and heart tissues 
compared to Y47 [67]. Furthermore, the YG8 and YG22 exhibited an FRDA-like 
molecular disease phenotype that included intergenerational and somatic instability of the 
GAA repeat expansion mutation [41, 103] as well as progressive functional deficits 
compared to wild-type controls that were consistent with FRDA disease [31]. To further 
investigate the pathological phenotype of FRDA mouse models, different functional 
analysis were carried out (chapter III) which revealed functional deficits in the YG8R, 
YG22R and YG8sR compared to the Y47R and B6 controls. The aims of this part of the 
investigation were to examine the frataxin mRNA and protein levels together with the 
somatic GAA repeat instability in the FRDA mouse models and to identify their 
correlation with FRDA-like pathological phenotype. Such studies are crucial to highlight 
the importance of careful interpretation of the phenotypes of the mouse models in 
selecting the optimum mouse models capable of reproducing most of the characteristic 
features of the FRDA disease. 
 
4.2 Materials and Methods 
    4.2.1 Collection and Preparation of Mouse Tissues  
Following the completion of functional analysis, the mice were sacrificed by cervical 
dislocation. The Tail (Ta), Brain (B), Cerebellum (C), Liver (L), Heart (H), Kidney (K), 
Pancreas (P) and Dorsal Root Ganglia (DRG) were collected from the control (B6 and 
Y47R) and FRDA (YG8R, YG22R and YG8sR) mice. The collected tissues were snap-
frozen in liquid nitrogen and stored at -80˚C. All procedures were carried out in 
accordance with the UK Home Office ‘Animals (Scientific Procedures) Act 1986’. 
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    4.2.2 Genomic DNA Isolation from Tissues 
Genomic DNA (gDNA) was isolated from mouse tissues using phenol/chloroform 
method as described in section 2.3.1.1 (chapter II). Tails of 5mm long and 50-100mg 
tissues (tail, brain, cerebellum, liver, heart, kidney and pancreas) were collected in 1.5ml 
tubes and digested by adding 400µl of digestion buffer and 10µl of 50mg/ml proteinase 
K. The samples were subsequently mixed and incubated in a 55˚C waterbath overnight. 
The following day, the incubated samples were vortexed and 400µl of phenol, 
equilibrated with Tris-HCl pH 8.0, was added. Samples were vortexed for 15 seconds and 
centrifuged at 16100 rcf for 5 minutes. The supernatant containing the DNA was removed 
and transferred to a clean 1.5ml microcentrifuge tube containing 500µl of 
chloroform/isoamyl alcohol (24:1, v/v). Subsequently, the samples were gently mixed by 
inverting the tubes and centrifuged at 16100 rcf for 5 minutes. Next, 350µl of the 
resulting supernatant was removed to a fresh microcentrifuge tube containing 800µl of 
absolute ethanol and 30µl of 3M Na-acetate (pH 5.2). Samples were mixed well by 
inverting the tubes several times and were subsequently placed at -80˚C for 10-15 
minutes. Genomic DNA was precipitated following this step and formed a visible mass. 
The DNA was pelleted by centrifugation at 16100 rcf for 30 minutes at 4˚C. After 
removing the supernatant, the DNA was washed with 1ml of 70% ethanol and centrifuged 
at 16100 rcf for 20 minutes at 4˚C. The ethanol was discarded and the DNA pellets were 
air-dried for 10-15 minutes at RT. The dried pellets were resuspended in 50µl T.E. buffer 
and stored at 4˚C. 
  
    4.2.3 Determination of Genomic DNA Quantity and Purity 
The concentration of DNA was read on the NanoDrop™ 2000c spectrophotometer 
(NanoDrop, Thermo Scientific) at 260 and 280nm wavelengths using 1µl of DNA.  
 
    4.2.4 Polymerase Chain Reaction (PCR) 
        4.2.4.1 GAA PCR 
The GAA PCR was performed on mouse genomic DNA samples to detect the genotype 
as previously described in section 2.3.1.2 (chapter II). The PCR products were visualised 
on a 1% ethidium bromide stained agarose gel. 
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        4.2.4.2 Long Gel GAA PCR 
In order to estimate the GAA repeat size in different FRDA mouse models, samples were 
initially tested for the presence of the FRDA YAC transgene by GAA PCR. 
Subsequently, the samples of interest were run along with 100bp and 1kb
+ 
DNA ladders 
overnight on a 20cm long gel made with 1.5% agarose and 1× TBE.  
 
    4.2.5 Extraction of Total RNA - Trizol
®
 Method  
Total RNA was isolated from the mouse tissues using an Invitrogen Trizol reagent 
following the manufacturer's instructions. To extract RNA, 30-40mg tissue samples were 
homogenised in 1ml of Trizol reagent by an Eppendorf homogenising rod and incubated 
for 10 minutes at RT. 200µl of chloroform (sigma-Aldrich) was then added per 1ml of 
Trizol to the samples. The samples were shaken vigorously for 15 seconds, incubated for 
15 minutes at RT and then centrifuged at 16100 rcf for 15 minutes at 4˚C. The chloroform 
caused the Trizol to separate into a colourless aqueous phase and an organic phase 
containing phenol and chloroform. RNA remained exclusively in an upper aqueous phase. 
DNA and protein can be extracted from the organic phase by further precipitation. The 
upper aqueous layer (~0.5ml) was removed to a new 1.5ml microcentrifuge tube and 
RNA was precipitated by adding 0.5ml of isopropanol (sigma-Aldrich). The samples were 
incubated for 10 minutes at RT and then centrifuged at 16100 rcf for 15 minutes at 4˚C. A 
pellet containing RNA was visible after the centrifugation. The supernatant was removed 
and the RNA pellet was washed with 1ml of 75% ethanol, vortexed and centrifuged at 
 
Fig. 4.1 Gel electrophoresis of the RNA samples using 1% agarose gel. Sharp, distinct 
bands corresponding to 28S (upper bands) and 18S (lower bands) ribosomal RNA 
indicate intact RNA. A 1kb
+ 
DNA ladder (Invitrogen) was used for size evaluation. 
-28S 
 
-18S 
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5250 rcf for 5 minutes at 4˚C. The supernatant was removed and the RNA pellet was left 
to air dry for about 5-10 minutes at RT. The pellet was resuspended in 20μl of nuclease 
free water and retropipetted several times. The samples were left on ice for at least one 
hour and stored at -80˚C. The concentration of RNA was read at 260 and 280nm with a 
Nanodrop spectrophotometer (Nanodrop 2000C, Thermo Scientific, UK) using 1μl of the 
RNA samples. RNA concentrations were measured to ensure a ratio of >1.7, indicating 
the RNA is free of proteins and DNA. Total RNA was also quality checked using 1µl of 
the RNA samples loaded onto a 1% agarose gel, Fig. 4.1.  
 
    4.2.6 DNase I Treatment of RNA 
Deoxyribonuclease I, Amplification Grade (DNase I, Amp Grade, Invitrogen) digests 
single and double stranded DNA to oligodeoxy-ribonucleotides containing 5´-phosphate. 
It is suitable for eliminating DNA during critical RNA purification procedures such as 
those prior to RNA-PCR amplification. DNase I, Amp Grade is purified from bovine 
pancreas and has a specific activity of ≥10,000U/mg.  
To remove any genomic DNA and inhibit RNase enzymes, following reagents were 
added to 1 µg of total RNA: 
 
- 1µl 10× DNase I reaction buffer 
- 1µl DNase I, Amp Grade, 1U/µl 
- Nuclease free water to 10µl 
 
The samples were left for 15 minutes at RT. DNase I reaction was inactivated by adding 
1μl of 25mM EDTA solution to the reaction mixture and heating it for 10 minutes at 
65˚C. The RNA samples were subsequently used for reverse transcription. 
 
    4.2.7 Complementary DNA (cDNA) Synthesis 
Cloned AMV first-strand cDNA synthesis kit (Invitrogen) was used to synthesise first 
strand cDNA. The following components were added to 5μl of the DNase I treated total 
RNA: 
 
- 1μl of Oligo (dT)20 Primer  
- 2μl of 10mM dNTP mix (10mM each of dATP, dGTP, dCTP, dTTP at neutral 
pH) 
- 4μl of DEPC-water 
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The mixtures were incubated for 5 minutes at 65˚C and then placed on ice for at least 1 
minute. The contents were collected and the following mixture was added: 
 
- 4μl of 5× cDNA synthesis buffer 
- 1μl of 0.1M DTT 
- 1μl of 40U/μl RNase Out 
- 1μl of 15U/μl cloned AMV RT 
- 1μl of DEPC-water 
 
The samples were gently mixed by pipetting up and down and were incubated at 55˚C for 
1 hour and then at 85˚C for further 5 minutes to terminate the reaction. The cDNA 
samples were used immediately or stored at -20˚C. 
 
    4.2.8 Reverse Transcriptase PCR (RT-PCR) 
The presence or absence of genomic DNA contamination in DNase I treated total RNA 
and cDNA, was also confirmed by PCR before performing mRNA quantification. 1μl of 
the cDNA and DNase I treated total RNA was used for amplification in PCR. The 
following reagents were added to the cDNA and DNase I treated total RNA: 
 
- 12.5µl of 2× Kapa Master Mix (Kapa Biosystem, UK) containing MgCl2, Taq 
DNA polymerase and dNTPs) 
- 1µl of 5µM FXNRT-R primer  
- 1µl of 5µM FXNRT-F primer  
- Nuclease free water to 25µl    
 
The samples were mixed and the reactions were carried out in a thermocycler (MJ 
Research). The details of the primers (Sigma, UK) and the program used are represented 
in Tables 4.1 and 4.2 respectively.  
 
Table 4.1 Primers used for RT-PCR and real-time PCR 
Primer  Sequence (5´3´) Product size (bp) 
FXNRT-F FXN expression 
(Human Specific) 
CAGAGGAAACGCTGGACTCT 
172 
FXNRT-R AGCCAGATTTGCTTGTTTGGC 
FRT I-F FXN expression 
(Human and Mouse) 
 
TTGAAGACCTTGCAGACAAG 
121 
RRT II-R AGCCAGATTTGCTTGTTTGG 
 
Gapdh-m-F Gapdh  
(Mouse) 
ACCCAGAAGACTGTGGATGG 
81 
Gapdh-m-R GGATGCAGGGATGATGTTCT 
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Table 4.2 RT-PCR program 
Steps Temperature Duration Cycles 
Denaturation 94ºC 1 min 1 
Denaturation 94 ºC 30 sec  
Annealing 54 ºC 30 sec 30 
Elongation 72 ºC 1 min  
Extension 72ºC 10 mins 1 
 
PCR products from cDNA and DNase I treated total RNA were analysed on 2% agarose 
gel made up in 1× TBE buffer solution. The PCR products were then visualised using a 
UVP GDAS 1200 Gel Documentation Analysis System under ultraviolet light, Fig. 4.2. 
    4.2.9 Quantitative Real-Time RT-PCR (qRT-PCR) 
The expression of genes of interest was quantitated on an ABI Prism 7900HT Sequence 
Detection System (Applied Biosystems) using 2× SYBR
®
 Green PCR Master Mix 
(Applied Biosystems). SYBR Green dye is attached to the cDNA and produces a 
fluorescent signal. The signal intensity is proportional to the quantity of the cDNA 
present in the reaction. Consequently, in each step of the PCR reaction, the intensity of 
the signal increases while the amount of product increases. Each PCR-reaction was 
performed in triplicate on a MicroAmp optical 96-well PCR plate (Applied Biosystems), 
 
Fig. 4.2 Gel electrophoresis of human FXN RT-PCR analysis of the DNase I treated total 
RNA and cDNA using 2% agarose gel. Lanes 1, 3, 5, 7, 9, 11 and 13 are RT-PCR product 
from DNase I treated total RNA;  Lanes 2, 4, 6, 8, 10, 12 and 14 are RT-PCR product 
from cDNA; Lanes 15 and 16 are 1kb
+ 
DNA Ladder (Invitrogen) and negative control 
respectively.  
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and each reaction well contained 5μl of 5× diluted cDNA products, 0.5μl of each 50μM 
optimised respective forward and reverse primers (see Table 4.1 for primers used), 4.8μl 
of nucleare free water and 10μl of SYBR Green Master Mix (2× concentration). Target 
and endogenous master mixes were prepared separately and added to the plate. 
Subsequently, the plate was sealed with a real time plate sealer (MicroAmp, Applied 
Biosystems) and then centrifuged for 1 minute at 101 rcf to bring all the contents to the 
bottom of the well. The real time PCR reactions were run using the following programs: 
Product specificity and efficiency was determined by SDS 2.1 software (Applied 
Biosystems) using dissociation curve analysis after each PCR run. The dissociation curve 
allows the check for primer dimer and non-specific amplification that may affect the 
quality of the data. Nonspecific PCR products are characterised by curves with several 
peaks. Best set of primers would only amplify the product of interest with no or a minimal 
quantity of primer dimer formation and decrease the distortion of the final fluorescence 
reading. Figure 4.4 represents the dissociation curve from real time PCR without primer 
dimer formation. 
 
    4.2.10 Protein Extraction 
To extract protein, 30-40mg tissue samples were homogenised in 300µl of RIPA 
(RadioImmunoPrecipitation Assay) buffer (Sigma-Aldrich) and 12μl of 25× protease 
 
Fig. 4.3 Schematic diagram of real-time PCR program 
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inhibitor (to prevent proteolysis and maintain phosphorylation of proteins) (Thermo 
Scientific, UK) by an Eppendorf homogenising rod and centrifuged at 16100 rcf for 30 
minutes at 4˚C. Subsequently, the total protein (supernatant) was separated from the 
cellular debris (pellet). The supernatant was then transferred to a clean 1.5ml 
microcentrifuge tube and stored at -80˚C. 
 
    4.2.11 Protein Quantification Using BCA Protein Assay 
Protein samples were quantified using a Pierce
®
 BCA Protein Assay Kit (Thermo 
Scientific) following the manufacturer's instructions.  The BCA protein assay is based on 
the reduction of Cu
2+
 to Cu
1+
 by protein in an alkaline medium with highly sensitive and 
selective colorimetric detection of the cuprous cation (Cu
1+
) using bicinchoninic acid 
 
Fig. 4.4 Dissociation curve. Dissociation curve for Gapdh and FXN primers showing a 
clean PCR product amplified under real time conditions without any signs of primer 
dimmer formation or secondary products.  
Gapdh FXN 
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(BCA). For the determination of the protein concentration, BCA protein assay reagents A 
and B were mixed with the ratio of 50:1 respectively. Subsequently, a serial dilution of 
bovine serum albumin (BSA) standard (0.025mg/ml-1.5mg/ml, Table 4.3) was made to 
construct a standard curve, Fig. 4.5. 10μl of BSA standards and protein samples (diluted 
1:20 with dH2O) were then added to 200μl BCA solution (A+B) and were incubated for 
30 minutes at 37˚C. 200μl of each sample was placed into a 96-well plate and the protein 
concentration was measured using a plate reader (BP800, BioHit) at 562nm. 
 
Table 4.3 Preparation of BSA standards for BCA analysis 
Tube Volume of dH2O  Volume of BSA  Final Volume Final BSA concentration 
A 10 µl 30 µl 20 µl 1500 µg/ml 
B 20 µl 20 µl 20 µl 1000 µg/ml 
C 20 µl 20 µl of A 40 µl 750 µg/ml 
D 20 µl 20 µl of B 20 µl 500 µg/ml 
E 20 µl 20 µl of D 20 µl 250 µg/ml 
F 20 µl 20 µl of E 30 µl 125 µg/ml 
G 40 µl 10 µl of F 50 µl 25 µg/ml 
H 40 µl - 40 µl 0 µg/ml 
 
 
Fig. 4.5 Standard curve used for protein quantification 
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    4.2.12 Dipstick Assay  
The level of frataxin protein was measured by lateral flow immunoassay with the Frataxin 
Protein Quantity Dipstick Assay Kit (MitoSciences) according to the manufacturer’s 
instructions.  2µg of protein in 25µl of extraction buffer (buffer A) was mixed with 25µl 
of 2× blocking buffer (buffer B) and was added to individual wells on a 96-well plate 
with gold-conjugated monoclonal antibody at the bottom of each well. The samples were 
incubated for 5 minutes, allowing the gold-conjugate to hydrate. The mixture was then 
resuspended gently using a pipette and dipsticks were inserted into the wells. 
Subsequently, frataxin within each sample was immunocaptured onto designated capture 
zones on the dipstick and the signal appeared 5-7mm from the bottom of the dipstick in 
approximately 20 minutes, Fig. 4.6. After the signal developed, the dipsticks were washed 
for 20 minutes with 30µl of washing buffer (buffer C) in an empty well of the microplate. 
The dipstick was air-dried for approximately 20 minutes and signal intensity was 
measured with a MS-1000 Immunochromatographic Reader (MitoSciences). 
 
 
 
Fig. 4.6 Quantification of human FXN using dipstick immunoassay. Upper bands 
correspond to internal control (goat anti-mouse antibody (GAM)); lower bands 
correspond to human frataxin (FXN). 
GAM 
 
FXN 
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    4.2.13 Statistical Analysis 
All statistical analysis was performed using Student’s t test and the level of significance 
used throughout was P≤0.05. 
 
4.3 Results 
    4.3.1 Somatic GAA Repeat Instability in FRDA Mouse Models 
Somatic instability of the GAA repeat was assessed in a variety of tissues (Tail (Ta), 
Brain (B), Cerebellum (C), Liver (L), Heart (H), Kidney (K), Pancreas (P)) from YG8R, 
YG22R, YG8sR and Y47R mice. As represented in Figs. 4.7 and 4.9, YG8R mice 
exhibited a smear of expanding GAA repeats, extending upward from 215 to 230 GAA 
repeats in the brain and particularly in the cerebellum tissues, and also small smeared 
expansion in the liver but not in any of the other tissues. 
 
 
Fig. 4.7 Somatic GAA repeat instability in YG8R mice. A representative 1.5% agarose 
gel showing GAA PCR products from different somatic tissues (Tail (Ta), Brain (B), 
Cerebellum (C), Liver (L), Heart (H), Kidney (K), Pancreas (P)) of YG8R lines: 478.6 
(male, Lanes 2 to 9), 478.10 (male, Lanes 10 to 16) and 8J.55 (female, Lanes 17 to 23). 
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Size analysis of GAA sequences from YG8R lines revealed four bands of GAA repeat 
alleles, ranging in size from 130 to 215 repeat units in male YG8R (478.6 and 478.10) 
lines and five bands in female YG8R lines (8J.55 and 822.126)  ranging from 125 to 215 
repeats Figs. 4.7 and 4.9. 
 
GAA repeat instability was also detected in the YG22R mice. Male YG22R (822.164 and 
822.154) exhibited a smear of expanding GAA repeats in the brain, cerebellum and liver 
tissues from approximately 215 to 230 repeats, the smear was more pronounced in the 
cerebellum and liver tissues. Other tissues showed the same characteristic appearance of 
150 to 215 repeats, Fig. 4.8. A similar expansion profile was also detected in YG22R 
females (822.118 and 822.119) with a shift of all sequences to a higher level, 
approximately 215 to 250 GAA repeats with smeared GAA expansions from 250 to 285 
repeats in the brain and particularly in the cerebellum and liver tissues, Figs. 4.8 and 4.9.  
 
Fig. 4.8 Somatic GAA repeat instability in YG22R mice. A representative 1.5% agarose 
gel showing GAA PCR products from different somatic tissues (Tail (Ta), Brain (B), 
Cerebellum (C), Liver (L), Heart (H), Kidney (K), Pancreas (P)) of YG22R lines: 822.164 
(male, Lanes 2 to 9), 822.154 (male, Lanes 10 to16) and 822.118 (female, Lanes 17 to 
23). 1kb
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and 100bp
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Y47R control line exhibited normal GAA repeat size of 9 units with no somatic 
instability, Fig. 4.9. 
 
YG8sR mice, established from YG8R breeding, were shown to contain a single GAA 
repeat sequence with approximately 120 GAA repeat units. The analysis of the GAA 
repeat sizes in the YG8sR male (8.2411) and female (8.2404) mice revealed a smear of 
expanding GAA repeats in the brain, cerebellum and liver tissues from approximately 120 
to 150 repeats, the smear was greater in the brain and cerebellum, Fig. 4.10. 
 
 
 
 
 
 
Fig. 4.9 Somatic GAA repeat instability in YG8R, YG22R and Y47R mice. A 
representative 1.5% agarose gel showing GAA PCR products from different somatic 
tissues (Tail (Ta), Brain (B), Cerebellum (C), Liver (L), Heart (H), Kidney (K), Pancreas 
(P)) of YG8R: 822.126 (female, Lanes 2 to 9); YG22R: 822.119 (female, Lanes 10 to 16) 
and Y47R: Y47.73 (female, Lanes 17 to 23) lines. 1kb
+ 
and 100bp
 
DNA ladders were 
used as the molecular marker.  
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    4.3.2 Quantification of FXN mRNA in Mouse Tissues 
        4.3.2.1 Quantification of FXN mRNA in Mouse Tissues Using Human Primers 
In order to assess the effect of GAA repeat expansion on FXN expression in the studied 
FRDA mouse models, qRT-PCR measurements were performed using primers designed 
to detect human frataxin cDNA, previously described in section 4.2.9. Different 
endogenous control genes were previously evaluated using qRT-PCR to identify stably 
expressed endogenous control genes in FRDA mouse models. The results indicated that 
Gapdh was the most stably expressed endogenous control gene which can be used for 
accurate qRT-PCR results in FXN expression (C. Sandi personal communication). 
Therefore, the results of FXN expression were normalised to mouse Gapdh expression as 
the endogenous control by calculating the differences in Ct values. The cDNA samples of 
two mice from each studied line (one male and one female for each group) were analysed 
 
Fig. 4.10 Somatic GAA repeat instability in YG8sR mice. A representative 1.5% agarose 
gel showing GAA PCR products from different somatic tissues (Tail (Ta), Brain (B), 
Cerebellum (C), Liver (L), Heart (H), Kidney (K), Pancreas (P)) of YG8sR lines: 8.2411 
(male, Lanes 2 to 9) and 8.2404 (female, Lanes 10 to 16). 1kb
+ 
and 100bp
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twice for each tissue and each reaction was carried out in triplicate. The mean value of 
each triplet was used for further calculations using the 2
-ΔΔCt
 method to obtain relative 
quantification (RQ) values. Subsequently, the relative transcription levels of FXN in the 
FRDA and control mouse tissues were calibrated by calculating the RQ mean values, 
setting the Y47R brain group arbitrarily as 100%. Initial determination of FXN transgene 
expression indicated that mean mRNA levels of YG8R and YG22R decreased to 49% 
(P<0.05) and 34% (P<0.01) in the liver compared to Y47R, respectively. However, no 
significant differences were identified in other YG8R and YG22R tissues. In contrast, 
YG8sR mice revealed a very significant reduction of FXN mRNA in the brain (27%,
 
P<0.001), cerebellum (18%, P<0.01), DRG (37%, P<0.01), liver (13%, P<0.01) and 
kidney (28%, P<0.001) compared to Y47R, Fig. 4.11A.  
 
To illustrate the gender-specific differences in mRNA expression level, gene expression 
levels were compared for males and females separately. The results from males revealed 
significantly reduced FXN mRNA levels in the liver of YG8R (28%, P<0.05), YG22R 
(44%, P<0.01) and YG8sR (16%, P<0.01) and also in the brain (23%, P<0.01) and kidney 
(20%, P<0.01) of YG8sR, Fig. 4.11B. In contrast, analysis of female mice indicated a 
significant reduction of FXN mRNA in the liver of YG22R (27%, P<0.05) and in the liver 
(11%, P<0.05) and kidney (35%, P<0.01) of YG8sR, Fig. 4.11C. The FXN gene 
expression was also decreased in  the  liver of YG8R females (64%) but the difference did  
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Fig. 4.11 qRT–PCR analysis of transgenic FXN mRNA in FRDA mice using human 
specific primers. A) Analysis of males and females together. Analysis of B) males and C) 
females separately. Data were normalised to the mean FXN mRNA level of Y47 brain 
samples taken as 100%. Error bars indicate SEM and values represent mean ± SEM. 
Asterisks indicate significant differences between the mutant and control (Y47R) mice 
(
*
P<0.05, 
**
P<0.01 and 
***
P<0.001). 
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not reach a statistical significance (P=0.06), Fig. 4.11C. These results suggested gender-
specific differences of FXN expression in the FRDA mouse models which might be 
correlated with the variation in size and pattern of the GAA repeat sequences. 
Furthermore, amongst all the FRDA mouse models the greatest FXN deficiency was 
detected in YG8sR. 
 
        4.3.2.2 Quantification of FXN mRNA in Mouse Tissues Using Mouse-Human 
Primers 
 
In order to assess the FXN mRNA expression level in the FRDA mouse models compared 
to the B6 control mice, qRT-PCR measurements were performed using primers designed 
to detect both human and mouse frataxin cDNA, previously described in section 4.2.9. 
Although the results were similar to those obtained using human specific primers in 
comparison to the Y47R control, the slight variations in the results may be due to the lack 
of robustness and efficiency of the technique. Therefore, it is suggested to use large 
sample sizes in the future studies to improve the accuracy and repeatability of the results. 
Analysis of the YG22R and YG8sR compared to Y47R control revealed that FXN mRNA 
levels reduced to 53% (P<0.01) and 17% (P<0.001) in the liver, 51% (P<0.001) and 18% 
(P<0.001) in the cerebellum, and 77% (P=0.06) and 22% (P<0.001) in the brain tissues,  
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Fig. 4.12 qRT–PCR analysis of transgenic FXN mRNA in FRDA mice using mouse-
human specific primers. A) Analysis of males and females together. Analysis of B) males 
and C) females separately. Data were normalised to the mean FXN mRNA level of Y47 
brain samples taken as 100%. Error bars indicate SEM and values represent mean ± SEM. 
Asterisks indicate significant differences between the mutant and control mice (
*
P<0.05, 
**
P<0.01 and 
***
P<0.001). Statistical differences between the mutant and B6 controls are 
indicated by the top line drawn over the bars while the bottom line indicates the 
differences between the mutant and Y47R controls. 
C 
P=0.1 
 P=0.4 
 
P=0.3 
 
** 
 
*** 
 
*** 
 
* 
* 
** 
 
* 
P=0.1 
 
P=0.08 
 
P=0.1 
 P=0.9 
 
P=0.1 
 
* 
 
* 
* 
B 
P=0.1 
 P=0.2 
 
P=0.3 
 ** 
 
* 
* 
 
P=0.1 
 
* ** * 
P=0.2 
 
P=0.09 
 
P=0.1 
 
P=0.9 
 P=0.1 
 
P=0.08 
 
P=0.06 
 
P=0.1 
 
135 
 
respectively. However, no significant differences were identified in YG8R mice (29% 
reduction in the liver which was not significant (P=0.2)). In addition, the YG8R and 
YG22R did not show any marked reduction of FXN mRNA compared to the B6 control 
which was consistent with the previous findings of Ataxia Research Group, Brunel 
University [unpublished results].  The FXN mRNA expression levels were also decreased 
to 47% (P<0.001) in the liver and 55% (P<0.001) in the cerebellum of the YG8sR 
compared to the B6 control, Fig. 4.12A.  On the other hand, analysis of the male YG8R, 
YG22R and YG8sR mice revealed reduced FXN mRNA levels of 62% (P<0.05), 70% 
(P=0.2) and 20% (P<0.01) in the brain, 62% (P<0.05), 50% (P<0.05) and 16% (P<0.01) 
in the cerebellum, and 36% (P=0.1), 55% (P=0.1) and 21% (P=0.08) in the liver, 
respectively, Fig. 4.12B. YG8sR male mice also showed to have reduced level of FXN 
mRNA expression in the brain (85%, P=0.3), cerebellum (56%, P=0.09) and liver (57%, 
P=0.1) compared to B6 control; however the difference was not statistically significant, 
Fig. 4.12B. In contrast, the levels of transgenic FXN mRNA expression in YG22R and 
YG8sR females were decreased to 84% (P=0.4) and 25% (P<0.01) in the brain, 51% 
(P<0.05) and 21% (P<0.01) in the cerebellum, and 50% (P<0.05) and 14% (P<0.05) in 
the liver tissues respectively, Fig. 4.12C. The FXN expression levels were also decreased 
in cerebellum (53%, P<0.05) and liver (38%, P<0.05) of YG8sR females compared to 
endogenous B6 Fxn mRNA, Fig. 4.12C. Therefore, YG8sR can be considered to be a 
suitable mouse model for the investigation of potential FRDA therapies since it was 
shown to have reduced level of FXN expression compared to both Y47R (human FXN) 
and B6 (mouse Fxn) controls.   
 
    4.3.3 Quantification of FXN Protein in Mouse Tissues 
To determine the levels of human frataxin expression in the FRDA mouse models, 
frataxin protein expression levels were measured by lateral flow immunoassay with the 
Frataxin Protein Quantity Dipstick assay kit. Analysis of FRDA males and females 
together revealed that the frataxin expression was significantly decreased in the liver 
tissues derived from YG8R, YG22R and YG8sR mice to approximately 65% (P<0.001), 
51% (P<0.001) and 24% (P<0.001) respectively compared to Y47R control, Fig 4.13A.  
Significant reduction in the FXN protein expression was also observed in the cerebellum 
of YG22R (77%, P<0.05) and YG8sR (70%, P<0.001), and in the brain of YG8sR (16%, 
P<0.001) compared to Y47R control, Fig 4.13A. Males and females were also analysed 
separately in order to determine the gender-specific differences in the FXN expression 
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level. The results from the males revealed a significant decrease of FXN expression in the 
liver of YG8R (52%, P<0.001), YG22R (47%, P<0.001) and YG8sR (22%, P<0.001) and 
also in the brain of YG22R (66%, P<0.001) and YG8sR (14%, P<0.001), Fig. 4.13B. The 
same trend was also observed in the cerebellum of YG8R (91%, P=0.2), YG22R (49%, 
P=0.3) and YG8sR (69%, P=0.08), and in the brain of YG8R (90%, P=0.1) males, 
however the differences did not reach a statistical significance, Fig. 4.13B. Analysis of 
the females showed a marked reduction of FXN expression in the liver of YG8R (79%, 
P<0.001), YG22R (55%, P<0.001) and YG8sR (25%, P<0.001), and in the brain (17%, 
P<0.001) and cerebellum (72%, P<0.05) of YG8sR female mice, Fig. 4.13C. The same 
trend was also observed in the cerebellum of YG22R females (68%, P=0.1), though the 
differences were not statistically significant, Fig. 4.13C. Therefore, it can be concluded 
that frataxin expression levels were higher in females than those in males, suggesting 
gender-specific differences in the FXN expression of the FRDA mice. Furthermore, 
amongst all FRDA mouse models the greatest FXN deficiency was detected in YG8sR 
compared to Y47R control. However, this approach was not applicable to compare the 
human frataxin levels in the FRDA rescue mice and B6 mouse frataxin levels due to the 
difficulties in detecting mouse Fxn protein. Consequently, YG8sR can be considered to 
be a suitable mouse model for the investigation of potential FRDA therapies. 
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Fig. 4.13 The dipstick immunoassay of human frataxin in FRDA mice. A) Analysis of 
males and females together. Analysis of B) males and C) females separately. Error bars 
indicate SEM and values represent mean ± SEM. Asterisks indicate significant 
differences between the mutant and Y47 control (
*
P<0.05 and 
***
P<0.001). 
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4.4 Discussion 
As discussed in chapter III, functional analysis of FRDA mouse models revealed FRDA-
like pathological phenotype and functional deficits in YG8R, YG22R and YG8sR 
compared to Y47R (with normal sized GAA repeats) and B6 controls. To further 
investigate the correlation between FRDA-like pathological phenotype and frataxin 
deficiency in the studied mouse models, the size of the GAA repeats as well as somatic 
GAA instability were examined in tissues of YG8R, YG22R, YG8sR and Y47R mice. 
The results revealed GAA repeat somatic instability pattern in the brain, cerebellum and 
liver of all the FRDA mouse models. These results were in good agreement with the 
previous studies which also showed somatic GAA repeat instability in the brain and 
cerebellum of both YG22 and YG8 transgenic mice [103, 41]. However, there were 
differences in the pattern and size of the GAA repeats between males and females, 
indicative of gender-specific differences in repeat sizes which might be related to the 
pattern of frataxin expression. Subsequently, frataxin mRNA and protein levels were 
investigated. The results indicated significant reduction in the levels of the FXN mRNA 
and protein in the liver of YG8R and YG22R compared to Y47R. However, no significant 
differences were identified in other YG8R and YG22R tissues compared to Y47R. In 
addition, the YG8R and YG22R mice did not exhibit any marked reduction in the FXN 
mRNA level compared to the B6 control, this was consistent with the previous findings of 
Ataxia Research Group, Brunel University [unpublished results]. This might be partially 
due to a base pair difference between the sequence of one of the mouse and human 
primers, although the base pair is within the less critical 5´ region of the primer. The 
second possible cause may be due to the differences in the functional potential and 
expression profiles of the mouse and human frataxin since they may be modulated by 
different regulatory factors. Therefore, such differences should be considered when using 
mice as preclinical models of human disease.  
 
In the case of the YG8sR line (containing a single band with approximately 120 GAA 
repeat units), a significant decrease in FXN mRNA was detected in all tissues compared 
to both Y47R human FXN and B6 mouse Fxn mRNA. Protein expression levels were also 
considerably decreased in all the tissues of the YG8sR compared to Y47R. However, this 
approach was not applicable to compare the human frataxin levels in the FRDA rescue 
mice and B6 mouse frataxin levels due to the use of a human-specific anti-FXN antibody 
in the dipstick assay. Of all FRDA mouse models studied, the greatest FXN reduction was 
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detected in the YG8sR tissues compared to both Y47R human FXN and B6 mouse Fxn 
mRNA. In addition, GAA repeat analysis identified a single GAA repeat band in YG8sR 
lines with no complexity compared to the other FRDA lines. Consequently, YG8sR can 
be considered to be a suitable mouse model for the investigation of potential FRDA 
therapies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER V  
 
TELOMERE LENGTH ANALYSIS IN FRDA 
CELLS 
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5.1 Introduction 
Maintaining genomic integrity is fundamental for the life of a cell and the survival of 
species. Telomeres are one of the key elements that play an essential role in the 
maintenance of genomic stability [231]. They are specialised nucleoprotein structures at 
the ends of chromosomes which consist of highly conserved hexanucleotide repeats 
(TTAGGG). Telomeres form a cap structure to protect the chromosome ends from 
exonucleolytic degradation and terminal fusions. Degradation of telomeres is caused by 
one of the following: an unsolved end-replication problem, exonuclease activity or DNA 
breakage within telomeric sequences due to oxidative damage [232, 233, 156]. Their 
maintenance is carried out either by the activity of a telomere specific DNA polymerase 
called telomerase or telomerase-independent pathway referred to as alternative 
lengthening of telomeres (ALT) [231]. ALT cells are characterised by recombinational 
events at telomeres, known as telomeric sister chromatid exchanges (T-SCE), and co-
localisation of telomeres and promyelocytic leukemia protein (PML) nuclear bodies 
[155]. Normal human somatic cells do not have sufficient telomerase or ALT activity, 
thus the cell population as a whole eventually undergoes telomere-mediated senescence 
after a limited number of divisions due to excessive telomere degradation and short 
dysfunctional telomeres [234]. However, immortalised human cell lines engage the ALT 
mechanism to lengthen telomeres through recombination. Therefore, the telomere length 
is generally stable in these cells since an equilibrium exists between telomere degradation 
and telomere renewal [231].  
 
As previously discussed in chapter I, Friedreich ataxia is an autosomal recessive 
neurodegenerative disorder caused by a reduction in frataxin expression that leads to 
mitochondrial dysfunction and oxidative damage. Moreover, frataxin deficiency induces a 
strong activation of inflammatory genes and neuronal death. Preliminary studies reported 
that FRDA cells were more sensitive to ionising radiation than control cells suggesting 
that FRDA is a DNA repair-deficient disorder [216]. In addition, oxidative stress has been 
reported to accelerate the rate of telomere attrition and chromosomal instability [156]. 
Therefore, it was hypothesised that telomere length might be shortened as a result of 
oxidative damage in FRDA patients. There is very limited information available 
regarding the status of telomere length in primary FRDA fibroblast cells. Nevertheless, 
the results from a recent study using human peripheral blood lymphocytes indicated a 
significant telomere shortening in FRDA patients compared to healthy controls [214].  
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The assessment of telomere dynamics is critically dependent on the technique of telomere 
length measurement. Several techniques are available including Southern blot analysis, 
quantitative fluorescence in situ hybridisation (Q-FISH), flow-FISH, hybridisation 
protection assay (HPA), single telomere length analysis (STELA) and quantitative PCR 
(qPCR). The aims of this part of investigation were to evaluate the length of telomeres in 
FRDA fibroblast cells using Q-FISH and qPCR and to measure rates of telomere 
shortening in these cells during replicative senescence.  
 
5.2 Materials and Methods  
    5.2.1 Cell lines  
Mouse fibroblast cell lines (YG8R, YG22R, Y47R and B6) established from kidney 
tissues, previously described in section 2.3.2.1 (chapter II), were grown in DMEM culture 
medium (Gibco) supplemented with 10% FBS (Gibco) and 2% Pen-Strep (Gibco) at 37˚C 
in a 5% CO2 humidified incubator. Mouse lymphoma LY-R (radio-resistant) and LY-S 
(radio-sensitive) cells were cultured in RPMI 1640 medium (Invitrogen) supplemented 
with 10% FBS and 2% Pen-Strep at 37˚C in a 5% CO2 humidified incubator. These cell 
lines were obtained from Dr. Predrag Slijepcevic and were used as reference for 
cytological testing telomeric measurements using interphase Q-FISH technique. All 
human fibroblast cell lines were obtained from the Coriell Cell Repository and were 
cultured in DMEM medium supplemented with 10-15% FBS and 2% Pen-Strep at 37˚C 
in a 5% CO2 humidified incubator, Table 5.1.  
 
Table 5.1 Details of the human primary fibroblasts 
Samples Sex Age (Year) Race FBS 
Number of GAA 
repeats 
H.Normal Male 27 Caucasian 10% Normal 
GM08399 Female 19 N/A 10% Normal 
GM04503 Female 31 Caucasian 15% Normal 
GM07492 Male 17 Caucasian 10% Normal 
GM07545 Female 22 Caucasian 15% Normal 
GM03816 Female 36 Caucasian 15% 330/380 
GM04078 Male 30 Caucasian 10% 541/420 
GM03665 Female 13 Caucasian 15% 445/740 
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The U2OS cell line (Mesenchymal adherent cells), originally derived from a 15 years old 
female with osteosarcoma, was grown in McCoy’s culture medium (Sigma-Aldrich) 
supplemented with 10% FBS, 2% Pen-Strep and 2mM glutamine (Gibco) at 37˚C in a 
10% CO2 humidified incubator. The HeLa cell line (epithelial adherent cells), originally 
established from a 31 years old female patient with cervical carcinoma, was grown in 
DMEM culture medium supplemented with 10% FBS and 2% Pen-Strep at 37˚C in a 10% 
CO2 humidified incubator. Both cell lines were obtained from Dr. Predrag Slijepcevic and 
were used as the controls. 
 
    5.2.2 Mycoplasma PCR Screening of Cell Cultures 
All cell lines were subjected to mycoplasma contamination test by PCR to isolate and 
eliminate contamination, previously described in section 2.3.2.1.1 (chapter II).  
 
    5.2.3 Cryopreservation of Cells 
The culture medium was aspirated off and the adherent cells were washed once with 
appropriate volume of PBS. The cells were digested with 0.05% Trypsin/EDTA (Fisher 
Scientific, UK) for 5 minutes at 37˚C. The detached cells in trypsin were neutralised with 
complete cultured medium and the cells were pelleted by centrifugation at 389 rcf for 5 
minutes. The supernatant was discarded and the cells were resuspended in 1ml of culture 
medium supplemented with 10% (v/v) DMSO, at the desired density. Aliquots of 0.5-
1.0×10
6 
cells/ml were gradually frozen down using a cooling container, containing 
isopropanol to avoid ice crystal formation, and were subsequently transferred into liquid 
nitrogen.  
 
    5.2.4 Thawing of Cryopreserved Cells 
Vials of cells were taken out of liquid nitrogen and swabbed with 70% IMS. Caps were 
loosened to release the pressure before rapidly thawing the cells in a waterbath at 37˚C. 
Cells were transferred into a 15ml conical tube containing 10ml of prewarmed complete 
culture medium and were centrifuged at 389 rcf for 5 minutes. The supernatant was 
discarded and the pellet was resuspended in either a 25cm
2
 or 75cm
2
 flask containing 
fresh culture medium. Finally, cells were incubated in a CO2 incubator at 37˚C and 92-
95% humidity. 
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    5.2.5 Population Doubling and Growth Curve of Human FRDA Fibroblast Cells 
Long term cell growth of FRDA and control fibroblasts was assessed by determining cell 
numbers and cumulative population doubling (CPD) levels. Cells were trypsinised with 
0.05% Trypsin/EDTA at 80% confluence, pelleted and resuspended in 1ml PBS. 10µl of 
the cell suspension was stained by 10µl of trypan blue (Invitrogen). Subsequently, 10µl of 
the mixture was added on a cell counting chamber slide (Invitrogen) and was counted by 
a Countess
TM 
automated cell counter (Invitrogen). Trypan blue is a vital diazo dye used to 
colour dead cells blue. Therefore, live cells with intact cell membranes are not coloured 
as trypan blue is not absorbed in the viable cells while dead cells are shown as a 
distinctive blue colour, enabling the cell counter to distinguish the live cells from the 
dead. When recording the phase of a cell population, age should be expressed in terms of 
population doubling (PD) rather than passage number since the passage number only 
indicates the number of trypsinisation steps performed during the culture period. 
Therefore, the passage number is not adequate in describing the age of a culture as 
trypsinisation can be performed at different split ratios. PD at each passage was 
determined using the following formula: 
 
PD = (Log N1 /Log2) - (LogNo/Log2) 
No = Number of cells at the beginning  
N1= Number of cells at the end of each cell culture period 
 
Cumulative population doubling (CPD) level was thus the sum of population doublings:  
CPDn = ΣPD (1, n)  
n: Number of passages 
 
    5.2.6 Telomere Length Measurement by qPCR 
Genomic DNA was extracted from the FRDA and control fibroblast cells (Table 5.1) 
using the phenol/chloroform method as previously described in section 2.3.1.1 (chapter 
II). Previously prepared lymphocyte genomic DNA was also obtained from FRDA patient 
and unaffected control blood samples, Table 5.2. 
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Table 5.2 Details of the human lymphocyte DNA samples 
Samples Type Sex 
Age of onset 
(Year) 
 
( 
Age at death 
(Year) 
Number of GAA 
repeats 
CA FRDA Male N/A 24 750/550 
MH FRDA Male N/A 46 1100/450 
HK FRDA Male 5 17 750/630 
LK FRDA Male 7 30 730/600 
      CR FRDA Male 15 40 930/570 
RS FRDA Female 3 35 930/600 
MS FRDA Female 7 36 700/700 
JA-T FRDA Male 6 25 780/780 
AB FRDA Female N/A N/A 950/300 
AG FRDA Female N/A N/A 900/550 
BL FRDA Male N/A N/A 1060/730 
BQ FRDA Female N/A N/A 950/250 
BT FRDA Male N/A N/A 930/760 
I CONN FRDA Female N/A N/A 950/950 
LH FRDA Female N/A N/A 800/250 
MB FRDA Female N/A N/A 1000/250 
RB FRDA Male N/A N/A 850/750 
S KEY FRDA Female N/A N/A 900/650 
2803 Normal N/A N/A N/A Normal 
2804 Normal N/A N/A N/A Normal 
2805 Normal N/A N/A N/A Normal 
2808 Normal N/A N/A N/A Normal 
2809 Normal N/A N/A N/A Normal 
141603 Normal N/A N/A N/A Normal 
141604 Normal N/A N/A N/A Normal 
141605 Normal N/A N/A N/A Normal 
141607 Normal N/A N/A N/A Normal 
141611 Normal N/A N/A N/A Normal 
141612 Normal N/A N/A N/A Normal 
141616 Normal N/A N/A N/A Normal 
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Telomere length was examined using a qPCR method [235]. Briefly, two master mixes of 
PCR reagents were prepared separately, one with telomere primer pair and the other with 
single copy gene primer pair (36B4), Table 5.3. The master mixes were prepared using 
the following reagents: 
 
- 10µl of 2× Power SYBR
®
 Green PCR Master Mix (Applied Biosystems) containing 
AmpliTaq Gold DNA polymerase, dNTPs, SYBR Green Dye, optimised buffers and 
passive reference dye (ROX) 
- 1µl of 2µM forward primer (Telomere-F or 36B4-F) (Sigma) 
- 1µl of 2µM reverse primer (Telomere-R or 36B4-R) (Sigma) 
- Nuclease free water to 20µl    
 
20µl of telomere master mix was added to each sample well (4µl of 5ng/µl DNA sample, 
no template control (NTC) and positive controls) and standard curve well (2µl of the 
telomere standard) of the first plate and 20µl of single copy gene master mix was added to 
each sample well (4µl of 5ng/µl DNA samples, no template control (NTC) and positive 
controls) and standard curve well (2µl of the single copy gene standard) of the second 
plate. Telomere standard curve was established by serial dilutions of telomere standard 
(1018400kb through to 10184kb dilution) and was used to measure the content of 
telomeric sequence per sample in kb, Fig. 5.2. A single copy gene (36B4), encodes the 
acidic ribosomal phosphoprotein PO, was used as a control for amplification of every 
sample performed and to determine genome copies per sample. Single copy gene standard 
 
Fig. 5.1 Schematic diagram of qPCR program 
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curve was generated by performing serial dilutions of 36B4 standard (3062500kb through 
to 6.125kb dilution). Plasmid DNA (pBR322) was also added to each standard curve well 
to maintain a constant 20ng of total DNA per reaction tube. Subsequently, the plate was 
sealed and centrifuged for 1 minute at 101 rcf. The qPCR reactions were run using the 
programs illustrated in Fig. 5.1 for both telomere and 36B4 amplicons and their 
corresponding dissociation curves were analysed. 
 
Table 5.3 Oligomers used for telomere length assay in human FRDA cells 
 
Oligomer Name Oligomer Sequence (5´3´) 
Amplicon 
size (bp) 
Telomere Standard 
(Human/Rodent) 
(TTAGGG)14 84 
36B4 standard 
(Human) 
CAGCAAGTGGGAAGGTGTAATCCGTCTCCACAGACAAGG
CCAGGACTCGTTTGTACCCGTTGATGATAGAATGGG 
75 
Telo-F 
(Human/Rodent) CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT 
>76 
Telo-R 
(Human/Rodent) 
GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT >76 
36B4-F (Human) 
CAGCAAGTGGGAAGGTGTAATCC 
75 
36B4-R (Human) CCCATTCTATCATCAACGGGTACAA 75 
 
Fig. 5.2 Absolute telomere length calculation using standard curve. Ct (cycle threshold) is 
the number of PCR cycles for which enough SYBR green fluorescence was detected 
above the background. A) Standard curve for calculating length of telomere sequence per 
reaction tube: X-axis represents the amount of telomere sequence in kb per reaction with 
correlation coefficient of 0.995. B) Standard curve for calculating genome copies using 
36B4 copy number: correlation coefficient 0.999. 
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The values (kb/reaction for telomere and genome copies/reaction for single copy gene) 
were exported to an excel file and were used to calculate the total telomere length in kb 
per human diploid genome. The telomere kb per reaction value was then divided by 
diploid genome copy number to give a total telomeric length in kb per human diploid 
genome. 
 
    5.2.7 Cytogenetic Analysis  
        5.2.7.1 Metaphase Preparation of Fibroblast Cell Lines 
Prior to harvesting, fibroblast cells were treated with 0.1µg/ml colcemid for 2 to 4 hours. 
Subsequently, the cells were digested with trypsin/EDTA for 5 minutes at 37˚C in the 
CO2 incubator. However, in order to maximise the number of collected mitotic cells, the 
culture supernatant was used to neutralise the trypsin/EDTA solution, ensuring that the 
suspended mitotic cells in the culture supernatant were retained and minimum metaphases 
were lost during the procedure. Fibroblast cells were collected by centrifugation at 249 rcf 
for 5 minutes and were treated with 3ml of prewarmed hypotonic solution (0.075M KCl) 
for 15 minutes at 37˚C and were subsequently fixed with methanol:acetic acid (3:1). The 
process of fixation was repeated two more times for 10 and 30 minutes at RT, 
respectively. During every fixation process 1ml of fresh fixative was added drop wise 
followed by the addition of extra 2ml of fixative solution. Subsequently, the cell pellets 
were resuspended in fresh fixative solution and 15µl of cell suspension was spread on a 
wet slide. The slides were finally air-dried and the cells were aged overnight at 54˚C on a 
heating block. For long term storage, slides were stored with desiccant at -20˚C. 
 
        5.2.7.2 Interphase Preparation of Fibroblast Cell Lines 
For interphase analysis, samples were produced according to standard cytogenetic 
methods with the exception of colcemid treatment. 
 
    5.2.8 Interphase Quantitative Fluorescence in situ Hybridisation (I-QFISH) 
        5.2.8.1 Pre-Hybridisation Washes 
The slides containing interphase cells were washed in PBS for 5 minutes on the shaker. 
The cells were then fixed in 4% formaldehyde in PBS for 2 minutes and were washed 
three times in PBS for 5 minutes. The cells were subsequently treated with 1mg/ml Pepsin 
solution (Sigma), 50ml of water acidified with 0.5ml of 1M HCl, pH 2.0, containing 10% 
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pepsin solution, at 37˚C for 10 minutes. The slides were then washed twice in PBS and 
were fixed in 4% formaldehyde in PBS for 2 minutes. Following fixation, cells were 
washed three times in PBS for 5 minutes and were dehydrated for 5 minutes in 70%, 90% 
and 100% ethanol respectively. Finally, the slides were left to air dry. 
 
        5.2.8.2 Hybridisation  
Dehydrated slides were denatured and probed with 20μl of a FITC-conjugated peptide 
nucleic acid (PNA) telomeric oligonucleotide (CCCTAA)3 probe at 70-75˚C for 2 
minutes on a heating block followed by hybridisation in a dark humidified chamber for 2 
hours at RT. Stock hybridisation mixture (1ml) for the telomeric probe was made up of 
700µl deionised formamide, 5µl blocking reagent (10% in maleic acid), 50µl MgCl2 
buffer (2.5M MgCl2, 9mM Na2HPO4, pH 7.0), 10µl Tris (1M, pH 7.2), 152µl ddH2O and  
83μl of PNA solution (6μl/ml FITC or Cy3-conjugated PNA, Applied Biosystems). 
 
        5.2.8.3 Post-Hybridisation Washes 
The slides were washed twice in 70% formamide solution (70ml formamide, 10ml 2× 
SSC and 20ml ddH2O) for 15 minutes and three times in PBS for 5 minutes in the dark on 
the shaker. Slides were then dehydrated for 5 minutes in 70%, 90% and 100% ethanol 
respectively. 15μl of VECTASHIELD® with fluorescence DAPI mounting medium 
 
 
Fig. 5.3 Telomere length analysis using the Q-FISH method. Representative images of A) 
FRDA (YG8) and B) control (Y47) interphase cells after hybridisation with telomeric 
PNA oligonucleotides. 
A B 
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(Vector) was added to the slides and covered with a 22×50mm coverslip prior to sealing 
with clear nail varnish. 
 
        5.2.8.4 Image Capture and Telomere Length Analysis 
Images of interphase cells were acquired on a digital fluorescence microscope (Zeiss 
Axioskop 2) equipped with a CCD camera (Photometrics) and Smart Capture software 
(Digital Scientific) using fixed exposure time of 0.5 second and magnification of 63×. 
Telomere fluorescence intensity per cell was analysed using IP Lab software (Digital 
Scientific), Fig. 5.3, and the average signal was evaluated by subtracting the background 
signal from the total telomeric signal intensity. 100 cells were quantified for each sample. 
  
    5.2.9 Chromosome Orientation Fluorescence in situ Hybridisation (CO-FISH) 
The CO-FISH technique was used to measure the rate of mitotic recombination at 
telomeres through counting telomeric-sister chromatid exchanges (T-SCEs). Cells were 
grown in 3μl of 5´-bromo-2´-deoxyuridine at the concentration of 10μM BrdU/BrdC (3:1 
ratio 7.5μM:2.5μM, Sigma-Aldrich) for 24 hours. During the cell cycle, BrdU is 
incorporated into replicating DNA strands opposite to the original parental strands. Cell-
cycle progression was blocked in metaphase with colcemid and cells were fixed using 
standard cytogenetic techniques, previously discussed in section 5.2.7.1. The slides were 
aged overnight at 54˚C in order to fix the chromosomes and to make their structure 
resistant to the subsequent DNA denaturing. 
 
        5.2.9.1 Washing, Digestion and Fixation 
The slides were washed in PBS for 15 minutes and were stained with 2.5μl of 0.5μg/ml 
DNA-binding fluorescent dye Hoechst 33258 in 2× SSC for 15 minutes at RT. To create 
nicks in the BrdU substituted strand, the slides were exposed to 365nm UV light 
(Stratalinker 1800 UV irradiator) for 30 minutes.  The nicked BrdU-substituted DNA 
strands were then degraded by 100μl of Exonuclease III solution (Promega) (1.5μl 
Exonuclease III, 10μl buffer and 88.5μl dH2O) at RT for 10 minutes. Subsequently, the 
slides were washed twice in PBS for 5 minutes on the shaker and were dehydrated for 5 
minutes in 70%, 90% and 100% ethanol respectively. Finally, the slides were air-dried at 
RT. 
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        5.2.9.2 Hybridisation 
Dehydrated slides were denatured and probed with 20μl of a Cy3-conjugated PNA 
telomeric oligonucleotide (CCCTAA)3 probe at 70-75˚C for 2 minutes on a heating block 
followed by hybridisation in a dark humidified chamber for 2 hours at RT. 
  
        5.2.9.3 Post-Hybridisation Wash 
The slides were washed twice in 70% formamide solution (70ml formamide, 10ml 2× 
SSC and 20ml ddH2O) for 15 minutes and three times in PBS for 5 minutes in the dark on 
the shaker. Slides were then dehydrated for 5 minutes in 70%, 90% and 100% ethanol 
respectively. 15μl of VECTASHIELD® with fluorescence DAPI mounting medium 
(Vector, VECTASHIELD
®
) was added to the slides and covered with a 22×50mm 
coverslip. Finally, the coverslips were sealed with clear nail varnish. 
 
        5.2.9.4 Image Analysis 
Images of metaphase spreads were acquired using a Zeiss fluorescence microscope 
equipped with a CCD camera (Photometrics) and ISIS Capture software (in situ imaging 
system “ISIS”, Meta Systems, Altlussheim, Germany). 20 metaphases were quantified for 
each sample. 
 
    5.2.10 Telomeric Repeat Amplification Protocol (TRAP) Assay Using TRAPEZE
®
 
Telomerase Detection Kit  
 
Telomerase enzymatic activity was determined in human FRDA fibroblast cell lines using 
TRAPeze
®
 Telomerase Detection Kit (Chemicon, Millipore). Cells were cultured in a 75 
cm
2
 tissue culture flask, trypsinised at 80% confluence, pelleted and resuspended in 1ml 
PBS. Cells were counted by a Countess
TM 
automated cell counter. For long term storage, 
the supernatant was removed and the samples were stored at -80˚C. 
 
        5.2.10.1 Protein Extraction and Quantification Using CHAPS Lysis Buffer and 
BCA Protein Assay 
 
Cells (10
5
-10
6
) were lysed in 200µl of CHAPS buffer, containing RNase inhibitor, and 
were incubated at 4˚C for 30 minutes. The lysate was then centrifuged at 15700 rcf for 20 
minutes at 4˚C. 160µl of the supernatant was transferred to a clean 1.5ml microcentrifuge 
tube and was stored at -80˚C. The protein concentration was measured using a Pierce® 
BCA Protein Assay Kit (Thermo scientific) following the manufacturer's instructions, 
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previously discussed in section 4.2.11 (chapter IV).  In order to obtain the final 
concentration of 125ng/µl, the protein concentration of the tested samples was measured 
from the standard curve and the samples were diluted in CHAPS lysis buffer accordingly.  
 
        5.2.10.2 Telomerase Activity Measurement Using the TRAP Assay 
The TRAP assay measures enzymatic activity of telomerase. To perform the TRAP assay, 
serial dilutions of TSR8 were prepared with CHAPS lysis buffer and 2µl of each TSR8 
dilution (20 amoles/µl, 2 amoles/µl, 0.2 amoles/µl and 0.002 amoles/µl, respectively. n.b. 
amole = attomole = 10
-18
 mole) was used to set up a standard calibration curve, Fig. 5.4. 
TSR8 is an oligonucleotide with a sequence identical to the TS primer extended with 
eight telomeric repeats AG(GGTTAG)7 which can be used as a standard for calculating 
the amount of TS primers with telomeric repeats extended by telomerase in a given 
extract. For a valid analysis, appropriate controls were included in every assay as follows: 
 
- Heat treated telomerase negative control: as telomerase is a heat sensitive enzyme, 
10µl of the extract aliquot was heated at 85˚C for 10 minutes to inactivate 
telomerase 
 
- Minus Telomerase Control (MTC): CHAPS lysis buffer was substituted for 
protein extract  
 
- No Template Control (NTC): nuclease free water was substituted for protein 
extract 
 
- Positive controls: telomerase-positive cell extracts provided in the kit and the 
human breast cancer cell line 21NT were used as positive controls  
 
Each PCR-reaction was performed in triplicate on a MicroAmp optical 96-well PCR plate 
(Applied Biosystems), where each reaction well contained 5µl of 5× TRAPEZE
®
 RT 
Reaction Mix (containing TS primer (5´-AAT CCG TCG AGC AGA GTT-3´),  
fluorescein-labelled Amplifluor
®
 RP (reverse) primer (5´'-GCGCGG 
[CTTACC]3CTAACC-3´) and dNTPs diluted in 10× reaction buffer S plus 10mM 
MgCl2), 4µl of 5U/µl Taq Polymerase, 2µl of the samples (TSR8 dilutions, positive 
controls, telomerase negative, NTC, experimental samples and heat treated telomerase 
negative controls) and nuclease free water up to 25µl. The qPCR reactions were 
performed using an ABI Prism 7900HT Sequence Detection System (Applied 
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Biosystems). The reaction mixture was initially incubated at 30˚C for 30 minutes to allow 
the telomerase in the protein extracts to elongate the TS primer by adding TTAGGG 
repeat sequences. PCR was then started at 95˚C for 2 minutes to inactivate the telomerase 
followed by a 35 cycle amplification (94˚C for 15 sec, 59˚C for 60 sec and 45˚C for 10 
sec). Telomerase activity in the cell lines was calculated based on the threshold cycle. 
    5.2.11 Determination of hTERT Expression Levels Using qRT-PCR 
        5.2.11.1 Extraction of Total RNA from Human FRDA Fibroblast Cells Using 
Trizol
®
  
 
Total RNA was extracted from 10
6
 cells using the Trizol
®
 method, previously described 
in section 4.2.5 (chapter IV). The cell pellet was washed with PBS and was collected by 
centrifugation at 389 rcf for 5 minutes. The cell pellet was loosened by gently flicking the 
tube and was resuspended in 1ml of Trizol
®
. Total RNA was extracted and the quality of 
the RNA was determined on agarose gel electrophoresis. RNA was quantified with 
spectrophotometry at 260 and 280nm. The RNA was stored at -80˚C for long term 
storage. 
 
 
 
 
Fig. 5.4 Logarithmic plot of the TSR8 standard curve 
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        5.2.11.2 DNase I Treatment of RNA 
Total RNA was treated with DNase I (DNase I, Amp Grade, Invitrogen) prior to RT-PCR 
using the following reagents: 
 
- 2µg total RNA 
- 2µl 10× DNase I reaction buffer  
- 2µl DNase I, Amp Grade, 1U/µl 
- Nuclease free water to 20µl 
The samples were left for 15 minutes at RT. DNase I reaction was inactivated by adding 
2μl of 25mM EDTA solution to the reaction mixture followed by heating for 10 minutes 
at 65˚C. The RNA samples were subsequently used for reverse transcription.      
        5.2.11.3 Complementary DNA (cDNA) Synthesis  
Cloned AMV first-strand cDNA Synthesis Kit (Invitrogen) was used to synthesise first 
strand cDNA. The following components were added to the DNase I treated total RNA: 
- 2μl of 250ng/μl random hexanucleotide primers  
- 2μl of 10mM dNTP mix (10mM each of dATP, dGTP, dCTP, dTTP at neutral pH) 
The mixtures were incubated for 5 minutes at 65˚C and were then placed on ice for at 
least 1 minute. The contents were collected and the following reagents were added: 
 
- 8μl of 5× cDNA synthesis buffer 
- 2μl of 0.1 M DTT 
- 2μl of 40U/μl RNase Out 
- 2μl of 15U/μl cloned AMV RT 
The samples were gently mixed by pipetting up and down and incubated at 55˚C for 1 
hour followed by 5 minute incubation at 85˚C to terminate the reaction. The cDNA 
samples were used immediately or stored at -20˚C. 
 
        5.2.11.4 Reverse Transcriptase PCR (RT-PCR) 
The quality of the cDNA was confirmed by PCR using FXN human specific primers, 
previously described in section 4.2.8 (chapter IV). 
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        5.2.11.5 Quantitative RT-PCR (qRT-PCR) 
hTERT mRNA expression levels in FRDA human fibroblast (GM03665, GM03816 and 
GM04078) and two normal human fibroblast (GM07492 and GM08399) cDNA samples 
were quantitated by qPCR and an ABI Prism 7900HT Sequence Detection System 
(Applied Biosystems) was employed for this assay. Two positive controls (21MT and 
21NT, human breast cancer epithelial samples) and one negative control (184, normal 
breast epithelial sample) were used as the controls. hTERT assay (Applied Biosystems), 
containing hTERT forward and reverse primers and a TaqMan TAMRA
™
 probe, and 
GAPDH assay (Assay ID: Hs99999905_m1, 124bp amplicon size, Applied Biosystems), 
containing GAPDH forward and reverse primers  and a TaqMan MGB probe, were used 
in this experiment, Table 5.4. The TaqMan MGB probe included a VIC
®
 reporter dye 
attached to the 5´ end, a nonfluorescent quencher (NFQ), and a minor groove binder 
(MGB) attached to the 3´ end (MGBs increase the melting temperature (Tm) without 
increasing the probe length, allowing the design of shorter probes). The TaqMan 
TAMRA
™
 probe included a FAM
™
 reporter dye attached to the 5´ end and TAMRA
™
 
quencher attached to the 3´ end.  
Each PCR-reaction was performed in triplicate on a MicroAmp optical 96-well PCR plate 
(Applied Biosystems), where each reaction well contained 4µl of cDNA products, 0.3μl 
 
Fig. 5.5 Schematic diagram of qPCR program 
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of hTERT primer mix for target master mix and 1µl of GAPDH primer mix for 
endogenous master mix, 10µl of 2× TaqMan
®
 Fast Universal Master Mix (Applied 
Biosystems) and nuclease free water to 20µl. Target and endogenous master mixes were 
prepared separately and were added to the plate. Subsequently, the plate was sealed with a 
plate sealer (MicroAmp, Applied Biosystems) and was then centrifuged for 1 minute at 
101 rcf. The qPCR reactions were run using the programs depicted in Fig. 5.5. 
 
The signal obtained for GAPDH was used as the reference housekeeping gene to 
normalise the amount of total RNA amplified in each reaction. Relative gene expression 
data were analysed using the 2
-∆∆Ct 
method. 
 
Table 5.4 Synthetic oligonucleotides for qPCR 
Primer 
Primers and 
TQ probes 
Reporter 
Dye 
Sequence (5´3´) 
Localisation 
Exon/Intron 
Product 
size (bp) 
hTERT 
12896-F* 
FAM 
GAGCTGACGTGGAAGATGAGC Exon2 
260 13156-R* GGTGAACCTCGTAAGTTTATGCAA Intron2 
13095-TQ* CACGGTGATCTCTGCCTCTGCTCTCC Intron2 
* TQ, TaqMan probe; F, forward; R, reverse 
 
    5.2.12 ImmunoFISH Using PML Antibodies 
        5.2.12.1 Cell Culturing 
Three FRDA human fibroblasts (GM03665, GM03816 and GM04078) and three controls 
(GM07492, U2OS (ALT positive) and HeLa (Telomerase positive)) were grown on poly-
L-lysine-coated slides (Poly-Prep slides, Sigma-Aldrich) for 24 hours prior to 
immunofluorescence staining.  
 
        5.2.12.2 Immunofluorescence 
The slides were fixed in ice-cold methanol-acetone (1:1) for 10 minutes and were washed 
three times in PBS. Cells were then blocked with 1% NCS (Newborn Calf serum) in PBS 
for 30 minutes and were covered with parafilm in a humid container. 75µl of 
promyelocytic leukemia (PML) primary antibody (Rabbit polyclonal antibody against 
PML, ab53773, Abcam) was added to the slides at the desired concentration (1:100 in 1% 
NCS/PBS) and the slides were incubated for 1 hour in a humid container covered with 
parafilm. The slides were washed in PBS three times for 5 minutes. 75µl of anti rabbit 
secondary antibody labelled with FITC (F1262-1ML, Sigma) was added to the slides at 
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the desired concentration (1:100 in 1% NCS/PBS) and the slides were incubated for 1 
hour in a dark and humid container covered with parafilm. The slides were washed in 
PBS three times for 5 minutes in the dark on the shaker. 15μl of VECTASHIELD® with 
fluorescence DAPI mounting medium (Vector) was then added to the slides and the slides 
were covered with a 22×50mm coverslip prior to sealing with clear nail varnish. 
 
        5.2.12.3 Immunofluorescence and FISH (Immuno-FISH) 
Cells were grown, fixed and immunostained with anti-PML antibodies, previously 
described in section 5.2.12.2. Subsequently, the FISH method was applied with a Cy3-
conjugated PNA probe (C3TA2)3 followed by standard formamide and SSC washes. Cells 
were counterstained with DAPI, covered with a 22×50mm coverslip and were sealed with 
clear nail varnish.  
 
        5.2.12.4 Cell Imaging and Quantification 
Images of cells were obtained on a Zeiss Axioplan fluorescence microscope equipped 
with a CCD camera (Photometrics) and Smart Capture software (Digital Scientific) using 
fixed exposure time of 1 second and magnification of 1000×. The co-localisation of PML 
and telomere signals was analysed using ImageJ software (National Institutes of Health, 
Bethesda, MD). 50 cells were quantified for each sample. 
 
    5.2.13 γ-H2AX Assay 
All adherent cells were grown on poly-L-lysine-coated slides (Poly-Prep slides, Sigma-
Aldrich) for 24 hours prior to immunofluorescence staining. The cells were fixed in 4% 
formaldehyde in PBS for 15 minutes and were permeabilised with 0.2% Triton X-100 
(Sigma-Aldrich) for 10 minutes at 4˚C. The cells were then blocked with 0.5% BSA in 
PBS for 30 minutes and were covered with parafilm in a humid container. 100µl of mouse 
monoclonal antiphospho-histone H2AX (Ser 139, Millipore) was added to the slides at 
the desired concentration (1:500 in 0.5% BSA/PBS) and the slides were incubated for 1 
hour in a humid container covered with parafilm. The slides were each rinsed three times 
for 5 minutes in TBST (Tris-Buffered Saline with 0.1% Tween20). 100µl of secondary 
FITC-conjugated anti-mouse IgG antibody (Sigma) was added to the slides at the desired 
concentration (1:1000 in 0.5% BSA/PBS) and the slides were incubated for 1 hour in a 
dark and humid container covered with parafilm. The slides were each washed in TBST 
three times for 5 minutes in the dark on the shaker. 15μl of VECTASHIELD® with 
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fluorescence DAPI mounting medium (Vector) was then added to the slides and the slides 
were covered with a 22×50mm coverslip prior to sealing with clear nail varnish.  
 
    5.2.14 Telomere Dysfunction-Induced Foci (TIF) Assay 
Cells were grown, fixed and immunostained with anti-H2AX antibodies, previously 
described in section 5.2.13. For telomere detection (previously discussed in section 5.2.8), 
the slides were dehydrated for 5 minutes in 70%, 90% and 100% ethanol respectively and 
were subsequently air-dried. The slides were hybridised for 2 minutes at 70-75˚C with 
Cy3-conjugated PNA (C3TA2)3 probe and were incubated in a dark humidified chamber 
for 2 hours at RT. The slides were each washed twice in 70% formamide solution for 15 
minutes and three times in TBST for 10 minutes in the dark on the shaker. Finally, the 
cells were counterstained with DAPI, covered with a 22×50mm coverslip, and were 
sealed with clear nail varnish. The slides were analysed using a Zeiss fluorescence 
Axioplan microscope equipped with a CCD camera and Smart Capture software. 50 cells 
were quantified for each sample. 
 
    5.2.15 Statistical Analysis 
For statistical analysis two-tailed Student’s t test or two-way analysis of variance 
(ANOVA) were used to assess the significance of the differences of the group data. 
 
5.3 Results  
    5.3.1 Telomere Length Analysis by Quantitative FISH (Q-FISH)  
To measure the telomere length in FRDA and normal fibroblast cells, Q-FISH was 
performed. A total of 100 interphase cells per cell line were captured and the mean 
telomere fluorescence intensity per cell was used to determine the mean difference 
between the FRDA and normal fibroblast cell lines.  
 
        5.3.1.1 Telomere Length Analysis in FRDA Mouse Models 
Initially, telomere fluorescence intensity was analysed in mouse FRDA (YG8R and 
YG22R) and control (Y47R and B6) fibroblast cells. In order to quantify the results, two 
mouse lymphoma LY-R and LY-S cells were used as calibration standards with known 
telomere lengths of 49kb and 7kb respectively [236]. The results revealed that the mouse 
FRDA cell lines (YG8R and YG22R) had significantly increased telomeric repeat 
fluorescence (P<0.001) compared to the controls (Y47R and B6), Fig. 5.6. LY-R control 
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also showed to have approximately 6 times greater telomere fluorescence than LY-S 
control which further confirmed the accuracy of the technique. The statistical significance 
of the differences was evaluated by the Student’s t test. 
 
        5.3.1.2 Telomere Length Analysis in Human FRDA Fibroblast Cells 
Subsequently, telomere fluorescence intensity of PNA probes was analysed in human 
FRDA (GM03665, GM04078 and GM03816) and control (GM07492, GM04503 and 
GM07545) fibroblast cell lines at the same growth stage, passage 7. The results indicated 
that the mean telomere fluorescence intensity of the PNA probes in all the FRDA cell 
lines was significantly greater (P<0.001) than those of the controls, Fig. 5.7.  
 
    5.3.2 Telomere Length Measurement by qPCR 
To further confirm the Q-FISH results, qPCR technique was performed to evaluate the 
telomere length in the FRDA and control cell lines.  
 
 
Fig. 5.6 Telomere length analysis of FRDA mouse models by Q-FISH. YG8R and 
YG22R mice showed to have significantly increased telomeric repeat fluorescence 
compared to Y47R and B6 controls. LY-R control also showed to have 6 times greater 
telomere fluorescence than LY-S control which further confirmed the accuracy of the 
technique. Error bars indicate SEM and values represent mean ± SEM. Asterisks indicate 
significant differences between the mutant and control mice (
***
P<0.001). 
*** 
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        5.3.2.1 Telomere Length Analysis in Human FRDA Fibroblast Cells 
Telomere length was measured in human FRDA (GM03665, GM04078 and GM03816) 
and control (GM07492, GM07545 and human normal) fibroblast cell lines at the same 
growth stage, passage 7, Table 5.1. Three controls (one 21NT human breast cancer 
epithelial sample and two 184 normal breast epithelial samples with growth passages of 7 
and 20), with known telomere length of 3kb, 15kb and 6kb respectively, were used as the 
controls to examine the accuracy of the technique. The telomere length of these samples 
was previously measured using Southern blot method by Dr. Hemad Yasaei. The results 
obtained by qPCR were in good agreement with those previously acquired by Q-FISH 
and Southern blot methods, Fig. 5.8A. The results demonstrated that the FRDA fibroblast 
cells had significantly higher average telomere length of 19kb compared to the normal 
fibroblasts (14kb, P<0.001) and 184 (passage 7) normal epithelial cells (15kb, P<0.05), 
Fig. 5.8B.  
 
 
 
 
 
 
 
Fig. 5.7 Telomere length analysis of human FRDA cells by Q-FISH. All the FRDA cells 
showed to have significantly higher telomere fluorescence compared to the controls. Error 
bars indicate SEM and values represent mean ± SEM. Asterisks indicate significant 
differences between the FRDA and control cells (
***
P<0.001). 
*** 
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 *** 
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Fig. 5.8 Telomere length measurement in FRDA fibroblasts using qPCR. A) The FRDA 
fibroblasts had higher telomere length compared to the controls. 21NT breast cancer 
epithelial cell, 184 (passage 7) and 184 (passage 20) normal epithelial cells, with average 
telomere length of 3kb, 15kb and 6kb respectively, were used as the controls. B) Mean 
telomere length of the FRDA patients was significantly greater than the fibroblast and 
epithelial (184 passage 7) controls. Error bars indicate SEM and values represent mean 
telomere length per genome. Asterisks indicate significant differences between the FRDA 
and control cells (
*
P<0.05 and 
***
P<0.001). 
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        5.3.2.2 Telomere Length Analysis in Human FRDA Lymphocyte Cells 
Genomic DNA samples, previously extracted from blood samples of 18 FRDA patients 
and 12 healthy controls, were used to measure the telomere length by qPCR method, 
 
 
Fig. 5.9 Telomere length measurement in FRDA lymphocytes using qPCR. A) There was 
a variation in the telomere length of the FRDA patients and control lymphocytes. B) 
Mean telomere length of the FRDA lymphocyte cells was significantly lower compared to 
the controls. Error bars indicate SEM and values represent mean telomere length per 
genome. Asterisk indicates significant difference between the FRDA and control cells 
(
*
P<0.05).  
A 
B 
* 
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Table 5.2. The results indicated that although there was a considerable variation in the 
telomere length of the patients, Fig. 5.9 A, the mean telomere length was significantly 
(P<0.05) shortened in the FRDA lymphocyte cells compared to the controls, Fig. 5.9 B. 
These results were in good agreement with those previously reported [214]. 
 
    5.3.3 Investigation of Telomerase Activity in Human FRDA Fibroblast Cells Using 
the TRAP Assay 
 
As previously discussed, the FRDA fibroblast cells were found to have chromosomes 
with relatively longer telomeric repeats. Therefore, these cells might have overcome 
telomere shortening through activation of telomerase. To validate this hypothesis, cells 
were screened for expression of telomerase activity using the TRAP assay. In this 
method, telomerase adds telomeric repeats to the forward primer provided that it is active 
in these cells. The extended primer would then be amplified by qPCR with a reverse 
primer complementary to the telomeric repeat. Telomerase activity was assessed in each 
sample at the same growth stage, passage 7. The results revealed that telomerase activity 
was not present in the FRDA fibroblasts, Fig. 5.10. The positive control and 21NT 
showed telomerase activity while the FRDA cells exhibited the same level of telomerase 
activity as the negative controls. Such observed activity in the FRDA cells was presumed 
to be due to the background since the higher number of PCR amplification cycles will 
enhance the sensitivity as well as the background. Consequently, the FRDA cell lines 
were considered to be negative for telomerase activity.  
 
 
 
 
 
 
 
 
Samples 
21NT 
Positive control 
 
Samples/Negative controls 
0.04 amoles/µl 
0.4 amoles/µl 
4 amoles/µl 
40 amoles/µl 
TSR8 Standard A B 
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    5.3.4 Investigation of hTERT Expression in Human FRDA Fibroblast Cells  
Since the TRAP assay is a semi-quantitative method and there exists a strong correlation 
between hTERT mRNA expression levels and telomerase activity [237], hTERT (human 
Telomerase Reverse Transcriptase) mRNA expression was measured in the FRDA cells. 
The quantitative assay for hTERT mRNA expression in the FRDA cells (GM03665, 
GM03816 and GM04078) was conducted using TaqMan qRT-PCR. Two human breast 
cancer epithelial samples, 21MT and 21NT, were used as the positive controls while a 
normal breast epithelial sample, 184, and two normal human fibroblasts, GM07492 and 
GM08399, served as the negative controls. The results indicated that the FRDA cells did 
not express hTERT gene, further confirming that the telomerase was negative in these 
cells, Fig. 5.11.  
 
 
 
 
 
Fig. 5.10 Telomerase activity determined by the TRAP assay in FRDA cells. A) Ten-fold 
serial dilutions of TSR8 quantitation control from 40 amoles to 0.04 amoles were used. B-
C) FRDA cells showed to be negative for telomerase activity. The breast cancer cell line 
21NT and telomerase positive control provided in the kit were used as the positive 
controls. No template control (NTC), heat treated telomerase negative control and minus 
telomerase control (MTC) served as the negative controls. 
 
C 
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Fig. 5.11 Quantification of hTERT transcripts in FRDA cells. Amplification plot (above) 
and results in gel electrophoresis (below) indicated that FRDA cells did not express 
hTERT. The breast cancer cell lines 21NT and 21MT were used as the positive controls. 
Normal human fibroblast GM07492 and GM08399 cell lines, normal breast epithelial cell 
line 184 and NTC (No Template Control) served as the negative controls. 
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    5.3.5 Co-localisation of PML Bodies and Telomeres in Human FRDA Fibroblast 
Cells  
 
As previously stated, the FRDA fibroblast cells exhibited a marked telomere lengthening 
with no detectable telomerase activity. To investigate whether the FRDA cells maintain 
their telomeres by ALT associated PML bodies (APBs), the FRDA cells were first 
examined for the presence of PML bodies using immunofluorescence. No difference was 
detected in the number and distribution of PML nuclear foci in the FRDA cells compared 
to the controls. Furthermore, co-localisation of PML bodies with telomeres was 
investigated in these cells using combined immunofluorescence to PML followed by Q-
FISH for telomere detection, Fig. 5.12. The results indicated that in 50 randomly analysed 
FRDA cells (GM03665, GM03816 and GM04078), approximately 35% of the PML foci 
co-localised with telomeric DNA. However, the mean co-localisation of PML and 
telomeres in ALT positive U2OS cell and; GM07492 and HeLa negative controls were 
99%, 11% and 8% respectively, Fig. 5.13A. These results suggested that the ALT 
mechanism was involved in the FRDA cells but it was not as frequent as the ALT positive 
cells. Subsequently, the size of co-localised PML bodies with telomeres was examined in 
the aforementioned cells. The results indicated that larger PML bodies in the FRDA cells 
were associated with telomeres, Fig. 5.13B. However, similar results were obtained in 
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Fig. 5.12 Detection of APBs by immuno-FISH in FRDA cell lines. PML bodies co-
localised with telomeres in the FRDA cell lines GM03665, GM03816 and GM04078. 
U2OS was used as the positive control while GM07492 and HeLa served as the 
negative controls. Interphase cells were permeabilised and stained with anti-PML 
(green) and telomeric Cy3-labeled PNA probes (red). Nuclei were counterstained with 
DAPI. 
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Fig. 5.13 Co-localisation of PML bodies with telomeres in FRDA cells. A) Percentage of 
the PML bodies associated with telomeres demonstrate high co-localisation in all the 
FRDA cells, GM03665, GM03816 and GM04078, compared to GM07492 and HeLa 
controls. 99% of the telomere foci co-localised with the PML bodies in the positive 
control U2OS. B) Size analysis of associated and non-associated PML bodies with 
telomeres. Asterisks indicate significant differences between the FRDA and control cell 
lines (
**
P<0.01 and 
***
P<0.001).  
33% 
37% 36% 
8% 
11% 
99% 
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the negative controls (HeLa and GM07492). In addition, no significant difference was 
detected in the ALT positive control U2OS. Previous results showed that cellular stress 
may promote aggregation of PML bodies or conversely disperse them into microspeckles 
[238]. However, in the current study similar results were obtained in the normal cells 
even though there was an increase in the size of PML bodies associated with telomeres in 
the FRDA cells. Consequently, these results did not provide any further information 
regarding the assembly or disassembly of PML bodies in the FRDA cells due to cellular 
stress. In order to further validate these results, it is of great importance to assess the co-
localisation of other PML components such as Sp100 and Daxx with telomeres in the 
FRDA cells [239]. 
 
    5.3.6 CO-FISH Analysis of FRDA Fibroblast Cells 
Subsequently, telomere recombination frequencies between sister telomeres were 
analysed in the human FRDA (GM03665, GM04078 and GM03816) and control 
(GM07492 and GM08399) primary fibroblast cell lines at the same growth stage, passage 
7, using the CO-FISH method. A total of 20 metaphases per cell line was analysed to 
examine the frequencies of T-SCEs in each cell line. The results indicated a significant 
increase (P<0.001) in T-SCE levels of the FRDA cell lines compared to the controls, Fig. 
5.14 and Fig. 5.15. These results suggested that T-SCEs occur much more frequently in 
the FRDA cells than the normal cells, further confirming the existence of ALT 
mechanism in these cells. 
 
 
  
A
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Fig. 5.14 T-SCE frequency in FRDA fibroblasts by CO-FISH. A) GM03665, B) 
GM04078 and C) GM03816 FRDA cells showed multiple T-SCEs events indicated by 
arrows. The process effectively removes the newly synthesised DNA strands and leaves 
behind the two parental strands which are located on sister chromatids. A single-stranded 
probe hybridises to complementary telomeric DNA on one chromatid of each 
chromosome arm producing a two-signal pattern instead of the four signals seen with 
ordinary FISH. D) In the normal GM07492 and GM08399 fibroblast cells T-SCE is a 
very rare event.  
 
 
Fig. 5.15 T-SCE analysis of human FRDA cells by CO-FISH. All FRDA cells showed a 
significant increase (P<0.001) in T-SCE levels compared to the controls. Error bars 
indicate SEM and values represent mean ± SEM. Asterisks indicate significant 
differences between the FRDA and control cell lines (
***
P<0.001). 
*** 
 *** 
 
*** 
 
*** 
C *** 
H 
*** 
 
C D  
171 
 
    5.3.7 Population Doubling and Growth Curve of Human FRDA Fibroblast Cells  
To investigate whether the FRDA cells activate ALT during culturing in vitro and become 
immortalised, growth curves and cumulative population doubling analysis were 
performed. Growth curve analysis of the human FRDA and control fibroblasts was 
carried out from the earliest passage number for each cell line. The cells harvested from 
the earliest passage were counted by a Countess
TM 
automated cell counter and were 
reseeded at 100,000 cells/25cm
2
 flasks every 6-7 days. As evident in Fig. 5.16A and 
Table 5.5, GM03816 and GM04078 FRDA fibroblast cell cultures underwent growth 
arrest after 175 days with average cumulative population doubling of 57 and 52 
respectively. In contrast, the normal fibroblast cells exhibited earlier growth arrest, after 
approximately 138 days, with an average of 36 cumulative population doubling, Fig. 
5.16B and Table 5.5. GM03665 FRDA fibroblast cell showed growth arrest with 
cumulative population doubling of 33 after 133 days, Fig. 5.16A. However, the earliest 
passage number of this cell line was not provided at the beginning of culturing and was 
assumed to be at passage 7. In addition, such subtle differences in the cellular ageing 
process of different primary human fibroblasts can be due to different cellular processes. 
Therefore, the analysis of variation in growth rate requires additional studies. These 
results indicated that the FRDA cells were unable to become immortalised by the ALT 
mechanism alone, suggesting that the frequency of the PML bodies may not have been 
sufficient to prevent senescence. However, the FRDA cells senesced approximately 11  
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Fig. 5.16 Growth curves of human fibroblast cells. A) CPD of the human FRDA and 
normal fibroblast cell lines. B) The FRDA cells senesced approximately 11 population 
doublings later than the control cells. Every cell passage is indicated by a point and the 
CPD was calculated based on the average sum of the cell proliferations over the 
cumulative time taken from the earliest passages until cells underwent senescence. Error 
bars indicate SEM and values represent mean ± SEM. Asterisks indicate significant 
differences between the FRDA and control fibroblasts (
***
P<0.001), evaluated by two-
way ANOVA. 
 
population doublings later than the controls (P<0.001). This delay in transition from 
proliferation to senescence in the FRDA cells could be due to the difference in the 
original telomere lengths of these cell lines. 
 
Table 5.5 CPDs of the human fibroblasts at different passages 
Cell line 
Duration in 
culture (Day) 
CPD at earliest 
passage (P-7) 
CPD at passage 
15th  
CPD at passage 
26th  
CPD at final 
passage 
GM07492 140 3 20 34 35 
GM07545 133 1 19 22 25 
GM08399 144 2 26 45 47 
GM03816 (FRDA) 175 3 27 56 57 
GM04078 (FRDA) 175 4 33 49 52 
GM03665 (FRDA) 133 1 20 32 33 
CPD, Cumulative Population Doubling; P, Passage number 
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    5.3.8 Telomere Length Shortening Rate Analysis in Human FRDA Fibroblast 
Cells  
 
The effect of replicative aging of culture cells at the 7
th
, 15
th
 and 26
th
 passages was 
studied by qPCR telomere length assay to determine telomeric DNA loss due to cell 
divisions. Three FRDA fibroblast cell lines (GM03665, GM03816 and GM04078) and 
two normal fibroblasts (GM07492 and GM07545) were monitored for telomere length 
loss, Fig. 5.17A and Table 5.6. The results from this study revealed an accelerated rate of 
telomere shortening in the FRDA fibroblasts, Fig. 5.17B. Although preliminary results 
indicated that the FRDA fibroblast cells had relatively longer telomeres at growth stage of 
passage 7 compared to the controls, further analysis of telomere length at different time 
points of passages 15 and 26 revealed that these cells lost telomeres more rapidly in 
culture than the normal cells, Fig. 5.17C and Fig 5.17D. The accelerated telomere 
shortening observed in the FRDA fibroblast cells suggested that telomeres were 
dysfunctional in these cells. In addition, it is possible that genetic changes or recruitment 
of other proteins at telomeres may alter the heterochromatic state of ALT telomeres, 
resulting in the repression of telomeric recombination [155]. 
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Table 5.6 Student’s t test analysis of telomere length shortening in FRDA fibroblasts 
Cell line Passage number Versus GM07492 Versus GM07545 
 
GM03665 
7 P= 0.01 P= 0.05 
15 P= 0.004 P= 0.01 
26 P= 0.0001 P= 0.003 
GM03816 
7 P= 0.02 P= 0.05 
15 P= 0.03 P= 0.03 
26 P= 5.30E-06 
 
P= 0.0008 
 
GM04078 
7 P= 0.04 P= 0.1 
15 P= 0.1 P= 0.3 
26 P= 0.05 P= 0.1 
 
 
 
Fig. 5.17 Rates of telomere shortening in human FRDA fibroblast cells. A) Telomere 
length analysis by qPCR in the FRDA fibroblast cells (GM03665, GM03816 and 
GM04078) compared to normal fibroblasts (GM07492 and GM07545) at different growth 
passages of 7, 15 and 26. B) The average telomere length of the FRDA cells compared to 
the controls at different growth passages. C) Rates of telomere shortening in the human 
FRDA and normal fibroblasts in bp/population doubling. D) The average rates of telomere 
shortening in the human FRDA and normal fibroblasts in bp/population doubling. Error 
bars indicate SEM and values represent mean ± SEM. Asterisks indicate significant 
differences between the FRDA and control cell lines (
**
P<0.01 and 
***
P<0.001). 
D 
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    5.3.9 TIF Analysis in Human FRDA Fibroblast Cells 
To confirm the presence of a telomere dysfunction phenotype in the FRDA cells, the 
telomere dysfunction-induced foci (TIF) assay was performed using an antibody against 
DNA damage marker γ-H2AX together with the synthetic PNA telomere probe. As 
evident in Fig. 5.18 and Fig. 5.19A, the frequency of γ-H2AX foci was significantly 
higher in the FRDA cells compared to the controls (P<0.001). Similarly, the FRDA cells 
had greater TIF frequencies in comparison to the controls (P<0.001), Fig. 5.19B, 
suggesting that the FRDA cells may have induced telomere dysfunction relative to the 
controls. 
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Fig. 5.18 Detection of γ-H2AX by immuno-FISH in FRDA cell lines. Cell nucleus in 
the FRDA cell lines (GM03665, GM03816 and GM04078) exhibiting a TIF. GM07492 
and GM04503 cell lines were used as the negative controls. Interphase cells were 
permeabilised and stained with antiphospho-histone γ-H2AX (green) and telomeric 
Cy3-labeled PNA probes (red). Nuclei were counterstained with DAPI.  
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5.4 Discussion  
FRDA is caused by a GAA triplet repeat expansion within the first intron of the frataxin 
gene. This expansion impairs the transcription of the gene, leading to deficiency of 
frataxin. This protein is a ubiquitous mitochondrial protein involved in mitochondrial iron 
transport and/or in the assembly of iron-sulphur cluster enzymes. Frataxin deficiency is 
associated with iron dysregulation and severe disruption of iron-sulphur cluster proteins. 
Lack of iron detoxification and the increase in the level of bioavailable iron are likely to 
enhance cellular sensitivity to oxidative stress, an important modulator of telomere length. 
Therefore, it was hypothesised that telomere length might be shortened in the FRDA 
patients.  
 
This study, which is to my knowledge the first to report on telomere length in the FRDA 
fibroblast cells, showed that human FRDA fibroblast cells had significantly higher 
telomere length compared to normal fibroblasts of the same growth passage. Similar 
results were obtained in the mouse FRDA fibroblast cells. However, the results published 
in a recent study using human FRDA lymphoblast cells indicated significant telomere 
 
 
Fig. 5.19 Frequencies of γ-H2AX positive foci and TIFs in FRDA cells. A) Average γ-
H2AX positive foci in each cell line. B) Average TIFs in each cell line. The results were 
obtained based on two independent experiments with an average of 50 cell nuclei scored 
per cell line. Asterisks indicate significant differences between the FRDA and control cell 
lines (
**
P<0.01 and 
***
P<0.001). 
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shortening in these cells [214]. Consequently, telomere length was also examined in the 
genomic DNA from FRDA lymphocytes in order to investigate such a discrepancy. The 
results indicated that the mean telomere length was significantly shortened in the FRDA 
lymphocytes relative to the controls which were in good agreement with the recently 
published results [214]. Nevertheless, there was a considerable variation in the telomere 
length of the patients. Therefore, the mean results cannot serve as a reliable biomarker of 
the FRDA disease as proposed by the authors [214]. The results from the fibroblast and 
lymphocyte cells revealed that telomere length varies within different cell types. This may 
be due to the different environmental conditions as the former was derived from in vitro 
culture while the latter was generated from in vivo cells. However, an explicit conclusion 
can only be drawn provided that a sufficiently large sample size is examined and the 
fibroblast cells are matched for age. Therefore, larger age matched sample sizes are 
required to evaluate the reliability and validity of the results presented in this study.  
 
To investigate the mechanisms which induce telomere lengthening in the human FRDA 
primary fibroblasts, cells were screened for the expression of telomerase activity using the 
TRAP assay. The results indicated that the observed telomere elongation in the FRDA 
fibroblasts did not involve the telomerase enzyme. A quantitative assay for hTERT 
mRNA expression in the FRDA cells was also conducted using TaqMan qRT-PCR. The 
results showed that the FRDA cells did not express hTERT, further confirming the 
finding that telomerase activity was negative in these cells. Therefore, it was hypothesised 
that the ALT mechanism may be responsible for the observed telomere lengthening in the 
FRDA fibroblasts. To investigate whether FRDA cells maintain their telomeres by ALT 
associated PML bodies (APBs), co-localisation of PML bodies with telomeres was 
investigated in these cells using combined immunofluorescence and Q-FISH. The results 
indicated that the FRDA fibroblast cells had significantly higher co-localised PML foci 
with telomeric DNA compared to the normal fibroblast cells. However, the mean co-
localisation of PML and telomeres was more pronounced in the U2OS ALT positive 
control. These results suggested that the ALT mechanism was involved in the FRDA cells 
but it was not as frequent as the ALT positive cells. Subsequently, the size of co-localised 
PML bodies with telomeres was examined in the FRDA cells. The results indicated that 
larger PML bodies in the FRDA cells were associated with telomeres. However, similar 
results were obtained in the negative controls. In addition, no significant difference was 
detected in the ALT positive control U2OS. Previous results showed that cellular stress 
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may promote aggregation of PML bodies or conversely disperse them into microspeckles 
[238]. However, in the current study similar results were obtained in the normal cells 
even though there was an increase in the size of PML bodies associated with telomeres in 
the FRDA cells. Consequently, these results did not provide any further information 
regarding assembly or disassembly of PML bodies in the FRDA cells due to cellular 
stress. In order to further validate these results, it is of great importance to assess the co-
localisation of other PML components such as Sp100 and Daxx with telomeres in the 
FRDA cells [239]. T-SCE frequencies were also analysed in the human FRDA cell lines. 
The results exhibited a significant increase in T-SCE levels of the FRDA cell lines 
relative to the controls, further confirming the existence of ALT mechanism in these cells.  
 
To investigate whether the FRDA cells activate ALT during culturing in vitro and become 
immortalised, growth curves and cumulative population doubling analysis were 
performed. The results showed that the FRDA fibroblast cell cultures underwent growth 
arrest with higher cumulative population doubling compared to the controls. These results 
indicated that the FRDA cells were unable to become immortalised by the ALT 
mechanism alone, suggesting that the frequency of the PML bodies may not have been 
sufficient to prevent senescence. However, the FRDA cells senesced approximately 11 
population doublings later than the controls. This promotion of the transition from 
proliferation to senescence in the FRDA cells could be due to the difference in the 
original telomere lengths of these cell lines or the activation of the ALT mechanism by 
which the mean cell population doubling may have been exceeded. In addition to the 
growth behaviour and the number of cells, the state of replicative senescence can also be 
determined by increased numbers of γ-H2AX DNA repair foci at telomeres as a result of 
cell-specific stress responses. Therefore, further analysis is required to confirm the 
senescent phenotype in the fibroblasts cells.  
 
Subsequently, the effect of replicative ageing of culture cells at 7
th
, 15
th
 and 26
th
 passages 
was studied by telomere length assay to determine telomeric DNA loss due to cell 
divisions. Analysis of telomere length results at different passage numbers revealed that 
the FRDA cells lost telomeres faster than the controls. These results suggested that 
dysfunctional telomeres in the FRDA cells, possibly due to oxidative stress, were 
responsible for the increased rate of telomere attrition [156]. In addition, previous studies 
have also shown that the FRDA cells were more sensitive to ionising radiation than the 
control cells, suggesting that FRDA is a DNA repair-deficient disorder [216]. 
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Furthermore, it is possible that genetic changes or recruitment of other proteins at 
telomeres may alter the heterochromatic state of ALT telomeres, resulting in the 
repression of telomeric recombination [155]. 
 
Finally, to confirm the presence of a telomere dysfunction phenotype in the FRDA cells, 
the TIF assay was performed. The results demonstrated that the frequency of γ-H2AX 
foci was significantly higher in the FRDA cells compared to the controls, indicating a 
higher degree of DNA damage. Similarly, the FRDA cells had greater frequencies of TIFs 
in comparison to the controls. Therefore, these results suggested that the FRDA cells may 
have induced telomere dysfunction relative to the control cells.  
 
The results presented in this chapter demonstrated a telomere dysfunction phenotype and 
accelerated telomere shortening in the FRDA fibroblasts. In addition, the results 
suggested that intertelomeric recombination was initiated in the FRDA cells but was not 
capable of maintaining the telomeres and preventing accelerated telomere shortening.  
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VI GENERAL DISCUSSION AND CONCLUSIONS 
FRDA is an autosomal recessive neurodegenerative disorder caused by a reduction in 
frataxin expression. The reduction in frataxin expression leads to oxidative stress, 
mitochondrial iron accumulation and consequential cell death with the primary sites of 
neurons of the dorsal root ganglia and the dentate nucleus of the cerebellum. To 
recapitulate such features of FRDA disease in the mouse, the Ataxia Research Group at 
Brunel University established GAA repeat expansion-based FXN YAC transgenic mouse 
models, YG8R and YG22R, containing 190+90 and 190 GAA repeat sequence 
respectively. A new line, designated YG8sR (YG8R with a small GAA band), line was 
recently generated from YG8R breeding.   
 
6.1 Determination of Amplification of the FXN Gene Using TaqMan Copy Number 
and Fluorescence In Situ Hybridisation Assays 
 
To determine the copy number of the FXN transgene in the enhanced GAA repeat 
expansion-based FRDA mouse lines, a TaqMan qPCR assay was developed. The results 
indicated that the YG22 and Y47 lines had a single copy of the FXN gene, while the YG8 
line was shown to have two copies. The YG8s line showed less than one copy of the 
target gene, indicating deletion of the FXN gene. Single integration sites of all transgenes 
were confirmed by dual colour FISH analysis of metaphase and interphase chromosomes. 
However, in YG8s, at least 25% of the YG8s cells had no signals, while the remaining 
cells showed one signal corresponding to the transgenic FXN gene. In addition, the 
analysis of FXN exons in YG8s mice by PCR confirmed the presence of all FXN exons in 
this line. These results suggest the incidence of somatic mosaicism in YG8sR cells. 
Further investigation of the somatic mosaicism in YG8sR mice could be carried out in the 
future studies using the BAC probes together with mouse centromere- and/or telomeres 
specific probe to confirm the incidence of mosaicism in this line. In addition, results from 
the Jackson Laboratory using SNP assay showed that the transgenes are localised on Chr. 
16 of the YG8R mouse chromosomes. Accordingly, it would be of particular interest to 
determine how the FXN transgenes in the YG8R line have become distributed at this 
locus. However, both TaqMan copy number and FISH assays are not capable of providing 
such information. Therefore, other techniques such as Fibre FISH should be utilised in 
future investigations to characterise the organisation of FRDA transgenes in different 
mouse models. 
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6.2 Functional Studies of FRDA Mouse Models 
Subsequently, extended functional analysis was carried out on different groups of mice 
from 4 to 12 months of age to determine the effect of reduced frataxin level on FRDA-
like pathological phenotype and functional deficits. Coordination ability of YG8R, 
YG8sR and YG22R ‘FRDA-like’ mice, together with Y47R and C57BL6/J wild-type 
control mice, was assessed using accelerating rotarod analysis. The results indicated a 
progressive decrease in the motor coordination ability of YG8R, YG22R and YG8sR 
mice compared to Y47R or C57BL6/J controls. Locomotor activity was also assessed 
using an open field beam-breaker, beam-walk, hang wire, grip strength and foot print 
tests. The results indicated substantial functional deficits in the FRDA mouse models. The 
body weight analysis of YG22R, YG8R and YG8sR demonstrated an increase in weight 
compared to C57BL6/J which may be attributed to the observed decreased locomotor 
activity of the mice. The identified functional deficits in the FRDA mouse models may be 
due to the reduced levels of frataxin, inducing an FRDA-like phenotype. If so, then these 
functional tests provide an experimental approach capable of detecting the phenotypic 
consequences of the reduced level of frataxin in the FRDA mice, making them amenable 
to novel therapeutic strategies. Another symptom of FRDA disease is susceptibility to 
diabetes. Consequently, glucose and insulin tolerance tests were performed to determine 
the prevalence of abnormalities in glucose handling and insulin sensitivity. The glucose 
tolerance results indicated that the FRDA mice were glucose intolerant and insulin 
secretion following a glucose injection was delayed. Furthermore, the glucose-lowering 
effect of exogenous insulin was enhanced in the FRDA mouse models during insulin 
tolerance test, suggesting insulin hypersensitivity in these lines. These results suggested 
that mitochondrial dysfunction due to frataxin deficiency in the FRDA mouse models 
may contribute to pancreatic ß cell dysfunction. Therefore, it would be of particular 
interest to assess the relative contribution of insulin resistance and ß cell dysfunction or 
deficiency in genes of the IRS family in the future studies. This may provide a novel 
treatment strategy for the FRDA patients. 
 
6.3 GAA Repeat Instability and FXN Gene and Protein Expression in FRDA Mouse 
Models  
 
Following comprehensive functional analysis of the FRDA mice, frataxin mRNA and 
protein levels as well as somatic GAA repeat instability were examined in the FRDA 
mouse models in order to investigate the correlation between FRDA-like pathological 
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phenotype and frataxin deficiency. The results revealed GAA repeat somatic instability in 
the brain, cerebellum and liver of all the FRDA mouse models. However, the pattern and 
size of the GAA repeats differed between males and females, indicative of gender-
specific differences in repeat sizes. Subsequently, frataxin mRNA and protein levels were 
investigated. Significant reduction in the levels of the FXN mRNA and protein in the liver 
of YG8R and YG22R compared to Y47R was detected. However, in the case of the 
YG8sR line, a significant decrease in FXN mRNA was observed in all the tissues 
compared to both Y47R human FXN and C57BL6/J mouse Fxn mRNA. Protein 
expression levels were also considerably decreased in all the tissues of YG8sR mice 
compared to Y47R mice. Of all FRDA mouse models studied, the greatest FXN reduction 
was detected in the YG8sR tissues compared to both Y47R human FXN and C57BL6/J 
mouse Fxn mRNA. In addition, GAA repeat analysis identified a single GAA repeat band 
in the YG8sR line with no complexity compared to the other FRDA lines. Therefore, 
YG8sR can be considered to be the most suitable YAC transgenic GAA repeat-based 
mouse model for the investigation of potential FRDA therapies. 
 
6.4 Telomere Length Analysis in FRDA Cells 
Since oxidative stress is considered to be an important modulator of telomere length and 
is reported to increase the rate of telomere attrition [156], it was hypothesised that 
telomere length might be shortened in the FRDA patients. The qPCR telomere length 
measurements revealed that the human FRDA fibroblast cells had significantly higher 
telomere length compared to the normal fibroblasts. Similar results were obtained in the 
mouse FRDA fibroblast cells. However, the results published in a recent study using 
human FRDA lymphoblast cells indicated significant telomere shortening in these cells 
[214]. Consequently, telomere length was also examined in the genomic DNA from 
FRDA lymphocytes in order to investigate such a discrepancy. The results indicated that 
the mean telomere length was significantly shortened in the FRDA lymphocytes relative 
to the controls which were in good agreement with the recently published results [214]. 
Nevertheless, there was a considerable variation in the telomere length of the patients. 
Therefore, the mean results cannot serve as a reliable biomarker of the FRDA disease as 
proposed by the authors [214]. The results from the fibroblast and lymphocyte cells 
revealed that telomere length varies within different cell types. This may be due to the 
different environmental conditions as the former was derived from in vitro culture while 
the latter was generated from in vivo cells. However, an explicit conclusion can only be 
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drawn provided that a sufficiently large sample size is examined and the fibroblast cells 
are matched for age. Therefore, larger age matched sample sizes are required to evaluate 
the reliability and validity of the results presented in this study. In addition, the human 
FRDA primary fibroblasts were screened for the expression of telomerase activity using 
the TRAP assay and a quantitative assay for hTERT mRNA expression using TaqMan 
qRT-PCR to investigate the mechanisms which induce telomere lengthening in these 
cells. The results indicated that the observed telomere elongation in the FRDA fibroblasts 
did not involve the telomerase enzyme. Therefore, it was presumed that ALT mechanism 
may be responsible for the observed telomere elongation and co-localisation of PML 
bodies with telomeres was investigated in these cells using immunoFISH. The results 
demonstrated that the FRDA fibroblast cells had significantly higher co-localised PML 
foci with telomeric DNA compared to the normal fibroblast cells. However, the mean co-
localisation of PML and telomeres were more pronounced in U2OS ALT positive control. 
These results suggested that the ALT mechanism was involved in the FRDA cells but it 
was not as frequent as the ALT positive cells. Subsequently, the size of co-localised PML 
bodies with telomeres was examined in the FRDA cells to investigate the effect of 
cellular stress on aggregation or dispersion of PML bodies. The results did not provide 
any information regarding assembly or disassembly of PML bodies due to cellular stress. 
In order to further validate these results, it is of great importance to assess the co-
localisation of other PML components such as Sp100 and Daxx with telomeres in the 
FRDA cells [239]. T-SCE frequencies were also analysed in the human FRDA cell lines. 
The results exhibited a significant increase in T-SCE levels of the FRDA cell lines 
relative to the controls, further confirming the existence of ALT mechanism in these cells. 
To investigate whether the FRDA cells activate ALT during culturing in vitro and become 
immortalised, growth curves and cumulative population doubling analysis were 
performed. The results showed that the FRDA fibroblast cell cultures underwent growth 
arrest with higher cumulative population doubling compared to the controls. These results 
indicated that the FRDA cells were unable to become immortalised by the ALT 
mechanism alone, suggesting that the frequency of the PML bodies may not have been 
sufficient to prevent senescence. However, the FRDA cells senesced approximately 11 
population doublings later than the controls. This promotion of the transition from 
proliferation to senescence in the FRDA cells could be due to the difference in the 
original telomere lengths of these cell lines or the activation of the ALT mechanism by 
which the mean cell population doubling may have been exceeded. In addition to the 
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growth behaviour and the number of cells, the state of replicative senescence can also be 
determined by increased numbers of γ-H2AX DNA repair foci at telomeres as a result of 
cell-specific stress responses. Therefore, further analysis is required to confirm the 
senescent phenotype in the fibroblasts cells. Subsequently, the effect of replicative ageing 
of culture cells at different passages was studied by telomere length assay to determine 
telomeric DNA loss due to cell divisions. Analysis of telomere length results at different 
passage numbers indicated that the FRDA cells lost telomeres faster than the controls. 
These results suggested that dysfunctional telomeres in the FRDA cells, possibly due to 
oxidative stress, were responsible for the increased rate of telomere attrition. In addition, 
it has been reported that the FRDA cells are more sensitive to ionising radiation than the 
control cells, suggesting that FRDA is a DNA repair-deficient disorder [216].  
 
Finally, to confirm the presence of a telomere dysfunction phenotype in the FRDA cells, 
the TIF assay was performed. The results demonstrated that the frequency of γ-H2AX 
foci was significantly higher in the FRDA cells compared to the controls, indicating a 
higher degree of DNA damage. Similarly, the FRDA cells had greater frequencies of TIFs 
in comparison to the controls. Therefore, these results suggested that the FRDA cells may 
have induced telomere dysfunction relative to the control cells.  In conclusion, the results 
demonstrated a telomere dysfunction phenotype and accelerated telomere shortening in 
the FRDA fibroblasts. In addition, the results suggested that intertelomeric recombination 
was initiated in the FRDA cells but was not capable of maintaining the telomeres and 
preventing accelerated telomere shortening. 
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Fig. S.1 Rotarod performance of mice (corrected for body weight). A) Rotarod analysis of 
YG22R, YG8R and YG8sR compared to B6 and Y47R controls shows a coordination 
deficit in all three rescue mice (n=10 mice per genotype) when both male and female 
values were taken together. Analysis of B) males and C) females separately (n=5 mice per 
genotype). Error bars indicate SEM and values represent mean ± SEM.  
 
Table S.1 Two-way ANOVA analysis of rotarod performance (corrected for body 
weight) in FRDA mice  
 
 
Mouse 
 
Genotype Gender Versus B6 
Versus B6 
(Male & 
Female) 
Versus 
Y47R 
Versus Y47R 
(Male & 
Female) 
 
YG22R 
FRDA 
YG22 
Rescue 
Male P=2.22E-21 
 
 
 
P=0.0007 
 
 
 
P=1.08E-20 
 
 
 
P=9.7E-08 
 
 
Female P=0.092 
 
P=0.006 
 
 
 
YG8R 
FRDA 
YG8 
Rescue 
Male P=3.1E-24 
 
 
 
 
P=2.94E-24 
 
 
 
P=4.76E-23 
 
 
 
 
P=1.02E-30 
 
 
 
Female P=8.22E-05 
 
 
P=0.005 
 
 
 
 
YG8sR 
 
FRDA 
YG8 Small 
Rescue 
Male P=0.021 
 
 
 
 
P=3.28E-05 
 
 
P=0.769 
 
 
P=0.081 
 
Female P=3.84E-11 
 
 
 
P=5.84E-14 
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Table S.2 Student’s t test analysis of rotarod performance (corrected for body weight) in 
FRDA mice from 4 to 12 months 
 
 
Mouse 
Male 
and 
Female 
4m 5m 6m 7m 8m 9m 10m 11m 12m 
 
YG22R 
Vs B6 
 
0.41  
 
0.24 
 
0.81 
 
0.72 
 
0.41 
 
0.05 
 
0.006 
 
0.03 
 
0.03 
 
Vs Y47R 
 
0.04 
 
0.15 
 
0.12 
 
0.004 
 
0.96 
 
0.0005 
 
0.08 
 
0.55 
 
0.02 
 
 
YG8R 
Vs B6 
 
0.000395 
 
0.75 
 
0.001 
 
0.0009 
 
2.23E-06 
 
7.58E-05 
 
0.0001 
 
7.29E-06 
 
0.002 
 
Vs Y47R 
 
3.47E-06 
 
0.007 
 
3.78E-05 
 
7.94E-09 
 
0.0002 
 
5.04E-08 
 
0.01 
 
0.04 
 
0.001 
 
 
YG8sR 
 
Vs B6 
 
0.51 
 
0.03 
 
0.25 
 
0.28 
 
0.83 
 
0.04 
 
0.008 
 
6.45E-05 
 
0.006 
 
Vs Y47R 
 
0.62 
 
0.63 
 
0.61 
 
0.027 
 
0.37 
 
0.0003 
 
0.09 
 
0.09 
 
0.003 
 
 
Mouse 
 
Male 4m 5m 6m 7m 8m 9m 10m 11m 12m 
 
YG22R 
Vs B6 
 
0.08 
 
0.04 
 
0.07 
 
0.02 
 
0.01 
 
1.02E-05 
 
1.43E-06 
 
0.0002 
 
9.8E-06 
 
Vs Y47R 
 
0.003 
 
9.83E-05 
 
0.0003 
 
4.27E-05 
 
0.04 
 
3.46E-07 
 
0.009 
 
0.15 
 
0.009 
 
 
YG8R 
Vs B6 
 
0.02 
 
0.08 
 
0.004 
 
0.0003 
 
0.0001 
 
8.48E-05 
 
2.95E-06 
 
0.002 
 
0.0001 
 
Vs Y47R 
 
0.0004 
 
0.0002 
 
1.59E-05 
 
6.76E-07 
 
0.0006 
 
2.38E-06 
 
0.02 
 
0.46 
 
0.05 
 
 
YG8sR 
 
Vs B6 
 
0.18 
 
0.97 
 
0.71 
 
0.24 
 
0.19 
 
3.64E-05 
 
0.0007 
 
0.009 
 
0.0002 
 
Vs Y47R 
 
0.008 
 
0.07 
 
0.003 
 
0.0008 
 
0.37 
 
8.21E-07 
 
0.42 
 
0.63 
 
0.14 
 
 
Mouse 
 
Female 4m 5m 6m 7m 8m 9m 10m 11m 12m 
 
YG22R 
Vs B6 
 
0.46 
 
7.85E-05 
 
0.19 
 
0.05 
 
0.47 
 
0.76 
 
0.23 
 
0.09 
 
0.86 
 
Vs Y47R 
 
0.38 
 
0.002 
 
0.033 
 
0.44 
 
0.07 
 
0.82 
 
0.50 
 
0.42 
 
0.42 
 
 
YG8R 
Vs B6 
 
0.01 
 
0.03 
 
0.20 
 
0.49 
 
0.0002 
 
0.08 
 
0.51 
 
0.0006 
 
0.73 
 
Vs Y47R 
 
0.01 
 
0.30 
 
 
0.75 
 
0.12 
 
0.54 
 
0.03 
 
0.83 
 
0.61 
 
0.29 
 
 
YG8sR 
 
Vs B6 
 
0.01 
 
0.0001 
 
0.23 
 
0.001 
 
0.74 
 
0.84 
 
0.08 
 
6.29E-05 
 
0.24 
 
Vs Y47R 
 
0.01 
 
0.001 
 
0.03 
 
0.11 
 
0.001 
 
0.48 
 
0.28 
 
0.16 
 
0.03 
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Fig. S.2 Beam-walk analysis of mice (corrected for body weight). A) Body weight 
corrected beam-walk analysis of YG8R, YG22R and YG8sR FRDA mice compared with 
B6 and Y47R controls (n=10 mice per genotype) when both male and female values were 
taken together. B) Analysis of male and C) female littermates (n=5 mice per genotype). 
Error bars indicate SEM and values represent mean ± SEM. Asterisks indicate significant 
differences between mutant and control mice (
*
P<0.05, 
**
P<0.01 and 
***
P<0.001). 
Statistical differences between mutant and B6 control mice are indicated by the top line 
drawn over the bars while the bottom line indicates the differences between mutant and 
Y47R control mice. 
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Fig. S.3 Stride length (average of left and right hindlimb; and left and right forelimb) 
analysis of mice. A) Analysis of YG8R, YG22R and YG8sR mice revealed significantly 
reduced stride length compared to B6 and Y47R controls when both male and female 
values were taken together (n=10 mice per genotype). Analysis of B) males and C) 
females separately (n=5 mice per genotype). Error bars indicate SEM and values 
represent mean ± SEM. Asterisks indicate significant differences between mutant and 
control mice (
*
P<0.05, 
**
P<0.01 and 
***
P<0.001). Statistical differences between mutant 
and B6 control mice are indicated by the top line drawn over the bars while the bottom 
line indicates the differences between mutant and Y47R control mice. 
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Fig. S.4 Base width (average of fore and hind base width) analysis of mice. A) Analysis 
of YG8R, YG22R and YG8sR mice revealed significantly shorter base width compared to 
B6 and Y47R controls when both male and female values were taken together (n=10 mice 
per genotype). Analysis of B) males and C) females separately (n=5 mice per genotype) 
revealed a significant decrease in base width of all mutant mice compared to controls. 
Error bars indicate SEM and values represent mean ± SEM. Asterisks indicate significant 
differences between mutant and control mice (
*
P<0.05, 
**
P<0.01 and 
***
P<0.001). 
Statistical differences between mutant and B6 control mice are indicated by the top line 
drawn over the bars while the bottom line indicates the differences between mutant and 
Y47R control mice. 
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Fig. S.5 Fold change analysis of glucose tolerance test in mice. A) Glucose concentration 
in YG8R, YG22R and YG8sR mice compared to B6 and Y47R controls when both male 
and female values were taken together (n=10 mice per genotype). Analysis of B) males 
and C) females separately (n=5 mice per genotype). Error bars indicate SEM and values 
represent mean ± SEM.  
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Fig. S.6 Fold change analysis of insulin tolerance test in mice. A) YG8R, YG22R and 
YG8sR mice showed lower blood glucose level after insulin injection compared to B6 
and Y47R controls when both male and female values were taken together. A similar 
tendency was observed when B) males and C) females were considered alone, except 
YG8R female mice that showed a similar response as controls. Error bars indicate SEM 
and values represent mean ± SEM.  
 
B 
 
C 
 
